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Artemisinin Combination Therapy (ACT) is the last standing force against multi-drug resistant 
malaria parasites. ACTs consist of the simultaneous administration of an artemisinin (ART) 
derivative and a chemically non-related antimalarial drug. Many studies have debated the use of 
ACTs as having many advantages, relying on the high efficacy and fast action of ART 
derivatives and on long-half life drugs used as partners in order to circumvent ART derivatives’ 
short half life. However, sub-standard drug administration, amongst other factors, has 
contributed to the appearance of resistance to each component of combination therapy.  Pre-
existing resistance to one partner drug of the combination may be an important factor 
contributing to the appearance of resistance to ACTs in the field. In addition, parasites which 
are resistant to each component may undergo genetic recombination in the mosquito and 
originate new strains showing resistance to both partner drugs simultaneously. 
In order to test these hypotheses and in an attempt to model ACT resistance as it might occur in 
the field, the rodent model Plasmodium chabaudi was used in this study. Although rodent 
laboratory models may not mimic Plasmodium falciparum natural parasite populations in their 
every characteristic, they provide important insights on the parasite’s biology, such as 
mechanisms used to escape drug action, and may provide tools for estimation of drug’s useful 
life and the help in the design of drug policies for endemic countries. 
Experimental evolution of the artesunate + mefloquine (ATN + MF) version of ACT was 
accomplished by selection through drug pressure using two different approaches: i) a MF-
resistant clone, AS-15MF, was subjected to consecutive sub-inoculations in mice treated with 
stepwise increasing doses of ATN alone; and ii) an ATN-resistant clone, AS-ATN, was 
subjected to consecutive sub-inoculations in mice treated with stepwise increasing doses of the 
ATN + MF combination. In both cases, the AS-MFATN-5 and AS-ATNMF-1 clones generated 
 19 
here showed higher levels of resistance to ATN + MF than their respective progenitors AS-
15MF and AS-ATN. 
Genetic analyses revealed that both AS-MFATN-5 and AS-ATNMF-1 gained an extra copy of 
the mdr1 gene during the evolution of resistance, and this extra copy was met with an increase 
in RNA and protein expression in AS-ATNMF-1. In addition, Solexa whole genome re-
sequencing showed that AS-ATNMF-1 carried other two further novel non-synonymous 
mutations in the PCAS_132020 and PCAS_143160 genes, the function of which are unknown.  
AS-ATNMF-1 was also compared with its progenitor AS-ATN in within-host competition 
assays is order to estimate if ATN + MF resistance would impose a biological cost to these 
parasites. In addition, AS-ATNMF-1 was compared with AS-ATN passaged through mice 
twenty seven times (AS-ATN27P) with the purpose of checking if consecutive sub-inoculations 
in mice would be associated with increased parasite fitness. Whilst AS-ATNMF-1 outgrew its 
progenitor AS-ATN, the same trend was not observed when in competition with AS-ATN27P.  
These results suggest that mdr1 amplification and overexpression may play a central role in 
ATN + MF resistance in our model. However, the newly acquired mutations may also influence 
parasite’s phenotype. In addition, acquisition of these mutations is not associated with increased 
fitness cost to the resistant clone when compared to its ATN + MF-sensitive progenitor. 
In conclusion, the efficacy of ACTs may be hampered by the development of a generic 
mechanism of drug-evasion that allows parasites to prevent the action of both drugs of the 
combination simultaneously. In addition, resistant parasites may show little or no reduction in 
fitness which could contribute to their rapid spread. The results of this work may provide 
valuable insights for improved deployment of drug combinations and for molecular surveillance 
of ACT efficacy in the field. 
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A utilização de Terapia Combinada com Artemisinina (ACT), administração simultânea de 
derivativos de Artemisinina (ART) com outros antimaláricos quimicamente distintos, 
representa atualmente o último recurso eficaz contra parasitas de malária humana resistentes a 
múltiplos fármacos. As vantagens da utilização de ACTs para o tratamento da malária foram 
debatidas em diversos estudos,  baseando-se fundamentalmente na elevada eficácia e rápida 
ação dos derivados de ART associadas à utilização de fármacos de semi-vida longa, com o 
objetivo de complementar a curta semi-vida dos derivativos de ART. No entanto, administração 
destes fármacos em níveis sub-terapêuticos, entre outros factores, contribuiu para o 
aparecimento de parasitas resistentes a cada componente da terapia combinada. O aparecimento 
de resistência a um dos componentes da combinação pode contribuir para o aparecimento de 
resistência aos ACTs em populações parasitárias. Adicionalmente, parasitas resistentes a cada 
um dos componentes dos ACTs podem sofrer recombinação genética em mosquitos vectores, o 
que poderia originar novas estirpes resistentes simultaneamente aos dois fármacos da 
combinação.  
Com o objectivo de testar estas hipóteses e visando criar um modelo capaz de representar a 
possível evolução de resistência aos ACT em parasitas de humanos, o parasita de malária 
murina Plasmodium chabaudi foi utilizado neste estudo. Apesar de poderem não reflectir os 
mecanismos ocorrentes em Plasmodium falciparum com exatidão, os modelos murinos 
representam um exelente recurso para obter indícios relativos à biologia do parasita, 
nomeadamente, aos mecanismos de evasão à acção de fármacos. Além disso, podem ainda 
fornecer ferramentas necessárias para que a vida útil de um determinado fármaco seja avaliada 
e contribuir para o desenvolvimento de políticas apropriadas para cada país onde a doença é 
endemica.  
No decorrer deste trabalho, a evolução experimental de resistência à versão de ACTs que 
consiste na combinação de artesunato e mefloquina (ATN + MF) foi obtida através de seleção 
 22 
por pressão de fármaco utilizando duas abordagens: i) o clone resistente à MF, AS-15MF, foi 
submetido a sub-inoculações consecutivas em murganhos tratados com doses crescentes de 
ATN; e ii) o clone resistente a ATN, AS-ATN, foi submetido a sub-inoculações consecutivas 
em murganhos tratados com doses crescentes da combinação ATN + MF. Em ambos os casos, 
os clones obtidos, AS-MFATN-5 e AS-ATNMF-1, apresentaram níveis acrescidos de 
resistência a ATN + MF quando comparados aos seus progenitores AS-15MF e AS-ATN, 
respectivamente. 
A análise genética dos clones AS-MFATN-5 e AS-ATNMF-1 revelou que os mesmos haviam 
adquirido uma cópia extra do gene mdr1, e que a aquisição desta cópia extra foi acompanhada 
pelo aumento nos níveis de expressão de RNA e proteína no clone AS-ATNMF-1. 
Adicionalmente, a re-sequenciação do genoma completo do clone AS-ATNMF-1 através do 
método Solexa revelou a presença adicional de duas novas mutações não sinónimas nos genes 
PCAS_132020 e PCAS_143160, ambos de função desconhecida. 
O clone AS-ATNMF-1 foi ainda comparado ao seu progenitor AS-ATN em ensaios de 
competição intra-hospedeiro, com o propósito de avaliar um potencial custo biológico da 
resistência à combinação ATN + MF. Além disso, o parasita AS-ATNMF-1 foi comparado com 
o clone AS-ATN sub-inoculado vinte e sete vezes em murganhos na ausência de tratamento 
com fármaco (AS-ATN27P), com o objectivo de verificar se sub-inoculações consecutivas 
estariam associadas a um aumento no fitness destes parasitas. Nestes ensaios, enquanto o clone 
AS-ATNMF-1 foi capaz de superar o seu progenitor AS-ATN em termos de multiplicação 
parasitária, esta mesma tendência não foi observada quando em competição com AS-ATN27P. 
Colectivamente, os resultados descritos neste trabalho sugerem que a amplificação do gene 
mdr1 desempenha um papel importante na resistência a ATN + MF gerada neste modelo 
experimental. No entanto, mutações adicionais podem também ter algum papel nessse fenótipo. 
 23 
Adicionalmente, a presença destas mutações não está associada a uma redução no “fitness” do 
clone resistente AS-ATNMF-1 quando comparado ao progenitor sensível a ATN + MF. 
Em conclusão, a eficácia do tratamento baseado em ACTs pode ser comprometida pelo 
aparecimento de parasitas portadores de um mecanismo genérico de evasão à acção 
farmacológica, que previna a actuação dos dois componentes da combinação em simultâneo. 
Além disso, parasitas resistentes podem não apresentar redução no “fitness”,  o que poderia 
contribuir para o seu rápido alastramento.  
Os resultados apresentados neste trabalho e a suas implicações inerentes poderão servir de base  
para o aperfeiçoamento das terapias utilizando combinações de fármacos e das ferramentas 
moleculares para a monitorização da eficácia dos ACTs em populações parasitárias selvagens. 
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This thesis describes the generation of resistance to Artemisinin Combination Therapy in the 
rodent malaria parasite Plasmodium chabaudi, the genetic mechanisms associated with it and 
the potential implications of resistance in parasite fitness. 
This dissertation is divided into three main chapters: 
I. General Introduction;  
II. Evolution of resistance to the artesunate + mefloquine combination and 
identification of genetic markers of resistance; 
III. Fitness cost of resistance to artesunate + mefloquine.  
 
Chapter I contains a brief review of the general aspects pertaining to the malaria parasite, such 
as pathogenesis, life cycle, genetics and control of the disease. Chapters II and III contain a 
brief introduction, in which a review of the literature will be presented, highlighting the most 
important points in the context of the work developed. The results obtained will be presented 
and discussed. 
A list of six Appendices is provided. The Appendices contain results of unsuccessful 
experiments as well as sequence alignments and lengthy tables.  
The Material and Methods section is presented last, where detailed description of procedures 
carried out throughout this work is provided. 
Finally, the literature used as support for this work will be compiled and displayed in 
alphabetical order in the References section. 
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CHAPTER I 
GENERAL INTRODUCTION 
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I.1. EPIDEMIOLOGY OF MALARIA 
 
Malaria is one of the most concerning health problems of the present time. The disease is 
present in more than 108 countries, the most affected being in sub-Saharan Africa, where the 
majority of cases and deaths are reported. Approximately 3,000 million people are at risk of 
being infected. In fact, more than 247 million cases occur each year, causing almost one million 
deaths (WHO – Fact sheet 94, April 2010). The most susceptible individuals are children under 
5 years of age and pregnant women. Also, travellers from non-endemic countries visiting 
endemic countries are highly susceptible due to their non-immune status (WHO – Fact sheet 94, 
April 2010).  
Besides high mortality rates, malaria is also responsible for high levels of morbidity 
among the affected populations, and is intimately associated with, and also responsible for 
hindering the economical development of countries where it is endemic (Sachs and Malaney, 
2002). 
Malaria is caused by a protozoan parasite of the genus Plasmodium. The four important 
species infecting humans are: Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and 
Plasmodium falciparum. The latter is the most virulent form, causing the most serious cases of 
the disease. In spite of P. falciparum’s high prevalence in endemic regions of Africa and South 
East Asia, other species, such as P. vivax, are spreading and the number of cases is increasing 
(Price et al, 2007). 
The symptoms of the disease include high fever, headache, chills, and vomiting, and if not 
treated in time, P. falciparum malaria can cause severe anaemia and death (WHO, 2006). In the 
most susceptible individuals, P. falciparum infections can also evolve to a deadly condition 
called cerebral malaria, characterised by seizures followed by coma and death (Idro et al, 
2005). Although malaria is a curable disease, relapses may occur, if patients infected with P. 
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vivax or P. ovale do not receive specific treatment against the “dormant” forms of the parasites 
called hypnozoites (see Section I.2). 
 
I.2. LIFE CYCLE OF THE MALARIA PARASITE 
Malaria is transmitted to humans by the bite of a female mosquito of genus Anopheles and 
Plasmodium parasites’ life cycle is composed of three stages: i) hepatic schizogony; ii) 
erythrocytic schizogony; and iii) sporogony. Throughout the three stages of development the 
parasite inhabits two different hosts: the two first stages take place in the mammalian host, 
whilst the last one occurs in the female Anopheline mosquito.  
Plasmodium’s life cycle (Figure 1) begins when the female Anopheles mosquito bites the 
mammalian host, introducing motile parasites forms known as sporozoites. The sporozoites 
reach the blood stream, travelling through it until they reach the liver. The parasites then invade 
and cross a few hepatic cells and finally establish in one of them. There they undergo several 
rounds of mitotic replication during 5 to 7 days, generating tens of thousands of merozoites. 
This eventually causes the rupture of the hepatocyte, releasing the merozoites into the host’s 
blood stream. Alternatively, P. vivax and P. ovale sporozoites can mature and evolve into a 
“dormant” form, known as hypnozoite that can re-awaken months or even years later, causing 
the relapses characteristic of the infection by these species.  
Upon reaching the blood stream, the merozoites invade the host’s erythrocytes where they 
feed on cell resources, grow, and develop into schizonts. The schizonts undergo many rounds of 
mitotic divisions, forming approximately 8-to-20 new daughter merozoites. The erythrocyte’s 
membrane is then disrupted, releasing the merozoites in the blood stream, where they will 
invade new erythrocytes, and again, grow into schizonts. This synchronous cycle happens at 
regular intervals, and its duration depends on the infecting species, e.g. 48 or 72 hours in P. 
falciparum or P. malariae infections, respectively. In addition, the synchronous release of the 
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merozoites and the disruption of the erythrocytes are responsible for the release of the 
intracellular material, causing the fever episodes characteristic of the disease.  
Alternatively, instead of undergoing mitosis and forming new merozoites, schizonts can 
differentiate into different types of cells, forming the precursors of micro or macrogametes 
(male and female, respectively), called gametocytes. When the female Anopheles mosquito 
bites an infected host, it must ingest both male and female gametocytes for the cycle to 
continue. Inside the mosquito’s midgut, the male and female gametocytes differentiate into 
gametes, which then fuse and become a diploid motile cell known as ookinete (zygote). It is in 
the ookinete that recombination of the genetic material from each parent takes place (Section 
I.3.2). The ookinete crosses the midgut wall, where it settles and undergoes one round of 
meiotic division. Finally, it matures into an oocyst which undergoes many mitotic 
multiplication rounds, generating about a thousand sporozoites. 5-to-7 days later, the 
sporozoites are released into the mosquito’s haemolymph and then migrate into the mosquito’s 
salivary gland. They will remain there rendering this mosquito infective throughout its whole 
life.  
Upon biting a new host, the infective mosquito injects the sporozoites into the mammalian 
host, restarting the cycle.  
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Figure 1 -  Plasmodium spp life cycle. Graphic representation from "Life cycle of the malaria parasite" from 
Epidemiology of Infectious Diseases. Available at: http://ocw.jhsph.edu. Copyright © Johns Hopkins 
Bloomberg School of Public Health. Creative Commons BY-NC-SA. 
 
 
I.3. GENETICS OF THE MALARIA PARASITE 
I.3.1. GENOME ORGANISATION AND STRUCTURE 
As described above, Plasmodium parasites are haploid during most parts of the life cycle, 
undergoing replication mostly by mitotic division. The only diploid phase takes place in the 
ookinete, the zygote resulting from the fusion of the two haploid gametes inside the mosquito 
midgut after the ingestion of infected blood (Sinden et al, 1985).  
During the haploid phase, the parasite’s genetic material is organised into three genomes: 
i) the mitochondrial genome, which is composed of 6 Kb in size and codes for a few specific 
mitochondrial genes, such as cytochrome b; ii) the plastid 35 Kb circular genome, coding 
mostly for tRNAs and rRNAs (Wilson and Williamson, 1997); and iii) the nuclear genome. 
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The nuclear genome of the malaria parasite is composed of 14 chromosomes of different 
sizes (~500 Kb – ~3 Mb) and totals approximately 20 Mb. The genome has a very high A + T 
content ranging from 55% to 80% depending on the Plasmodium species (Carlton et al, 2002; 
Gardner et al, 2002; Hall et al, 2005; Carlton et al, 2008). The A + T content is not constant 
along the chromosomes, with telomeric and sub-telomeric regions having higher A + T content 
than central chromosomal areas. In addition, non-coding regions are more A + T rich than 
coding regions (Carlton et al, 2005). 
The whole genome of Plasmodium falciparum codes for approximately 5,300 genes, and 
at the time of the publication of the last P. falciparum genome assembly, 60% of all genes had 
no known function (Gardner et al, 2002). However, the genome is constantly being updated, as 
new molecular data on gene functions (Tuikue et al, 2008; Moyano et al, 2009) and new 
bioinformatics tools for comparative genomic analysis become available (Brehelin et al, 2008).  
In general, the organisation (order and orientation) of genes in internal areas of the 
chromosomes is highly conserved between Plasmodium spp.; referred to as gene synteny (Hall 
et al, 2005; Kooij et al, 2005). On the other hand, sub-telomeric regions of chromosomes are far 
less conserved and contain different families of species-specific variable genes which are 
believed to be involved in antigenic variation and evasion from the host’s immune system (van 
Lin et al, 2000). 
When analysing genome sequence variations comparing parasites belonging to the same 
species, sub-telomeric genes show the most variable sequences mainly due to frequent 
recombination events (Mu et al, 2005). However, sequence variation can also occur in core 
regions of chromosomes. In addition to recombination, genome sequence variations can happen 
due to single nucleotide polymorphisms (SNPs) (Wootton et al, 2002) , insertions/deletions 
(indels) (Anderson et al, 2005), large scale deletions (Biggs et al, 1989), amplifications 
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(Cowman et al, 1994), inversions (Pologe et al, 1990), and translocations (Hinterberg et al, 
1994). 
Although no variation is found in chromosome number, variation in size of one 
chromosome when comparing different strains of the same species may be observed. This is 
believed to take place due to recombination events between homologous regions of different 
chromosomes, and also due to gene amplification events and/or indels. In the case of in vitro 
cultured strains, this variation may happen due to chromosome breakage and the consequent 
healing of blunt ends by the addition of telomeric repeats (Janse, 1993; Lanzer et al, 1995; 
Carlton et al, 2005). 
The completion of Plasmodium falciparum genome in 2002 (Gardner et al, 2002) has 
opened the so-called “post-genomic” era in the investigation of the parasite’s biology. The 
knowledge of the complete sequence of the P. falciparum genome, added to studies on 
conservation of gene order between different species (gene synteny) ) (Hall et al, 2005; Kooij et 
al, 2005) provided new ways of identifying genetic markers involved in the expression of 
different phenotypes, such as drug resistance. Prior to this, advances in understanding the 
genetics of the malaria parasite were made relying on labour intensive performances of genetic-
crosses, based on knowledge of a limited number of markers distinguishing different parasite 
strains. 
The analysis of polymorphisms in target genes also led to some advances in understanding 
the mechanisms underlying different phenotypes. For instance, using a candidate gene 
approach, Sidhu and colleagues identified a mutation responsible for resistance to azithromycin 
in P. falciparum (Sidhu et al, 2007).  
An important innovation in the search for genetic variations has been the recent 
developments in genome sequencing techniques. The advent of second generation sequencing 
(such as the Illumina Solexa and Roche 454 platforms) has greatly facilitated the rapid 
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discovery of genome-wide variants without prior knowledge of candidate genes (Morozova and 
Marra, 2008). The Illumina Solexa platform (Bentley, 2006) in particular has been adopted in 
the study of genetic variants in P. chabaudi, allowing the identification of candidate genes 
underlying various drug resistance phenotypes (Hunt et al, 2010, Martinelli unpublished 
results). 
Another very useful genome-wide analysis tool is a technique known as Linkage Group 
Selection (LGS). This method was developed in P. chabaudi, and may potentially also be 
applied to other species for comparing two different strains displaying any selectable feature 
(Culleton et al, 2005; Martinelli et al, 2005; Carter et al, 2007). A map of genetic markers 
covering the whole genome of the parasites must be known, in order to allow the distinction 
between the two strains in a parasite mixture. LGS consists of performing a genetic cross 
(Section I.3.2) between the two strains of interest and then applying a selective pressure on the 
uncloned progeny obtained from the genetic cross. The selective pressure is meant to eliminate 
the most susceptible parasites from the cross progeny, promoting the survival of parasites 
showing the most favourable traits. Thus, the markers in closer linkage with the genes 
determining the phenotype of interest will be maintained, whilst the most distant will be 
eliminated. By comparing the percentage of each marker across the whole genome of the 
selected progeny and the unselected progeny of the same cross, it is possible to observe a 
selection valley around the locus/loci in linkage with the phenotype of interest. In theory, the 
gene that determines the phenotype under investigation should be located at the bottom of the 
selection valley (Culleton et al, 2005; Martinelli et al, 2005). In combination with second-
generation sequencing, LGS provides an even more powerful and rapid method for the 
identification of mutations underlying selectable phenotypes (Hunt et al, 2010).  
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I.3.2. SEXUAL REPRODUCTION AND GENETIC RECOMBINATION 
It is inside the mosquitoes’ midgut that male and female gametes of the parasite will fuse, 
originating a diploid zygote, the ookinete. In high transmission areas infections usually consist 
of 3 to 7 genetically distinct parasite clones simultaneously circulating in human host blood 
stream (Arnot, 1998). When the mosquito ingests gametocytes deriving from different parasites 
clones, two outcomes are possible: i) self-fertilisation, when two gametes from the same clone 
fuse, and in this case, the resulting offspring is genetically identical to the parental clone; or ii) 
cross-fertilisation, when two gametes from different parasite clones form the zygote, and 
therefore, in this situation, recombination of the genetic material belonging to each parental 
takes place. The cross-progeny then will harbour a mixture of different alleles inherited from 
both parents (Figure 2). 
The existence of genetic recombination was first shown in the rodent model P. chabaudi, 
in 1975 (Walliker et al, 1975). Since then, many advances were made in this field. It is now 
known that the rates of recombination events in Plasmodium are usually higher in sub-telomeric 
regions and non-coding repetitive sequences. Genes in internal regions of the chromosomes 
seem to be less prone to undergo rearrangement, unless they are under strong selective pressure 
(Carlton et al, 2005).  
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Figure 2 – Schematic representation of the possible outcomes when gametocytes are ingested in the bloodmeal of a 
female Anopheles mosquito. Two gametocytes are represented (red and black bars), indicating parasites carrying 
different genetic material. When two gametocytes carrying the same genetic material fuse forming an ookinete (A 
and C) the resulting progeny will have exactly the same alleles as the parental (Selfing). When two gametocytes 
carrying different alleles fuse (B), genetic recombination will occur, generating parasites that can either be like one 
of the parentals or carry a mixture of alleles belonging to each parental.  
 
 
 
I.4. STRATEGIES FOR MALARIA CONTROL  
 
The causative agent of malaria was discovered in 1880 by Alphonse Laveran. However, 
reports of the disease date from many centuries before (Cox, 2010). Nonetheless, malaria is still 
responsible for high morbidity and mortality to the present day. In the 1950’s, many efforts 
were focused on the worldwide eradication of the disease. This program was successful in 
many regions, such as Europe, North America and the Caribbeans, however meeting with 
Gametocytes
Ookinete
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limited success in Sub-Saharan African countries. In 1969, this ambitious goal was abandoned, 
and by 1992 efforts were focused on the control of the disease. This new strategy resulted in the 
reduction of the number of cases (Tanner and Savigny, 2008). However, due to the appearance 
and dissemination of resistance to the most widely used antimalarial drugs, and to mosquito 
resistance to insecticides, the number of cases increased once more. Very recently the aim of 
eradication has been revisited (Delacollette and Rietveld, 2006; WHO, 2007). 
Strategies used for malaria control, as well as their pitfalls will be described below. Special 
focus will be placed on antimalarial treatment of infections, mechanisms of action and 
mechanisms underpinning resistance to the most important drugs currently available. 
 
I.4.1. VACCINATION 
 
Ideally, the prevention of new cases of malaria should be made by vaccination of people at 
risk of infection. This would provide the basis of control and possible eradication of the disease. 
However, in spite of the discovery of promising candidates, until the present date, no fully 
effective vaccines were produced (WHO, Parasitic Diseases - 
http://www.who.int/vaccine_research/diseases/soa_parasitic/en/print.html).  
   
I.4.2. VECTOR CONTROL 
A few species of Anopheles mosquitoes are highly efficient in transmitting the disease. In 
endemic areas, one strategy adopted for reducing transmission is the prevention of contact 
between mosquitoes and human hosts. This is done in two distinct ways: i) use of indoor 
residual spraying (IRS) of households in affected areas; and ii) the distribution of insecticide 
treated bednets (ITN) (WHO, 2006b).  
WHO efforts for vector control between the 1940’s and 1960’s caused a drastic reduction 
in mosquito population, and consequently a decrease in the number of malaria cases. However, 
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logistical difficulties in reaching the breeding areas, in conjunction with the spread of resistance 
to insecticides amongst the mosquito population pose a threat to the effective control of the 
disease (Mabaso et al, 2004). 
 
I.4.3. ANTIMALARIAL TREATMENT AND RESISTANCE 
 
Since an effective vaccine is still to be achieved and control of the vector population has 
shown to be very difficult to sustain for long periods of time, malaria control relies mostly on 
treatment of patients with drugs targeted to the erythrocyte stages of the parasite’s life cycle. 
Effective drugs, however, have their action limited by the gradual emergence of resistant 
parasites. The WHO defines “drug resistance” as the “ability of a parasite strain to survive 
and/or multiply despite the administration and absorption of a drug given in doses equal to or 
higher than those usually recommended but within tolerance of the subject”, and “the form of 
the drug active against the parasite must be able to gain access to the parasite or the infected 
erythrocyte for the duration of the time necessary for its normal action” (WHO, 1986).  
At the present time, resistance to most drugs used in therapy of malaria has already 
emerged and spread worldwide. The only exceptions are the artemisinin (ART) derivatives, 
which are currently administered in combination with other drugs, constituting the so-called 
Artemisinin Combination Therapy (WHO, 2006c). However, recent reports indicate that the 
efficacy of ART compounds also seems to be declining (Carrara et al, 2009; Dondorp et al, 
2009; Noedl et al, 2009; Lim et al, 2010). Taking into account the long time required for the 
development and implementation of newly synthesised drugs, if high levels of resistance to 
ART derivatives should become established in Plasmodium populations, malaria cases could 
become almost incurable.  
In order to contain the advance of drug resistance it is important to understand the 
mechanisms behind the mode of action as well as the mechanisms underlying resistance to 
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antimalarial drugs currently in use. The history and evolution of resistance to the most 
important drugs used in malaria therapy will be briefly presented in Chapter II. 
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CHAPTER II  
EVOLUTION OF RESISTANCE TO THE ARTESUNATE + MEFLOQUINE 
COMBINATION AND IDENTIFICATION OF GENETIC MARKERS OF 
RESISTANCE 
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This Chapter will deal with the selection and genetic analysis of artesunate + mefloquine 
(ATN + MF)-resistant clones and will be subdivided in three sections: i) Introduction - initially, 
a brief description of the mechanisms of action and the strategies evolved by the malaria 
parasites to escape the effect of the most important anti-malarials in use in endemic areas will 
be presented, mainly focusing on the use of Artemisinin Combination Therapies. Subsequently, 
the rodent malaria parasite Plasmodium chabaudi, used in this work as model for the selection 
of resistance to ATN + MF, will be described; ii) Results – firstly, the selection of ATN + MF 
resistance using different strategies will be described; and secondly, the presence of genetic 
mutations following the evolution of ATN + MF resistance will be presented; iii) Discussion – 
the results obtained in the previous section will be discussed.  
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II.1. INTRODUCTION 
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II.1.1. ANTIMALARIAL DRUGS – MECHANISMS OF ACTION AND DRUG 
RESISTANCE 
II.1.1.1. CHLOROQUINE  
In 1940’s, a newly synthesised quinoline named chloroquine (CQ) was deployed as a 
treatment for malaria. CQ showed high efficacy, had little side effects and a very low 
production cost. For these reasons CQ was adopted as the first-line treatment against the disease 
in all endemic countries (WHO, 1984). 
Many studies describe CQ as targeting the food vacuole (FV) of the Plasmodium parasite 
during the intra-erythrocitic stage. However, CQ’s precise mode of action is still controversial 
(Ursos and Roepe, 2002).  
The most accepted theory is that CQ acts by blocking the detoxification of haem radicals 
resulting from the digestion of haemoglobin by the parasite (Fitch, 1970; Chou et al, 1980). By 
uptaking and digesting the erythrocyte’s haemoglobin in its FV, the parasite obtains most of the 
aminoacids necessary for the de-novo synthesis of proteins. The by-product resulting from 
haemoglobin digestion is the toxic ferrous radical haem which in abundance can cause severe 
damage to the parasite (Fitch, 2004). For that reason, the parasite inactivates haem toxicity by 
polymerising free haem radicals into an inert compound known as haemozoin (Pagola et al, 
2000). CQ is believed to bind free haem inside of the FV, blocking haemozoin formation (Fitch, 
1970; Chou et al, 1980). Free haeme or haeme-CQ adducts (Ginsburg et al, 1998) cause 
extreme oxidative stress, leading to the parasite’s death (Fitch, 2004). 
In spite of its initially high therapeutic efficacy, the long term selective pressure exerted by 
CQ administration associated with its indiscriminate prescription as treatment for all cases of 
fever in endemic areas (Trape, 2001), has led to the emergence of resistant P. falciparum 
parasites, less than 20 years after CQ’s deployment. The first foci were reported simultaneously 
in South America (YOUNG and MOORE, 1961) and South-East Asia (Harinasuta et al, 1962), 
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and from there CQ resistance spread to other areas. At the present time, apart from few 
exceptions, CQ-resistant parasites are highly prevalent and use of CQ monotherapy is 
discouraged as a first-line treatment for malaria (WHO, 2008). 
CQ resistance seems to be intimately related with the presence of mutations in the pfcrt 
gene (Bray et al, 2005). This gene codes for a transmembrane pump known as Chloroquine 
Resistance Transporter (CRT) expressed in the FV of the parasite (Fidock et al, 2000).  
The physiological function of this protein or the mechanism by which mutated CRT would 
mediate CQ transport out of the FV (as a channel or a carrier) has been the focus of extensive 
investigation (Sanchez et al, 2010). Similarly, many efforts have been made for elucidating the 
role of mutations found in the pfcrt gene. Many mutations have been identified, but the 
substitution of a lysine to a threonine in aminoacid 76 (K76T) is the most frequently found in 
resistant P. falciparum parasites, and is described as having a central role in CQ resistance 
(Fidock et al, 2000; Sidhu et al, 2002; Wootton et al, 2002; Johnson et al, 2004; Lakshmanan et 
al, 2005). Nonetheless, other studies demonstrate that pfcrt K76T may not be the sole 
determinant of CQ resistance. Genetic transfection experiments carried out in in vitro cultured 
parasite lines indicate that parasites with distinct genetic backgrounds may differ in the level of 
resistance conferred by mutations in pfcrt, suggesting a role for other loci in CQ resistance 
resistance (Fidock et al, 2008; Valderramos et al, 2010). 
For example, one gene also implicated in CQ resistance in P. falciparum is pfmdr1. It 
codes for a transmembrane efflux pump MDR1 (homologue of human P-gp1) belonging to the 
ATP-binding cassette family (Foote et al, 1989). Similarly to CRT, MDR1 is also expressed in 
the parasite’s FV (Cowman, 1991; Sanchez et al, 2008), where it is believed to mediate the 
uptake of CQ into the FV (Sanchez et al, 2010).  
Resistance to CQ seems to be associated with many polymorphisms in different residues 
of MDR1. The substitution of an asparagine by a tyrosine residue at aminoacid 86 (N86Y) 
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seems to be the most frequent in parasites displaying high levels of CQ resistance (Duraisingh 
and Cowman, 2005). Mutations in pfmdr1 are believed to cause increased tolerance to CQ, in 
parasites that harbour the K76T mutation in pfcrt (Foote et al, 1990; Reed et al, 2000; Babiker 
et al, 2001). 
Alternatively, rodent malaria models have provided additional candidate genes as 
mediators of CQ resistance, as is the case of the rodent malaria parasite Plasmodium chabaudi, 
which will be presented in Section II.1.2.1.  
 
II.1.1.2. SULPHADOXINE + PYRIMETHAMINE  
After the emergence and spread of chloroquine resistance, its use was replaced in some 
areas by the combination of two antifolate drugs: sulphadoxine + pyrimethamine (SP). As a 
consequence, a drastic reduction in cases of treatment failure was observed in the first year of 
SP application. However, resistant parasites quickly appeared in South East Asia, and rapidly 
spread to Africa (Roper et al, 2004). 
SP’s mode of action and its mechanisms of resistance are relatively simple: pyrimethamine 
(PYR) inhibits the parasite’s dihydrofolate reductase (encoded by the pfdhfr gene) whilst 
sulphadoxine (SDX) acts on dihydropteroate synthase (encoded by the pfdhps gene) (Bruce-
Chwatt et al, 1986). Consequently, SP acts by synergistically blocking the parasite’s folate 
synthesis, which halts the parasite’s pyrimidine synthesis and DNA synthesis/replication (Hyde, 
2005). 
Mutations in both the pfdhfr and pfdhps genes are described as causing resistance to SP in 
P. falciparum, and are frequently associated with treatment outcome (Wang et al, 1997). The 
first mutation described in natural P. falciparum populations was the substitution of a serine for 
an asparagine in residue 108 (S108N) of DHFR, which increases resistance to PYR by reducing 
the affinity between the drug and the enzyme (Walter, 1986). Further mutations were soon 
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identified in pfdhfr, such as the substitution of an asparagine to an isoleucine in position 51 
(N51I), of a cysteine to an arginine in aminoacid 59 (C59R), and of an isoleucine to a leucine in 
aminoacid 164 (I164L). These mutations are believed to have appeared successively in that 
order, and acquisition of each one confers an extra increase in the level of resistance to PYR 
(Sirawaraporn et al, 1997). 
Mutations in pfdhps have also been described to cause alterations in residues 436, 437, 
540, 581, 623 (Duraisingh et al, 1998), being responsible for increased resistance to SDX 
(Triglia et al, 1997). 
 
II.1.1.3. MEFLOQUINE  
In 1985, Thailand was the first country to introduce the bis-quinoline-methanol  
mefloquine (MF) as first line treatment for P. falciparum malaria and its use was soon adopted 
in other endemic areas. Initially MF treatment was administered in combination with 
sulphadoxine + pyrimethamine, but in 1990 treatment that was changed, as MF doses were 
increased and the drug was administered as a monotherapy. By 1992, cases of therapeutic 
failure were about 40% in the Thai-Cambodian border (ter Kuile et al, 1992), indicating the 
emergence of MF-resistant parasites in that population (Nosten et al, 1991; Wongsrichanalai et 
al, 2001). In the face of widespread MF resistance, malaria treatment was consequently 
switched to MF in combination with artesunate (described in detail below). 
Similarly to chloroquine (CQ), the most accepted mechanism of MF’s anti-parasitic 
activity seems to be by inhibiting haemozoin formation (Sullivan, Jr. et al, 1998). There is also 
evidence that MF can inhibit the parasite’s endocytic pathway, blocking the ingestion of 
nutrients (Hoppe et al, 2004). 
MF has a very long elimination half-life of about 2-to-3 weeks (White, 1992). For that 
reason, it is postulated that a broad window of selection is created, i.e. sub-therapeutic levels of 
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the drug are present in the patient’s bloodstream for a long period of time, allowing for the 
selection of parasites showing increased levels of tolerance to the drug (White, 1999).  
As has been reported in CQ-resistant parasites, the N86Y polymorphism – amongst other 
point mutations – in the pfmdr1 gene was described as conferring increased levels of resistance 
to MF (Duraisingh et al, 2000; Lopes et al, 2002; Price et al, 2004). Conversely, other studies 
have indicated that mutations in alternative codons of pfmdr1 seem to increase sensitivity to MF 
(Sidhu et al, 2005). 
However, the most accepted determinant of increased resistance to MF seems to involve 
the amplification of pfmdr1 (Price et al, 1997; Price et al, 2004; Alker et al, 2007), associated 
with its increased transcription and expression (Wilson et al, 1989). In addition to field 
evidence, the induction of resistant laboratory strains was shown to select increased copy 
numbers, transcription levels and protein amounts of pfmdr1 (Cowman et al, 1994; Peel et al, 
1994), while the gene’s deamplification has been reported as re-establishing sensitivity to MF 
and also other antimalarial drugs (Sidhu et al, 2006). 
In the rodent malaria parasite P. chabaudi, the amplification of pcmdr1 (the orthologue of 
pfmdr1),  also seems to play an important role in MF resistance (Cravo et al, 2003; Borges, 
2009). However, there are indications that other loci might also be implicated in MF resistance. 
For instance, a genetic cross performed between a MF-sensitive and a MF-resistant clone 
carrying two copies of pcmdr1 produced sixteen clones, one of which showed MF resistance 
without a duplicated copy of the gene (Cravo et al, 2003). On the other hand, in this same 
experiment, none of the clones carrying a duplicated copy of pcmdr1 gene showed a MF-
sensitive phenotype. 
Both field and in vitro experiments indicate that there seems to be an inverse relation 
between MF and CQ-sensitivity. Thus, the selection for high levels of MF resistance and the 
presence of increased pfmdr1 copy number are associated with increased sensitivity to CQ 
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(Price et al, 1999; Price et al, 2004; Duraisingh and Cowman, 2005; Nelson et al, 2005). The 
opposite has also been observed, i.e. selection of high levels of CQ resistance leads to pfmdr1 
de-amplification and MF-susceptibility (Barnes et al, 1992). 
 
II.1.1.4. ARTEMISININ DERIVATIVES AND COMBINATION THERAPY 
Therapeutic application 
Artemisinin (ART) or qinghaosu is extracted from the wormwood plant Artemisia annua.  
It has been used for about 2000 years by the Chinese traditional medicine for the treatment of 
fevers. ART has been “re-discovered” by Western medicine in the 1970’s as a highly effective 
treatment for malaria. It is a sesquiterpene trioxane lactone, with an endoperoxide bridge. Its 
use became disseminated by the end of the 1990’s, and at the present time it is recommended by 
WHO – in combination with other drugs – as first-line treatment for P. falciparum malaria 
worldwide (WHO, 2005). 
ART acts extremely fast against all blood stages of the parasite (ter Kuile et al, 1993; 
Meshnick et al, 1996), including the sexual forms (Kumar and Zheng, 1990), which contributes 
to reducing transmission rates. After administration, ART reaches the blood stream within 
minutes, where it is quickly converted into its active form dihydroartemisinin (Balint, 2001). 
ART is also quickly metabolised, with a half-life of about 1h, which favours the reappearance 
of parasites after treatment is completed (Meshnick et al, 1996), a situation known as 
recrudescence. In addition, ART shows very low solubility in water and consequently a very 
poor bio-availability. 
In order to improve ART’s chemical properties, synthetic analogues were produced, the 
so-called ART derivatives. The most important ART derivatives are artesunate, artemether, 
artemisone, artelinic acid, and dihydroartemisinin (the active metabolite of all ART derivatives) 
(Meshnick et al, 1996). Although more soluble in water, these compounds still have a very 
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short half life, and in order to successfully eliminate the parasites from the bloodstream, 
monotherapy with ART derivatives must be carried out during 7 days (Luxemburger et al, 
1995). Long treatment courses (mefloquine and chloroquine are usually administered in a 3-day 
regimen) usually lead to very low compliance by patients, increasing the chance of treatment 
failure (White, 1997). In order to circumvent these disadvantages, and also to “protect” ART 
derivatives against the eventual emergence of resistant parasites, the WHO recommends their 
administration in combination with long-lasting antimalarials (Olliaro and Taylor, 2004; 
Menard et al, 2005; WHO, 2005) a practice known as Artemisinin Combination Therapy 
(ACT).  
 
Artemisinin Combination Therapy 
As mentioned above, WHO’s directive for the first-line treatment of uncomplicated P. 
falciparum malaria cases is to use an arteminsinin (ART) derivative in combination with a long-
lasting partner drug. The partner drug must also be chemically unrelated to ART and have 
distinct intracellular targets or modes of action (WHO, 2001). 
Many combinations are currently available in endemic areas and vary according to 
geographic region of administration. The most common versions of ACTs are: artesunate 
(ATN) + mefloquine (MF), widely used in South-east Asia and some countries of South-
America; ATN + amodiaquine, widely used in West-African countries; ATN + sulphadoxine + 
pyrimethamine (SP), used in Eastern Mediterranean countries; artemether + lumefantrine 
(Coartem®), used in Central African countries; dihydroartemisinin + piperaquine, used in 
China, Indonesia, Viet Nam and Myanmar (Olliaro and Taylor, 2004; Menard et al, 2005; 
WHO, 2005). 
In fact, the concepts behind Artemisinin Combination Therapies (ACTs) are not new. 
Other drug combinations have been used for the treatment of malaria. For instance, SP has been 
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used in combination with chloroquine or with MF (Salako et al, 1992; Menard et al, 2005). 
Indeed, SP is already a combination of two drugs. However, as an example of combination 
therapy, SP fails to meet the pre-requisites determined by the WHO, since sulphadoxine and 
pyrimethamine act in the same metabolic pathway (Sibley et al, 2001; WHO, 2001). 
In the case of ACTs, on the other hand, ART derivatives are used in combination with 
chemically unrelated drugs, and ACT use should have many advantages. Firstly, it combines 
the rapid and efficacious action of ART derivatives with the long-term protection provided by 
the partner drug, such that any parasites surviving after the complete elimination of the ART 
derivative component would be killed by the partner drug (White, 1997; White, 1999).  
Secondly, if a parasite arises that is resistant to one of the drugs, the other drug should eliminate 
it, preventing the spread of newly arising resistant strains (White, 1999). However, it is now 
accepted that this mismatch in elimination half-lives may not be as advantageous as previously 
assumed (Hastings and Watkins, 2006; Martinelli et al, 2008). This is because after the removal 
of the ART derivative from the organism, the long-lasting drug remains in the blood stream in 
sub-therapeutic levels, blocking the growth of sensitive strains, but favouring the survival of the 
most tolerant ones (Hastings and Watkins, 2006; Martinelli et al, 2008). 
Another theoretical advantage of the use of ART derivatives with chemically unrelated 
partner drugs would reside on the parasite’s intrinsic mutation rate. Considering the rate of 
mutation of malaria parasites as being 10
-8
 per nucleotide site per generation, the chances of 
emergence of a parasite carrying mutations conferring resistance to both drugs simultaneously 
would be represented by the product of the mutation rate for each drug alone, therefore, 10
-16
 
(White, 1999). For this reason, the use of ACTs was believed to nearly abolish the chances of 
appearance of parasites showing resistance to the combination.   
In addition, considering the possibility of resistance to two drugs would be caused by two 
different mutations in two different genes, genetic recombination in the mosquito could break 
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the resistant haplotype apart, rendering the progeny sensitive to one of the two drugs of the 
combination (Dye and Williams, 1997). However, mutation rates may not be the limiting factor 
for the acquisition of resistance to two drugs in a combination. There is a phenomenon that 
suggests that parasites previously resistant to one or more drugs have an increased ability to 
acquire resistance to additional drugs. This is known as Accelerated Resistance to Multiple 
Drugs (ARMD) phenotype, and the mechanisms underlying this phenotype are still not fully 
understood (Rathod et al, 1997). Considering some areas where parasites already display high 
levels of resistance to one or more drugs, it would be expected that these parasites would more 
easily evolve resistance to any other drugs, including when administered as combinations. 
In addition, the existence of multi-drug resistant parasites may consist of yet another 
problem: ACTs are often deployed in regions where parasites have already been extensively 
exposed to one of the drugs used in the combination. This implies that parasites showing high 
levels of resistance to one of the partner drugs would only need to develop resistance to the 
other drug of the combination.  
Also, it is essential to bear in mind that in some cases the parasite may harbour mutations 
in genes related to unspecific efflux mechanisms (such as the mdr1 gene), which are capable of 
blocking the action of chemically unrelated drugs by preventing their interaction with their 
intracellular target. In this case, if the two drugs of the combination are substrates of this 
mutated efflux pump, ACT would be nearly ineffective in the mutated parasites. 
Finally, the exposure of parasites to sub-therapeutic doses of ACTs may also shorten their 
useful therapeutic life. In a similar fashion as previously described to other antimalarials, self-
medication, incomplete treatment courses, sub-standard or counterfeit drugs, etc… may result 
in selection of a tolerant sub-population and eventually give rise to parasites showing high 
levels of resistance. 
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Unfortunately, increased tolerance to ACTs has already been described and its possible 
mechanisms will be presented below. 
 
Mode of action 
Artemisinin (ART) derivatives mode of action is still unclear and their intracellular target 
is still an object of great controversy. The presence of the endoperoxide bridge in ART’s 
chemical structure was described as being essential for its antimalarial activity (Brossi et al, 
1988). Some studies have shown that ARTs interact with the parasite’s free intracellular iron 
(Meshnick et al, 1991; Haynes and Krishna, 2004), while other groups have found that ART 
reacts with haem (Robert et al, 2005) forming adducts that then alkylate the parasite’s proteins 
and membranes, but not DNA (Meshnick, 1996; Kannan et al, 2005).  
Due to its structural similarity to thapsigargin, another sesquiterpene lactone, a different 
mode of action has been proposed: ART would act as an inhibitor of thapsigargin’s specific 
target, the orthologue of the human Sarco-endoplasmic Reticulum Ca
++
 ATPase (SERCA), 
known in Plasmodium as ATPase6. In fact, ART can inhibit the activity of ATPase6 in 
transfected Xenopus laevis oocytes (Eckstein-Ludwig et al, 2003), and a single aminoacid 
substitution in ATPase6 (L263E) is enough to prevent ART’s inhibitory effects (Uhlemann et 
al, 2005). By replacing the wild-type version of pfatpase6 gene for one carrying the L263E 
mutation in P. falciparum laboratory strains, a barely significant small reduction in the 
susceptibilities to ART and dihydroartemisinin, but not to ATN was observed when compared 
to the wild-type strain (Valderramos et al, 2010). A field study published in 2005 appeared to 
support ATPase6 as ART’s intracellular target, by showing that the presence of a mutation in 
pfatpase6 was associated with increased tolerance to artemether in vitro (Jambou et al, 2005).  
Alternative intracellular targets have also been proposed for ART derivatives. For 
instance, Li and colleagues (2005) have found that ART seems to be activated by, and to 
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interfere with the components of the mitochondrial electron transport chain (Li et al, 2005). 
Also, ART’s interaction with the translationally controlled tumor protein (TCTP) has been 
proposed in different malaria models (Bhisutthibhan et al, 1998; Walker et al, 2000). 
ART derivatives have also been found to inhibit the endocytosis of macromolecules and 
the digestion of haemoglobin by malaria parasites (Hoppe et al, 2004). Also, the accumulation 
of ART within food vacuole-associated lipid bodies has been demonstrated (Hartwig et al, 
2009). Taken together, these studies seem to indicate a role of ART in interfering with ingestion 
of nutrients by the parasite. 
 
Resistance 
A threshold for determining artemisinin (ART) in vivo or in vitro resistance has not yet 
been defined by the WHO. However, it is clear that the efficacy of these compounds in the 
treatment of malaria cases is slowly decreasing. This is reflected in various studies as an 
increase in parasite clearance time observed after treatment with artesunate (ATN) alone or 
Artemisinin Combination Therapy (ACT). Interestingly, in some cases, no increases in in vitro 
IC50 were reported (Noedl et al, 2009; Dondorp et al, 2009; Carrara et al, 2009; Anderson et al, 
2010).  
The majority of cases of increased parasite clearance time are found in the Thai-
Cambodian border. In fact, in this region the parasite population was subjected to strong drug 
pressure during the past 30 years. In the 1980’s, mefloquine (MF) monotherapy was deployed 
(ter Kuile et al, 1992), and later replaced by ATN monotherapy in some areas (Dondorp et al, 
2009). In 1998, the ACT version ATN + MF was implemented as first-line treatment for 
uncomplicated malaria cases, reaching a cure rate of 100% (Nosten et al, 2000).  
Previous selective pressure with each drug of the combination administered separately 
may have been associated with other factors which are characteristic of this region. First, South-
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East Asia is a region where transmission rate is relatively low. This results in low levels of 
genetic recombination between different parasite strains (see Section I.1.3.2). As another 
consequence of low transmission rates, the affected population shows low levels of immunity. 
Thus, most malaria cases are symptomatic, and consequently treated (Luxemburger et al, 1997), 
adding up to the strong selective pressure exerted over the parasite population. Together, these 
factors may explain why this region was the first where the initial signs of ART resistance have 
appeared. 
Nonetheless, increased tolerance to ART derivatives was not only found in the Thai-
Cambodian border. In Central Africa, 15% of cases treated with ATN monotherapy have shown 
recrudescence of parasites (Menard et al, 2005). Similarly to South-East Asian cases, no change 
in in vitro IC50 over time was observed. On the other hand, parasites recrudescing after 
treatment showed a higher IC90 when compared with the parasites from cured infections 
(Menard et al, 2005). 
Regardless of the increasing frequency at which therapy failure cases are reported, the 
mechanisms that may underlie increased ART-tolerance – and maybe ART-resistance in a near 
future – are still not known. A very recent study has attributed a high heritability level to 
increased clearance time after ART treatment, indicating genetic factors as underlying ART 
increased tolerance (Anderson et al, 2010).  
Indeed, many genes have been implicated in resistance to this class of compounds. One 
important candidate is pfatpase6 gene, described as a target for this drug in the previous 
section. The first study to implicate this gene in ART resistance showed that a substitution of a 
serine for an asparagine in position 769 (S769N) was found in six out of seven field samples 
showing lower in vitro sensitivity to artemether in parasites from French Guiana (Jambou et al, 
2005). Many other studies, however, showed that the correlation between mutations in 
pfatpase6 gene and ART tolerance is not always observed (Dahlstrom et al, 2008; Jambou et al, 
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2010). In fact, assuming pfatpase6 has any role in ART resistance and in spite of the many 
polymorphisms found in this gene in different endemic regions, it has been suggested that, 
possibly, not enough ART pressure has been exerted over natural populations in order to select 
the most favourable genotypes (Jambou et al, 2010).  
Amplification of the pfmdr1 gene seems to be involved in ART resistance in many malaria 
models. In field studies, pfmdr1 amplification has been associated with treatment failure 
following ACTs (Price et al, 2004; Alker et al, 2007; Lim et al, 2009; Rogers et al, 2009) and 
increased in vitro tolerance to ATN (Price et al, 1999; Pickard et al, 2003; Lim et al, 2009; 
Chaijaroenkul et al, 2010). Also in P. falciparum laboratory strains, selection of ART-resistant 
parasites has resulted in increased pfmdr1 copy number, followed by increased mRNA and 
MDR1 expression levels (Chavchich et al, 2010). These results are in line with the work 
described by Sidhu and colleagues, where the disruption of one of the two pfmdr1 copies 
present in a P. falciparum drug-resistant strain has led to increased sensitivity to ART (Sidhu et 
al, 2006).  
Evolution of ART-resistance in the rodent model P. yoelii, also selected for parasites 
harbouring 2-to-3-fold increased pymdr1 copy number (Ferrer-Rodriguez et al, 2004). In 
another rodent model, P. chabaudi, MF-resistant parasites carrying two copies of the pcmdr1 
gene show increased tolerance to ART and ATN (Borges, 2009). 
Besides gene amplification, the presence of the Y184F polymorphism in pfmdr1 was 
identified in parasites showing increased in vitro ART-tolerance (Pickard et al, 2003). In 
addition, in a genetic cross performed between a drug-sensitive and a drug-resistant P. 
falciparum clone, the inheritance of the pfmdr1 drug-sensitive allele was associated with 
sensitivity to ART (Duraisingh et al, 2000). Also, analysis of field samples have shown the 
presence of selective sweeps around this locus indicating this gene is under great selective 
pressure associated with ACT use (Nair et al, 2007; Vinayak et al, 2010).   
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Other studies however suggest no implication of changes in the mdr1 gene in ART 
resistance. In these studies, no correlation was found between ART in vivo or in vitro resistance 
and gene amplification or polymorphisms in pfmdr1 sequence (Dondorp et al, 2009; 
Muangnoicharoen et al, 2009; Imwong et al, 2010). Also, in the rodent model P. chabaudi, 
selection for ART or ATN resistance did not result in parasites carrying mutations or 
amplification of pcmdr1 gene (Afonso et al, 2006).  Alternatively, the selection of ART 
resistance in the rodent model P.yoelii has shown changes in expression levels of TCTP. 
However, the resistance phenotype exhibited by this strain was unstable (Walker et al, 2000). 
Stable ART and ATN resistance was first achieved experimentally in the rodent model P. 
chabaudi (Afonso et al, 2006). These parasites showed a mutation in a gene coding for a de-
ubiquitinating enzyme (pcubp1) (Hunt et al, 2007)as will be presented below. 
The appearance of ACT tolerance in natural P. falciparum populations, associated with 
data obtained using laboratory strains suggest that evolution of high levels of resistance to 
ACTs in the field may be not only likely, but also imminent. Therefore, it is important to 
unravel the mechanisms underlying resistance to these drugs.   
 
II.1.2. THE RODENT MALARIA MODEL OF PLASMODIUM CHABAUDI 
Malaria studies do not rely uniquely in the investigation of P. falciparum. As mentioned 
throughout the previous sections many other species are currently used for elucidating aspects 
of the disease, such as pathogen life cycle, host-pathogen interactions, aspects of transmission, 
response to drugs and drug resistance (Janse and Waters, 1995; Carlton and Carucci, 2002; 
Waters, 2002). 
Amongst the many species affecting different vertebrate hosts, rodent models present 
many advantages including easy handling and maintenance of rodent hosts under laboratory 
conditions (Carlton et al, 2005). 
 56 
One of the best models used for building up the current knowledge of malaria is the rodent 
parasite P. chabaudi chabaudi, referred here as P. chabaudi (Carlton et al, 2001). This species 
was first isolated from its original host, the African thicket rat and adapted to laboratory mice 
and rats (Landau and Chabaud, 1965). Its complete schizogonic cycle is synchronous, lasting 
lasts for 24h (Cambie et al, 1990). Apart from its synchronicity, P. chabaudi also shares other 
similarities with the human parasite P. falciparum: for example, it preferentially infects mature 
erythrocytes (Culleton, 2005) and some sequestration of mature trophozoites occurs.  
One great advantage of working with P. chabaudi as a model for malaria studies is that it 
is possible to follow the parasite’s complete life cycle, including sexual recombination in 
mosquitoes. This would be virtually impossible using P. falciparum due to ethical and logistical 
constraints.  
In addition, P. chabaudi shows high level of gene synteny with P. falciparum, i.e. the 
organization of genes along chromosomes shows high degree of conservation when comparing 
rodent and human parasites (Kooij et al, 2005), allowing easy mapping of orthologous genes 
between the two species. 
P. chabaudi’s genome is 18.8Mb in size and has an A + T content of about 77%, which is 
similar to the A + T content observed in P. falciparum (Hall et al, 2005). Currently, the 
Welcome Trust Sanger Institute is focusing efforts in the sequencing and assembly of its 
complete genome. So far, 4391 genes were identified as having orthologues in P. falciparum, 
whereas 736 have none. Most of the genes with no orthologues in P. falciparum are located in 
chromosomic sub-telomeric regions (Hall et al, 2005).  
It is important to note that in spite of the many similarities between Plasmodia species and 
technical advantages of working with rodent models, direct extrapolation to P. falciparum 
malaria must be done with caution. Similarly, results obtained from other models, such as in 
vitro cultured P. falciparum parasites – which represent a well accepted model – must also be 
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interpreted carefully. Although differing in their advantages and shortcomings, the different 
models used for the study of malaria do not faithfully reproduce the biological mechanisms, the 
population size and distribution, selective pressure, host conditions, etc. pertaining to P. 
falciparum natural populations, and therefore, can only help in providing insights for 
understanding the complex phenomena involving the evolution of malaria worldwide, and 
cannot act as a substitute for in vivo research with P. falciparum. 
 
II.1.2.1. AS LINEAGE 
There are many different strains of Plasmodium chabaudi, however, two of them deserve 
special attention within the context of the present work: AS and AJ. Both are sensitive to 
antimalarials used to treat the human pathogen P. falciparum, however, AJ is more virulent 
than AS (de Roode et al, 2005). These two parasites have different genetic backgrounds which 
make them easy to distinguish by simple molecular methods. This allowed their use in several 
studies on parasite virulence and fitness (Mackinnon et al, 2005; de Roode et al, 2005), as well 
as the development of analytical methods for the study of parasite genetics (Walliker et al, 
1975; Grech et al, 2002; Culleton et al, 2005). 
The AS strain has been historically used in the experimental evolution of drug resistance, 
resulting in a series of isogenic parasites which are resistant to many different drugs. These 
parasites were obtained over successive generations through exposure to different antimalarials 
(Figure 3). As a consequence, these parasites should have the same genetic background, with 
mutation in genes involved in resistance to the drug used for the selection of each clone. These 
parasites are part of what will be referred in this work as the AS lineage.  
Initially, as the original drug-sensitive AS-SENS clone were inoculated into laboratory 
mice and exposed to one round of treatment with pyrimethamine (PYR). Parasites that 
recrudesced after treatment were cloned (Walliker et al, 1975) and showed the substitution of a 
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serine to an asparagine in position 106 (S106N) in the orthologue of P. falciparum’s pfdhfr, the 
pcdhfr gene (Hayton et al, 2002). This clone was named AS-PYR and was used for the 
selection of two different clones. One of them AS-50SP, was obtained by sub-inoculation of 
AS-PYR into mice followed by treatment with 4 daily doses of the combination sulphadoxine 
(SDX) and PYR (SP). AS-50SP is resistant to 25 mg/kg of SDX in combination with 1.25 
mg/kg of PYR and shows no mutation in pcdhps, the orthologue of P. falciparum’s pfdhps, 
(Hayton et al, 2002). Instead, the critical mutation is K392Q in the pcmdr2 gene (Martinelli 
unpublished results). The other clone generated from AS-PYR is resistant to low doses of 
chloroquine (CQ), and was named AS-3CQ (Rosario, 1976). In spite of being resistant to CQ, 
no mutation on pcccg10 (orthologue of P. falciparum’s pfcrt) was found (Hunt et al, 2004). 
Recently a mutation has been identified in a gene known as pcaat1, coding for an aminoacid 
transporter, expressed in the parasite’s food vacuole (Modrzynska, 2010). 
AS-3CQ was submitted to further selection with CQ, generating parasites capable of 
surviving intermediate doses of CQ (Padua, 1981). These parasites, named AS-15CQ did not 
represent a clonal population, and, furthermore, underwent mosquito passaging, resulting in 
genetic recombination among the various parasites of the population. The unclonal nature of 
AS-15CQ parasites affected the genetic analysis of AS-15CQ and of the three clones derived 
from it.  
One of the three clones derived from AS-15CQ is AS-30CQ, which is resistant to high 
levels of CQ (Padua, 1981). This clone was subsequently used for the generation of AS-ART, 
by being submitted to stepwise increasing doses of artemisinin (ART) (Afonso et al, 2006). No 
specific mutation was found in AS-ART in the candidate genes previously suggested as 
candidate determinants of resistance to this drug – pcatp6, pctctp and pcmdr1 (Afonso et al, 
2006). Instead, a valine to a phenylalanine in position 2728 (V2728F) of the pcubp1 gene, 
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coding for a de-ubiquitinating enzyme (Hunt et al, 2007) was identified. However, this 
mutation was already present in AS-ART’s parental AS-30CQ.  
The second clone deriving from AS-15CQ was selected by exposure to stepwise increasing 
doses of mefloquine (MF). The selected clone was named AS-15MF and is resistant to four 
daily doses of 5 mg/kg/day of MF. AS-15MF carries two copies of gene pcmdr1 (Cravo et al, 
2003). Pcmdr1’s amplification was shown to be part of a large duplication event where the 
terminal segment of chromosome (chr) 12 underwent a duplication event followed by its 
translocation to the end of chr 4 (Cravo et al, 2003). The duplication of gene pcmdr1 is 
involved in AS-15MF’s resistance to MF, and also to ART and lumefantrine (Borges, 2009). 
Additionally, AS-15MF carries a substitution of a threonine to a proline in position 823 
(T823P) in a gene coding for a putative lysine decarboxylase, whose role in resistance to MF or 
other drugs is still to be determined.  
Finally, AS-15CQ served as progenitor for the generation of a third clone, AS-ATN 
(Afonso et al, 2006). This clone was selected by treatment with stepwise increasing doses of 
ATN, until parasites were capable of recrudescing after treatment with three daily doses of 60 
mg/kg/day of ATN (Afonso et al, 2006). Similarly to AS-ART, AS-ATN does not show 
mutations in the candidate genes involved in resistance to ART derivatives in other models 
(Afonso et al, 2006). Instead, AS-ATN carries a different mutation in the pcubp1 gene, the 
substitution of a valine for a phenylalanine in position 2687 (V2687F). Although in different 
positions (Hunt et al, 2007), both the V2728F mutation (present in AS-30CQ and AS-ART) and 
the V2687F mutation (found in AS-ATN) seem to be present at key functional sites of the 
enzyme coded by pcubp1. These mutations are postulated to cause changes in the enzyme’s tri-
dimensional structure, diminishing its affinity to its substrate (Hunt et al, 2007).  
The summary of the AS lineage, including the mutations known so far is presented in 
Figure 3. 
 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Schematic representation of the AS lineage. Drugs used for the selection of each clone are highlighted 
in red: PYR – pyrimethamine; SP – sulphadoxine-pyrimethamine; CQ – chloroquine; MF – mefloquine; ART – 
artemisinin; ATN - artesunate. The mutations arising in each step are shown in gray.  
 
In conclusion, the parasites belonging to P. chabaudi AS lineage described above have so 
far provided an excellent biological platform for studies on drug resistance. Although many 
studies aimed at the generation and investigation of resistance to drugs which are commonly 
used in ACTs, such as MF and ATN, selection of parasites showing high levels of resistance to 
both drugs simultaneously has never been attempted in P. chabaudi or, to my knowledge, in P. 
falciparum either.  
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II.1.3. AIMS 
In this Chapter, parasites showing different resistant backgrounds were used in order to 
select resistance to the Artemisinin Combination Therapy (ACT) version artesunate + 
mefloquine by different approaches.  
The parasites obtained here were analysed regarding the genetic variants involved in 
resistance to these two drugs. This may provide invaluable data for the surveillance of the 
efficacy of ACTs before the emergence and establishment of high levels of resistance in natural 
parasite populations.   
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II.2. RESULTS 
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II.2.1. SELECTION OF ARTESUNATE + MEFLOQUINE RESISTANCE 
Resistance to the artesunate + mefloquine (ATN + MF) version of Artemisinin 
Combination Therapy (ACT) could emerge in natural P.falciparum populations in two different 
ways. The first is through the appearance of mutants exhibiting low levels of resistance to the 
combination due to inadequate drug treatment  (patients receiving sub-optimal drug doses due 
to mal-absorption, vomiting, counterfeit medication, etc.)  (White et al, 2009) that could then 
give rise to a population of parasites showing high levels of resistance. In addition the presence 
of parasites which are resistant to one of the two drugs of the combination could be present and 
this could facilitate the emergence of parasites that could withstand high levels of ATN and MF 
administered in combination, rendering this version of ACT ineffective. 
An alternative way through which resistance to the ATN + MF combination could emerge 
is by genetic recombination of parasites bearing the genetic traits responsible for resistance to 
each component of the ACT separately, which applies to areas where each component was used 
as a monotherapy over a significant period of time. 
In order to test these assumptions and in an attempt to mimic the conditions occurring in 
natural parasite populations, different approaches were attempted here for the generation of 
resistance to the ATN + MF version of ACT, using the rodent model P. chabaudi. 
 
II.2.1.1. SELECTION OF ARTESUNATE + MEFLOQUINE RESISTANCE THROUGH 
DRUG PRESSURE 
In order to select rare parasite mutants displaying high levels of resistance to the artesunate 
+ mefloquine (ATN + MF) combination, two different parasite clones that had been exposed to 
antimalarials for many generations were used as starting material. One of them was initially 
resistant to mefloquine (MF) and was exposed to stepwise increasing doses of artesunate 
(ATN). The other one was initially resistant to ATN and was exposed to stepwise increasing 
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doses of the ATN + MF combination. In both cases, in each round of selection the drug-
exposed parasite biomass was maximised by infecting individual mice with a very high parasite 
inoculum (10
7
 parasitised red blood cells). In addition, the parasites were allowed to grow for 
two days before drug pressure was applied. Two clones derived from different genetic and 
phenotypic backgrounds were selected as will be described in the following sections. 
 
II.2.1.1.1. EXPOSURE OF A MEFLOQUINE RESISTANT CLONE (AS-15MF) TO 
ARTESUNATE 
SELECTION 
In Plasmodium falciparum natural populations, resistance to mefloquine (MF) was first 
described in South-East Asia in 1990’s, few years after its deployment as first line treatment for 
malaria (ter Kuile et al, 1992). In this region, MF treatment was replaced by artesunate (ATN) 
monotherapy (Dondorp et al, 2009) or for the combination of both drugs (Nosten et al, 2000). 
Recent reports indicate that in this area malaria parasites have developed increased tolerance to 
treatment with this drug combination (Carrara et al, 2009; Dondorp et al, 2009; Noedl et al, 
2009; Anderson et al, 2010). 
In Plasmodium chabaudi, Cravo and colleagues (2003) have generated the MF-resistant 
AS-15MF clone by exposure of a chloroquine-resistant clone (but MF-sensitive) to stepwise 
increasing doses of MF. This clone is resistant to 5 mg/kg/day administered to the host mice for 
three consecutive days (Cravo et al, 2003). Further analysis showed that these parasites also 
display some degree of resistance to artemisinin (ART) in spite of never being exposed to this 
drug previously (Borges, 2009). 
In order to interrogate one of the ways through which resistance to artesunate + 
mefloquine (ATN + MF) in the field may arise, AS-15MF was exposed to stepwise increasing 
doses of ATN alone. Thus, mice were initially inoculated with 10
7
 pRBC and were treated with 
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ATN on Days 3, 4 and 5 post-inoculum (pi). Parasitaemias were monitored and parasites 
surviving after treatment were further passaged into uninfected mice. This procedure was 
repeated for several consecutive rounds. In addition, the AS-15MF parental clone was 
inoculated into mice that were left untreated. These parasites were sub-inoculated in parallel to 
those that were being treated. 
The treated group received an initial dose of 10 mg/kg/day of ATN and parasites were able 
to reach parasitaemias of 5.5% on Day 7 pi (Figure 4). This dose was maintained for a further 
week and at the third week, this was increased to 15 mg/kg/day (Figure 4). At that stage, 
parasites grew well and reached parasitaemias of about 13%, after which the ATN dose was 
increased once more, to 25 mg/kg/day of ATN (Figure 4). Following this round of selection, 
parasites were almost eradicated, being incapable of reaching 1% parasitaemia on Day 7 pi. For 
this reason, the ATN amount was reduced, allowing for improved parasite recovery. 
Subsequently, drug doses given to mice oscillated along the selection procedure, depending on 
the empirical evaluation of parasite recovery following treatment. The evolution of drug doses 
along time is shown in Figure 4. After thirty six weeks the parasites under drug pressure were 
already able to grow after treatment with 60 mg/kg/day of ATN.  
The parallel line of parasites left untreated was also passaged thirty six times through mice 
and will be referred herein as AS-15MF36P. 
 
 
 66 
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
 
 
 Figure 4 – Evolution of doses of artesunate given to mice infected with the AS-15MF clone along the course of 
thirty six weeks of selection.  
 
CLONING 
As shown in Figure 4 above, after thirty-six weeks under drug pressure, parasites were 
able to survive a dose of 60 mg/kg/day of ATN for 3 days. These parasites were then cloned by 
limiting dilution, as described on Material and Methods, Section 2.2.  
After 15 days, one animal showed detectable parasitaemia in the group of twenty mice 
inoculated with 0.5 pRBC, and therefore, the other 19 (95%) of the mice receiving this 
inoculum were parasite-free (see Material and Methods Section 2.2). As such, it was assumed 
that the parasite population carried by this one mouse was clonal. This clone was named AS-
MFATN-1 and stored in liquid nitrogen. 
Similarly, out of twenty animals inoculated with the equivalent of one pRBC, four mice 
showed detectable parasitaemias after 15 days. In this case, 16 (80%) of the mice showed no 
detectable parasitaemia, and parasite-positive mice were also considered as carrying a clonal 
population. Therefore, the parasite clones were extracted from their respective host mice and 
named AS-MFATN-2, AS-MFATN-3, AS-MFATN-4, and AS-MFATN-5. AS-MFATN-5 
displayed the fastest growth following the cloning procedure (Figure 5), and was selected for 
further analysis. The remaining clones were stored in liquid Nitrogen. 
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 Figure 5 – Schematic representation of selection and cloning. The AS-15MF clone used here as starting material 
was submitted to increasing doses of artesunate (ATN) over thirty six weeks and cloned by limiting dilution. This 
process originated five clones. The AS-MFATN-5 clone was characterised further. 
 
 
DRUG SENSITIVITY TEST 
In order to ascertain whether drug resistance was retained after cloning, the growth of AS-
MFATN-5 parasites was assessed under treatment with different drugs. The responses of the 
original parental, AS-15MF, the ATN-resistant AS-ATN clone, and the ATN and MF-sensitive 
AS-3CQ clone were also investigated. The response of the AS-15MF36P parasites (passaged in 
absence of drug treatment during the selection of AS-MFATN-5 clone) was assessed in 
separate experiments, in comparison to the original AS-15MF clone. 
For all drug tests performed here, a group of mice was inoculated with each clone and left 
untreated as a control for parasite growth. The untreated parasites grew as expected, reaching 
peak parasitaemias of 40-to-60 % at Day 6 (Figure 6A and 7A).  
The behaviour of the each clone after treatment will be described in detail below. 
 
 AS-MFAT-5 response to artesunate  
The AS-MFATN-5 clone was obtained by the exposure of a MF-resistant clone to 
increasing doses of ATN alone. Therefore, it could be expected that this clone would be able to 
AS-15MF 
MF resistant clone  
10 mg/kg/day of ATN  60 mg/kg/day of ATN  
AS-MFATN-1 
AS-MFATN-2 
AS-MFATN-3 
AS-MFATN-4 
AS-MFATN-5 
36 weeks  
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survive after treatment with higher doses of this drug, when compared to its progenitor AS-
15MF. Indeed, after treatment with 70 mg/kg/day of ATN, AS-MFATN-5 was able to establish 
a peak parasitaemia of about 20% on Day 8. The parental AS-15MF and AS-ATN showed a 
lower response (peak at 5% on Day 9 and 9% Day 10 p.i., respectively). In contrast, the 
sensitive AS-3CQ clone only reached peak parasitaemia around Day 15 (Figure 6B). 
 
AS-MFAT-5 response to mefloquine 
As mentioned previously, AS-MFATN-5 derives from AS-15MF which survives 5 
mg/kg/day of MF for four days (Cravo et al, 2003).  
As shown in Figure 6C, after treatment with 8 mg/kg/day of MF, the AS-MFATN5 clone 
was able to grow and reach peak parasitaemia of about 25%, whereas AS-15MF only showed a 
peak parasitaemia of about 3.5%, both on Day 9. This indicates that the AS-MFATN-5 clone 
selected here seems to have evolved an increase in the level of MF resistance when compared to 
its progenitor, AS-15MF. This dose was enough to prevent the ATN-resistant clone, AS-ATN, 
to recrudesce until about Day 12. The ATN and MF-sensitive AS-3CQ clone was almost 
completely eradicated by this dose (Figure 6C).   
 
 AS-MFAT-5 response to the combination of artesunate and mefloquine 
We wished to investigate whether the increase in resistance of AS-MFATN-5 to ATN and 
MF when given separately would also be reflected as increased resistance to the combination. 
When treated with doses of 7 mg/kg/day of MF in combination with 45 mg/kg/day of 
ATN, the AS-MFATN-5 clone recrudesced on Day 4, reaching peak parasitaemias of about 
60% on Day 7. Mice inoculated with AS-15MF showed detectable parasitaemias on Day 4-5 
but these animals reached peak of parasitaemias of only 13% on Day 7. AS-ATN recrudesced 
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on Day 10, reaching peak parasitaemia of 10.6% on Day 15. AS-3CQ recrudesced on Day 13, 
showing peak parasitaemia of 10% on Day 15 (Figure 6D). 
 
 
 
 
          
 
 
          
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Response to drug of different clones was assessed. (A) Untreated controls received DMSO vehicle. 
Clones were treated with different drugs as follows: (B) treatment with 70 mg/kg/day of artesunate (ATN); (C) 
treatment with 8 mg/kg/day of mefloquine (MF); and (D) treatment with 7 mg/kg/day of MF in combination with 
45 mg/kg/day of ATN. Each point represents the mean percentage (%) parasitaemia of at least five mice 
determined daily. Red squares represent the clone selected here AS-MFATN-5; black squares represent the 
parental AS-15MF clone; gray triangles represent AS-ATN clone; burgundy diamonds represent AS-3CQ. 
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AS-15MF36P PHENOTYPE 
As described above, a group of parasites was left untreated and was passaged through mice 
thirty six times simultaneously with the treated parasites that gave origin AS-MFATN-5. These 
parasites were named AS-15MF36P and their response to drugs was assessed and compared to 
the original AS-15MF clone.  
The AS-15MF36P parasite population seems to have experienced a reduction in its level of 
resistance to ATN. The dose of 50 mg/kg/day was enough to prevent its growth until Day 8. 
After treatment with the same dose, the original AS-15MF recrudesced on Day 4, reaching peak 
parasitaemia of about 7%, on Day 7 (Figure 7B). 
When treated with 5 mg/kg/day of MF, AS-15MF36P parasites were not able to grow 
beyond vestigial levels (about 0.5%) until Day 8. In accordance with previously published data 
(Cravo et al, 2003), the original clone, AS-15MF was able to grow after treatment with this 
dose of MF. Thus, AS-15MF showed parasitaemias of 1.5% on Day 4, with peak parasitaemia 
at about 14.5% on Day 7 (Figure 7C). In addition, AS-15MF36P was not able to grow after 
treatment with the ATN + MF combination. Treatment with 3 mg/kg/day of MF plus 20 
mg/kg/day of ATN was enough to prevent AS-15MF36P parasite growth beyond vestigial 
levels. Under treatment with the same dose, the original AS-15MF reached peak parasitaemia at 
about 2% on Day 7 (Figure 7D). 
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Figure 7 – Response to drug of different clones was assessed. (A) Untreated controls received DMSO vehicle. 
Clones were treated with different drugs as follows: (B) treatment with 50 mg/kg/day of artesunate (ATN); (C) 
treatment with 5 mg/kg/day of mefloquine (MF); and (D) treatment with 3 mg/kg/day of MF in combination with 
20 mg/kg/day of ATN. Each point represents the mean percentage (%) parasitaemia of at least five mice 
determined daily. Black squares represent the parental AS-15MF and gray squares represent the population 
passaged thirty six weeks in absence of drug, AS-15MF36P.  
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SUMMARY 
As described above the objective intended here was to select an artesunate + mefloquine 
(ATN + MF)-resistant clone by exposure of mefloquine (MF)-resistant parasites to stepwise 
increasing doses of artesunate (ATN) alone. Thus, five clones were obtained: AS-MFATN-1, -
2, -3, -4, and -5. The AS-MFATN-5 clone was further analysed regarding its level of resistance 
to the combination ATN + MF, as well as to each drug alone.  
Collectively, results showed that a resistant parasite was successfully generated, as AS-
MFATN-5 displayed higher levels of resistance to ATN and the ATN + MF combination when 
compared to its progenitor AS-15MF.  Interestingly, AS-MFATN-5 shows increased resistance 
to MF too, despite no further selection with this drug, suggesting that the genetic determinants 
of ATN resistance also mediate augmented MF resistance phenotypes.   
In addition, the AS-15MF clone was passaged through mice in absence of drug pressure 
simultaneously with the treated parasites that generated AS-MFATN-5. After thirty six 
passages, the untreated parasites AS-15MF36P had their response to drug assessed. AS-
15MF36P displayed a reduced level of resistance to ATN, MF and to the ATN + MF 
combination when compared to the original AS-15MF clone. Thus, these results suggest that 
the original AS-15MF resistance phenotype was reversed after prolonged in vivo passaging in 
the absence of drugs. 
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II.2.1.1.2. EXPOSURE OF THE ARTESUNATE RESISTANT CLONE AS-ATN TO 
ARTESUNATE + MEFLOQUINE 
SELECTION 
The previous sections described the selection of artesunate + mefloquine (ATN + MF) 
resistance using the mefloquine (MF)-resistant AS-15MF clone as starting material. In parallel, 
the AS-ATN clone, resistant to four daily doses of 60 mg/kg/day of artesunate (ATN) (Afonso 
et al, 2006) was used as starting material for selection of ATN + MF resistance. This clone was 
submitted to treatment with ATN in combination with MF, on Days 3, 4 and 5 post-inoculum 
(pi). On Day 7, the parasites surviving after treatment were passaged into uninfected mice. In 
addition to the treated parasites, a line of AS-ATN was sub-inoculated consecutively in parallel, 
but left untreated. 
The starting selecting dose was 1 mg/kg/day of MF in combination with 5 mg/kg/day of 
ATN, and on Day 7 pi the parasites reached a parasitaemia of almost 30%. ATN was then 
increased to 10 mg/kg/day, whereas the MF dose was maintained (1 mg/kg/day). For the 
following two weeks, parasites seemed to adapt well, and accordingly drug doses were 
increased to 2 mg/kg/day of MF plus 20 mg/kg/day of ATN. However, after two weeks, this 
drug dose appeared to have caused the complete eradication of the parasite population in the 
host mice, forcing a restart of the process from the previous round of selection. The dose of 2 
mg/kg/day of MF plus 20 mg/kg/day of ATN was thus maintained for a further four weeks, 
until parasites were able to reach high parasitaemias on Day 7 (around 24%). ATN amounts 
were then increased to 25 mg/kg/day, but this was met with limited success, as parasites did not 
recover well after treatment. In order to avoid losing the parasites for a second time, ATN was 
lowered again. From this stage onwards, parasites started to display a slightly improved 
recovery (Figure 8). 
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At the end of the 27
th
 week of selection, parasites were able to survive a treatment of 3.5 
mg/kg/day of MF in combination with 30 mg/kg/day of ATN.  
As mentioned at the beginning of the section, AS-ATN was also inoculated into mice that 
were left untreated and were passaged to new mice in parallel with the treated group for twenty 
seven times. This parasite population will be herein referred to as AS-ATN27P. 
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Figure 8 – Evolution of doses of mefloquine (MF) (gray squares) and artesunate (ATN) (black diamonds) 
administered in combination to mice infected with AS-ATN along the course of twenty seven weeks of selection.  
 
CLONING 
After twenty-seven weeks the parasites selected by drug pressure as described above were 
cloned by limiting dilution. Thus, blood of mice infected with drug selected parasites was used 
for inoculating new mice as described in Material and Methods, Section 2.2.  
On Day 11, eight animals from the group of twenty mice inoculated with the equivalent of 
one pRBC showed detectable parasitaemias, which means that 60% of mice were not infected.  
On the other hand, after eleven days, only five out of twenty mice inoculated with the 
equivalent of 0.5 pRBC were parasitized, i.e. 75% of mice did not show detectable 
parasitaemias. Considering that in both cases the percentage of uninfected mice was higher than 
37%, theoretically both one and 0.5 pRBC inoculums resulted into successful cloning (see 
Material and Methods, Section 2.2). However, only the parasites present in the five mice 
Time (weeks) 
D
o
se
 o
f 
M
F
 (
m
g
/k
g
/d
ay
) 
D
o
se o
f A
T
N
 (m
g
/k
g
/d
ay
) 
 75 
inoculated with 0.5 pRBC were stored for further analysis, since these are statistically more 
likely to be clonal. These clones were named AS-ATNMF-1, AS-ATNMF-2, AS-ATNMF-3, 
AS-ATNMF-4, and AS-ATNMF-5 (Figure 9), with AS-ATNMF-1 clone exhibiting the fastest 
growth rate. 
AS-ATNMF-1 was further characterised regarding its phenotype and genetic background, 
whereas the other four clones were only inspected for the presence of mutations identified by 
Solexa whole genome re-sequencing analysis below.  
 
 
 
 
 
 
 
 Figure 9 – Schematic representation of selection and cloning. The AS-ATN clone used here as starting material 
was submitted to increasing doses of mefloquine (MF) in combination with artesunate (ATN) over twenty seven 
weeks, after which was cloned by limiting dilution. This process originated five clones. The AS-ATNMF-1 clone 
is the one exhibiting the fastest growth rate and will be further characterised.  
 
DRUG SENSITIVITY TEST 
After twenty seven weeks of being passaged under treatment with ATN + MF combination 
and following cloning in the absence of drug, the level of resistance of AS-ATNMF-1 to both 
drugs given separately or in combination was assessed. The responses of the original parental 
AS-ATN, the parasites passaged in absence of drug treatment AS-ATN27P, the MF-resistant 
AS-15MF clone and the ATN and MF-sensitive AS-3CQ clone were also investigated. 
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Five groups of mice were inoculated with each clone and left untreated. These parasites 
grew normally and reached peak parasitaemias of 40-to-80% at Day 5 or 6 post-inoculum (pi) 
(Figure 10).  
The responses of each clone to the different drug treatments will be described in detail in 
the following sections. 
 
AS-ATMF-1 response to artesunate 
In order to assess whether the evolution of ATN + MF resistance could have caused 
increased resistance to ATN given alone, AS-ATNMF1 was tested for its response to this drug 
in comparison to its AS-ATN progenitor. 
After treatment with 80 mg/kg/day of ATN, AS-ATNMF-1 recrudesced earlier than its 
progenitor (Figure 10B). AS-ATNMF-1 recrudesced on Day 4 while AS-ATN recrudesced one 
day later (Day 5).  
The untreated parasite AS-ATN27P displayed an increased growth delay, recrudescing on 
Day 8 only, and showing peak parasitaemias of 26% on Day 12 (Figure 10B). 
Interestingly, ATN did not cause significant delay in recrudescence and growth of the MF-
resistant parasite AS-15MF in comparison to AS-ATNMF-1 (Figure 10B). By observing the 
first seven days of the drug test, AS-15MF appears to display a phenotype resembling that of 
AS-ATNMF-1, as both clones show recrudescence on Day 4, and approximately similar 
parasitaemias by Day 7 (12% and 16%, respectively). However, there was a noticeable 
persistence in the infection for AS-ATNMF-1 and AS-ATN until at least Day 14 p.i. which was 
not observed for AS-15MF.  The ATN and MF-sensitive AS-3CQ recrudesced on Day 6. 
However, it was never able to establish parasitaemias above 4%. 
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AS-ATMF-1 response to mefloquine 
In order to assess AS-ATNMF-1’s response to MF administered alone, AS-ATNMF-1’s 
growth was compared to the progenitor AS-ATN, and also to the MF-resistant AS-15MF clone 
and to the ATN and MF-sensitive AS-3CQ clone after treatment with three daily doses of 8 
mg/kg/day of MF. 
AS-ATNMF-1 is more resistant to MF alone than its progenitor, AS-ATN, when treated 
with 8 mg/kg/day of MF. Mice infected with AS-ATNMF-1 were able to show detectable 
parasitaemias on Day 4 pi, reaching peak parasitaemia of about 21% on Day 8 pi. In contrast, 
AS-ATN was not able to recrudesce until Day 11 pi. The parasites derived from AS-ATN, 
passaged through mice twenty seven times in the absence of drug pressure (AS-ATN27P), 
showed similar growth as AS-ATN (Figure 10C). 
The MF-resistant AS-15MF clone displayed parasitaemias of about 2.5% on Day 4 pi. 
However, this clone was never able to establish high parasitaemias, reaching its peak on Day 8 
at 5.5%. AS-3CQ was not able to recrudesce after treatment (Figure 10C). 
 
AS-ATMF-1 response to the combination of artesunate and mefloquine 
AS-ATNMF-1 was selected by treatment with increasing doses of the combination ATN + 
MF. In order to assess if selection resulted in parasites displaying high levels of resistance to 
these two drugs in combination, AS-ATNMF-1’s growth was compared with AS-ATN, AS-
15MF and AS-3CQ, after 3 daily doses of 4 mg/kg/day of MF in combination with 40 
mg/kg/day of ATN. 
Under the above mentioned conditions AS-ATNMF-1 was able to recrudesce on Day 7 
and reach peak parasitaemia of about 47% on Day 11. When treated with the same dose, its 
progenitor, AS-ATN was able to recrudesce on Day 8, reaching parasitaemias of about 20% on 
Day 14 (Figure 10D). Interestingly, the AS-ATN27P population derived from AS-ATN after 
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twenty seven weeks in absence of drug treatment took longer to recrudesce than AS-ATN 
(around Day 12). Similarly, the MF-resistant AS-15MF clone was also able to recrudesce on 
Day 12, whilst mice infected with the ATN and MF-sensitive AS-3CQ clone never showed 
detectable parasitaemias during the follow-up period (Figure 10D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (days pi) 
%
 P
ar
as
it
ae
m
ia
 
%
 P
ar
as
it
ae
m
ia
 
Untreated controls 
Time (days pi) 
B 
A 
80 mg/kg/day of ATN 
 79 
0.0
20.0
40.0
60.0
4 5 6 7 8 9 10 11 12 13 14
AS-3CQ
AS-15MF
AS-ATN
AS-ATN27P
AS-ATNMF-1
0.0
20.0
40.0
60.0
80.0
100.0
4 5 6 7 8 9 10 11 12 13 14
AS-3CQ
AS-15MF
AS-ATN
AS-ATN27P
AS-ATNMF-1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 10 – Response to drug of different clones was assessed. Clones were treated with different drugs as follows: 
(A) untreated controls (DMSO vehicle); (B) treatment with 80 mg/kg/day of artesunate (ATN); (C) treatment with 
8 mg/kg/day of mefloquine (MF); and (D) treatment with 4 mg/kg/day of MF in combination with 40 mg/kg/day of 
ATN. Each point represents the mean percentage (%) parasitaemia of at least five mice determined daily. Red 
triangles represent the clone selected here AS-ATNMF-1; gray triangles represent the parental AS-ATN clone; 
gray diamonds and dashed line represente the parasites passaged twenty seven weeks in absence of drug; black 
squares represent AS-15MF; and burgundy diamonds represent AS-3CQ.  
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SUMMARY  
The objective was to select and clone parasites resistant to the artesunate + mefloquine 
(ATN + MF) combination using a clone showing limited resistance to artesunate (ATN) as 
starting material. To that purpose, the AS-ATN clone was exposed to stepwise increasing doses 
of ATN and mefloquine (MF) administered simultaneously. Five clones were obtained: AS-
ATNMF-1, -2, -3, -4, and -5. AS-ATNMF-1 was further analysed regarding its response to the 
ATN + MF combination, as well as to ATN and MF administered separately.  
Collectively, the results showed that by following this approach, a resistant parasite was 
generated, as AS-ATNMF-1 displayed higher levels of resistance to the ATN + MF 
combination, as well as to MF administered alone when compared to its progenitor, AS-ATN, 
and to the MF-resistant clone, AS-15MF. In addition, AS-ATNMF-1 shows a slight increase in 
its level of resistance to ATN administered alone when compared to its progenitor AS-ATN, 
but not to the MF-resistant AS-15MF.  
In addition, during the selection procedure, the AS-ATN clone was passaged through mice 
in absence of drug treatment in parallel with the treated parasites. After twenty seven sub-
inoculations, the response to drug treatment with the ATN + MF combination as well as each 
drug alone of the AS-ATN27P parasites was assessed. Our observations indicated that after 
consecutive sub-inoculations in the absence of drug, AS-ATN27P shows a slight decrease in its 
level of resistance to ATN + MF combination, as well as to ATN and MF administered 
separately, when compared to the original AS-ATN clone, suggesting that the resistance 
phenotype was reversed in the absence of continuous drug pressure. 
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II.1.1.2. SELECTION OF ARTESUNATE + MEFLOQUINE RESISTANCE THROUGH 
GENETIC CROSSING 
It has been postulated that one of the advantages of the administration of artemisinin 
derivatives in combination with drugs with a distinct mode of action is that the appearance of 
resistance to both drugs simultaneously would require the appearance of parasites bearing 
mutations in at least two different genes belonging to each of the pathways targeted by each 
drug (White, 1999). However, in the case of the use of each component of the combination as 
monotherapy, resistance to each drug could appear separately, and therefore, two different sub-
populations of parasites could exist. If a single host were infected with each of these sub-
populations and then, gametes generated by these sub-populations were to mate in the 
mosquito, a “double-resistant” parasite could rise from the cross progeny, due to genetic 
recombination of the two parental groups of parasites. The “double-resistant” offspring would 
carry resistant alleles of genes underlying resistance to each drug, and as a consequence, be 
resistant to the two drugs administered simultaneously.   
In order to test this hypothesis, a mosquito cross between the ATN-resistant AS-ATN 
clone and the MF-resistant AS-15MF clone was attempted. Two genetic markers originating 
from each of the two parental clones were analysed. This analysis revealed that only the AS-
ATN parental alleles were present in the resulting cross progeny. There are two possible 
explanations to this finding: i) no self-fertilisation of AS-15MF gametes or cross-fertilisation of 
AS-15MF gametes with AS-ATN gametes took place; or ii) cross-fertilisation did take place 
between AS-ATN and AS-15MF clones, however, the AS-15MF alleles of markers analysed 
here were present in the cross-progeny in small amounts, and remained undetected. 
As this genetic cross did not produce clear results, the analysis of the parasites generated here 
was discontinued. The full description of the results obtained for this experiment are presented 
as an Appendix (Appendix I). 
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SECTION SUMMARY 
Two different clones with distinct genetic backgrounds were used for the selection of 
resistance to the combination ATN + MF. In this context, AS-ATNMF-1 and AS-MFATN-5, 
were generated from AS-ATN and AS-15MF, respectively.  
In addition, the above parasites displayed increased tolerance to each of the drugs of the 
combination when administered separately.  
In parallel, the parental AS-15MF and AS-ATN were passaged by consecutive sub-
inoculations in mice, and two groups of parasites were obtained: AS-15MF36P and AS-
ATN27P.  Whereas AS-ATN27P seems to have a very slight decrease in the level of sensitivity 
to ATN and MF compared to AS-ATN, AS-15MF36P displayed reduced levels of resistance to 
these drugs when compared to the original AS-15MF. 
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II.2.2. GENETIC CHARACTERISATION OF RESISTANT CLONES 
As described above, two distinct clones were successfully selected by drug pressure. One 
of them derives from the mefloquine (MF)-resistant AS-15MF clone, and was named AS-
MFATN-5. The other one derived from the artesunate (ATN)-resistant AS-ATN clone, and was 
named AS-ATNMF-1. In spite of their different backgrounds, both clones display considerably 
high levels of resistance to the artesunate + mefloquine (ATN + MF) combination, as was the 
first objective intended here.  
Two main approaches were employed to determine the genetic basis of the phenotype 
displayed by the multi-drug resistant clones generated in the course of this study; a candidate 
gene approach and a ‘de novo’ genetics/genomics approach.  Firstly, the sequences of candidate 
genes which were previously related to resistance to ATN and MF were investigated. Thus, the 
coding sequences of the pcatp6 and pcubp1 genes were determined for both AS-ATNMF-1 and 
AS-MFATN-5 clones and compared with their progenitors. The copy number, mRNA 
expression and protein amounts of MDR1 was also determined in resistant clones. 
Secondly, a genome-wide approach (Linkage Group Selection, LGS) was applied in order 
to locate the locus or loci where phenotypically relevant mutations have occurred. For this 
purpose, a genetic cross between the AS-ATNMF-1 clone and the sensitive and genetically 
unrelated AJ clone, under treatment with different drugs was produced and analysed.  
Complementary to LGS, the whole genome of the AS-ATNMF-1 clone was re-sequenced 
using a second generation genome re-sequencing method, known as Solexa (Illumina, Inc.), and 
some of the mutations found using this methodology were validated through traditional di-
deoxy sequencing.  
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II.2.2.1. GENETIC ANALYSIS OF RESISTANT CLONES 
In order to assess if the evolution of resistance to artesunate + mefloquine (ATN + MF) 
had selected particular genetic mutations, a candidate gene approach was used. The 
involvement of genes previously described as putatively involved in resistance to artesunate 
(ATN) and mefloquine (MF) were analysed as described below. 
 
pcatpase6 
SERCA type Ca
++
 ATPase is considered a possible intracellular target of artemisinin 
(ART) derivatives (Eckstein-Ludwig et al, 2003). In P. chabaudi, the homologue of this protein 
is coded by the pcatpase6 gene (PCHAS_020540). Overlapping fragments covering the gene’s 
coding sequence were amplified by PCR and sequenced for both AS-ATNMF-1 and AS-
MFATN-5. 
No changes were found when comparing each clone with the reference sequence retrieved 
from the Welcome Trust Sanger Institute website (see Material and Methods Section 3.7.1).  
 
pcubp1 
When inducing increased ATN resistance, Hunt and colleagues (2007) identified a 
mutation in a gene denoted pcubp1 (PCHAS_020720). This gene codes for a deubiquitinating 
enzyme, which is involved in protein turn-over pathways. The G8089T mutation found in AS-
ATN is exclusive to this clone and codes for the substitution of a valine to a phenylalanine in 
aminoacid 2697 (V2697F) (Hunt et al, 2007). This mutation is believed to be involved in the 
expression of the ATN-resistant phenotype. Pcubp1 is also mutated in other clones of the AS 
lineage, i.e. AS-15MF, AS-30CQ and AS-ART. However, in these clones, a G to T mutation is 
found in position 8182 and codes for a valine to phenylalanine substitution in aminoacid 2728 
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(V2728F). This mutation is also believed to have a role in resistance to ART derivatives (Hunt 
et al, 2007). 
Similarly to what was described above for pcatpase6, overlapping fragments were 
amplified and sequenced for both AS-ATNMF-1 and AS-MFATN-5, as well as for their 
respective progenitors, AS-ATN and AS-15MF. Only the final 3500 bp of pcubp1 gene were 
sequenced.  This is because this work was carried out prior to a new annotation which merged 
this gene with the preceding gene (full length gene is 8766 bp, as currently annotated in 
GeneDB)  
The analysis of the final 3500 bp fragment of pcubp1 revealed no changes when 
comparing the sequences obtained for each of the clones selected for ATN + MF resistance and 
their respective progenitors. Therefore, AS-ATNMF-1 carries the G8089T mutation, also 
present in its progenitor AS-ATN, and AS-MFATN-5 shows the G8182T mutation, which is 
also borne by it progenitor AS-15MF. 
As will be presented below, the complete genome sequence of AS-ATNMF-1 clone was 
obtained by Solexa whole genome sequencing technique, and no additional mutations were 
identified in the initial 5266 bp segment of pcubp1 gene.  
The whole genome analysis of AS-MFATN-5 is scheduled to be performed in the near 
future; alternatively, the overlapping fragment technique could be applied for the initial 
fragment of pcubp1, allowing the determination of additional mutations appearing in this 
portion of the gene. 
 
pcmdr1 
Copy number variation 
Amplification of the mdr1 gene is responsible for increased resistance to MF and also to 
ART derivatives both in human parasites (either field or laboratory strains) (Price et al, 1997; 
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Price et al, 1999; Pickard et al, 2003; Price et al, 2004; Alker et al, 2007; Lim et al, 2009; 
Chaijaroenkul et al, 2010; Chavchich et al, 2010) and in rodent models (Gervais et al, 1999; 
Cravo et al, 2003; Ferrer-Rodriguez et al, 2004; Borges, 2009). As such, pcmdr1 copy number 
was determined for AS-MFATN-5 and AS-ATNMF-1 clones. Three clones were used as 
controls, as follows:  AS-SENS and the two progenitors AS-15MF and AS-ATN.  Note that 
AS-15MF is known to carry two copies of the pcmdr1 gene (Cravo et al, 2003); AS-ATN and 
AS-SENS, each harbouring a single copy of this gene (Afonso et al, 2006). The data normalised 
against AS-SENS and AS-ATN is presented in Table 1 below. 
The MF-resistant AS-15MF clone was confirmed to carry 2 copies of the pcmdr1 gene 
relative to the AS-ATN clone (1.5 ± 0.12 (p<0.00001), and the AS-SENS clone (1.6 ± 0.12 
(p<0.001). This gene amplification is in line with previous work that indicates that the pcmdr1 
gene is duplicated in AS-15MF (Cravo et al, 2003).  
Importantly, AS-MFATN-5 has acquired a further copy of pcmdr1 relative to its 
progenitor AS-15MF (p<0.0002).  Mdr1 gene copy number is estimated to be 2.8 (± 0.85, 
p<0.001) and 2.7 ( ± 0.44, p<0.00001) relative to the negative controls AS-SENS and AS-ATN, 
respectively) (Table 1). 
For AS-ATNMF-1 too, there was an increase in pcmdr1 copy number; to 1.8 (± 0.37, 
p<0.001) and 1.8 (± 0.09, p<0.00001) relative to AS-SENS and the progenitor AS-ATN, 
respectively (Table 1).  
Interestingly, the AS-15MF36P parasite population shows the loss of one of the two copies 
originally present in the original unpassaged AS-15MF clone (0.9 ± 0.09 relative to AS-ATN, 
p<0.0001) (Table 1).  
In agreement with previous work (Afonso et al, 2006), the analysis carried out here 
showed that the ATN-resistant AS-ATN clone harbours a single copy of pcmdr1 gene (1.0 ± 
0.20 relative to AS-SENS) (Table 1). Similarly, the AS-ATN27P parasite population passaged 
 87 
twenty seven times in absence of drug remained unchanged when comparing to the original AS-
ATN. Thus, AS-ATN27P also shows a single copy of pcmdr1 (0.7 ± 0.08 relative to AS-ATN).  
 
 
mean SE mean SE
AS-SENS ‾ 1,0 ± 0,09
AS-15MF 1,6 ± 0.12   * 1,5 ± 0.05  **        
AS-MFATN-5 2,8 ± 0.38   * 2,7 ± 0.20  **  
AS-15MF36P 0,9 ± 0,1 0,9 ± 0,04
AS-ATN 1,0 ± 0,09 
AS-ATNMF1 1,8 ± 0.17   * 1,8 ± 0.04  **
AS-ATN27P 0,7 ± 0,04
AS-SENS AS-ATN
 †
 
 
Table 1 – Copy number of pcmdr1 gene. Genomic DNA of different clones was analysed by Real-Time PCR. The 
values were normalized against the drug-sensitive AS-SENS clone or the artesunate-resistant AS-ATN clone, as 
indicated. Results are expressed as means of five experiments ± standard error (SE) of the mean. (*) p< 0.001; (**) 
p<0.00001; (†) p<0.0002.  
 
 
 RA expression  
Changes in copy number of pcmdr1 gene have been previously associated with 
modifications in the level of RNA expression (Wilson et al, 1989; Peel et al, 1994; Cowman et 
al, 1994; Chavchich et al, 2010). 
In order to assess whether this is the case for the ATN + MF-resistant AS-ATNMF-1 
clone, RNA was extracted from blood infected with the AS-3CQ, AS-15MF, AS-ATN, AS-
ATN27P, and AS-ATNMF-1 clones. cDNA was synthesised, as described in Material and 
Methods, Sections 3.3 and 3.4, and subsequently analysed by Real-Time PCR. Here, AS-3CQ 
mdr1 Copy Number 
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was used as a control instead of AS-SENS. Similarly to AS-SENS, used for the determination 
of pcmdr1’s copy number, AS-3CQ is also ATN and MF-sensitive and carries a single copy of 
pcmdr1 gene. 
AS-ATNMF-1 showed increase expression of the pcmdr1 gene as indicated in Table 2. In 
line with an increase of genomic copies, AS-ATNMF-1 also displayed higher levels of pcmdr1 
RNA expression relative to its progenitor, AS-ATN clone and to AS-3CQ (2.6 ± 0.03, 
p<0.00002 and 3.4 ± 0.22, p<0.00002, respectively). AS-15MF (which contains two copies of 
this gene) presented similar levels of RNA expression when compared to AS-ATNMF-1 (2.5 ± 
0.39, p<0.00002 and 2.1 ± 0.34, p<0.01, normalised against AS-3CQ and AS-ATN, 
respectively). Additionally, in agreement with the results obtained for copy number, the AS-
ATN clone and the untreated population derived from it, AS-ATN27P (both shown to carry a 
single copy of this gene) have similar levels of RNA expression when normalised against AS-
3CQ (1.4 ± 0.06 and 1.2 ± 0.22, respectively). 
One surprising feature worth highlighting is the difference in expression found when 
comparing AS-ATN and AS-3CQ. Although both clones only carry one copy of pcmdr1 gene, 
AS-ATN seems to have statistically significant increased level of RNA expression relative to 
AS-3CQ (1.4 ± 0.006, p<0.0003) (Table 2). 
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AS-3CQ AS-ATN 
  mean   SE mean   SE 
AS-3CQ -   0.7 ± 0.08  * 
AS-ATN 1.4 ± 0.06  ** -   
AS-ATNMF1 3.4 ± 0.22  *** 2.6 ± 0.17  *** 
AS-ATN27P 1.2 ± 0.07 0.9 ± 0.03 
AS-15MF 2.5 ± 0.39  * 2.1 ± 0.34   † 
 
Table 2 – RNA expression of pcmdr1 gene determined by Real-Time PCR. cDNA was synthesised from RNA and 
analysed. Values were normalised against the artesunate and mefloquine-sensitive AS-3CQ clone and the 
artesunate-resistant AS-ATN clone, as indicated. Results are expressed as means of five experiments ± standard 
error (SE). (†) p<0.01, (*) p<0.004, (**) p<0.0003, (***) p<0.00002.  
 
 
 
Protein expression  
The mdr1 gene codes for the homologue of the human P-gp1, an ATP-dependent efflux 
pump known in Plasmodium as MDR1 (Foote et al, 1989; Wilson et al, 1989). 
In order to ascertain whether an increase in copy number and higher levels of RNA 
expression is also reflected in the level at which MDR1 protein is expressed, Western Blot 
analyses were carried out. In addition to AS-ATNMF-1, MDR1 expression was quantified in 
AS-ATN, AS-ATN27P, AS-15MF and AS-3CQ (Figure 11).  
AS-ATNMF-1 revealed a 4-to-6-fold increase in MDR1 expression, relative to AS-3CQ 
and to AS-ATN (5.8 ± 0.44, p<0.005 and 4.5 ± 0.78, p<0.05 respectively) (Figure 11B). These 
observations are in agreement with the duplication of pcmdr1 and the higher levels of RNA 
expression displayed by AS-ATNMF-1. However, while there seems to be a duplication in both 
gene copy number and RNA levels, the levels of MDR1 expression are four-to-five-fold higher 
mdr1 RNA Expression 
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when comparing AS-ATNMF-1 and AS-ATN. This disproportional increase may be indicative 
of some type of post-transcriptional or post-translational regulation. 
Also, in line with copy number and RNA expression of pcmdr1, the AS-15MF clone 
seems to have similar levels of MDR1 expression of to those of AS-ATNMF-1 (6.2 ± 0.88, 
p<0.005 and 5.1 ± 0.28, p<0.005 normalised against AS-3CQ and AS-ATN, respectively). 
Again, in AS-15MF, MDR1 expression levels show a disproportional increase (five-to-six-fold) 
when compared to pcmdr1 gene copy number and RNA expression (about two-fold). 
When comparing AS-3CQ and AS-ATN, both carrying a single copy of pcmdr1, there 
seems to be a slight difference between the two. AS-ATN shows 1.39 ± 0.17 expression of 
MDR1 when compared to AS-3CQ (p<0.05) (Figure 11B). These results seem to be in 
agreement with the level of RNA expression displayed by these clones, where AS-ATN seems 
to show a slightly higher level of RNA expression of pcmdr1 than AS-3CQ. 
Interestingly, in spite of having only one copy of pcmdr1 and showing similar levels of 
RNA expression as AS-ATN, the untreated parasites AS-ATN27P seem to have an almost two-
fold increase in expression of MDR1 when compared to the original AS-ATN (1.8 ± 0.16, 
p<0.05 and 2.4 ± 0.32, p<0.01, normalised against AS-ATN and AS-3CQ, respectively). 
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AS-3CQ 
 
 
AS-ATN 
  mean   SE mean   SE 
AS-3CQ -   0.7 ± 0.09 
AS-ATN 1.4 ±  0.17  * -   
AS-ATNMF1 5.8 ±  0.44  *** 4.5 ±  0.78  * 
AS-ATN27P 2.4 ±  0.32  ** 1.8 ±  0.16  * 
AS-15MF 6.2 ±  0.88  *** 5.1 ±  0.28  *** 
 
 
Figure 11 - pcmdr1 expression (MDR1 expression) determined by Western Blot. Protein extracts were prepared 
from erythrocyte stage parasites and analysed. Values were normalised against AS-3CQ and AS-ATN, as 
indicated. Results are expressed as means of five experiments ± standard error (SE).  (*) p<0.05, (**) p<0.01, 
(***) p<0.005. 
 
 
A summary of all the results obtained for copy number, RNA and protein expression of 
pcmdr1 gene are depicted in Figure 12. The values were normalised against AS-3CQ (or AS-
SENS, for copy number) (Figure 12A) or AS-ATN (Figure 12B). 
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Figure 12 – Summary of data obtained for copy number, RNA and protein expression of pcmdr1 gene. Copy 
number (gDNA, for genomic DNA) is shown as black bars; RNA expression (cDNA, for complementary DNA), as 
dark gray bars; and protein expression, as light gray bars. The bars represent the mean of at least five experiments 
and standard errors are represented by black lines. (A) Samples were normalised against AS-SENS (copy number) 
or AS-3CQ (RNA and protein expression). (B) Samples were normalised against AS-ATN. (+) AS-3CQ or AS-
SENS.  
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SUMMARY 
In an attempt to identify genetic changes underlying the artesunate + mefloquine (ATN + 
MF)-resistant phenotype exhibited by AS-MFATN-5 and AS-ATNMF-1, the pcatp6, pcubp1 
and pcmdr1 genes, previously described as involved in resistance to mefloquine and/or 
artesunate (ATN) were analysed. When comparing AS-MFATN-5 and AS-ATNMF-1 with 
their respective progenitors, no mutations were found in the whole coding sequence of the 
pcatpase6 gene. Similarly, the final 3500 bp of gene pcubp1 presented no mutations in AS-
MFATN-5 and AS-ATNMF-1 clones when compared with their respective progenitors AS-
15MF and AS-ATN. 
The analysis of AS-MFATN-5 indicated that exposure of AS-15MF to consecutive rounds 
of selection with ATN selected parasites which underwent further amplification of pcmdr1 
gene, as AS-MFATN-5 harboured three copies of pcmdr1. On the other hand, consecutive 
passaging through mice in absence of drug has induced the loss of one of the two copies 
originally present in AS-15MF, as AS-15MF36P carries a single copy of pcmdr1 gene. 
The induction of ATN + MF resistance using AS-ATN clone as starting material selected 
parasites with a duplicated copy of pcmdr1, in AS-ATNMF-1. An increase in RNA and protein 
(MDR1) expression were also observed in this clone. However, whereas the RNA level seems 
to be slightly increased when compared to copy number (about two-to-three-fold higher in AS-
ATNMF-1 when compared to AS-ATN), the level of MDR1 expressed in AS-ATNMF-1 seems 
to be five-to-six-fold increased when compared to the parental AS-ATN. In addition, AS-
ATNMF-1 and AS-15MF, both carrying a duplication of pcmdr1 gene, show similar levels of 
RNA and protein expression. 
In spite of carrying a single copy of pcmdr1, AS-ATN shows increased levels of RNA and 
protein expression when compared with AS-3CQ. AS-ATN27P, which also harbours a single 
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copy of pcmdr1 gene and has similar levels of RNA expression as the original unpassaged AS-
ATN, shows increased levels of MDR1 protein expression when compared with AS-ATN. 
 
II.2.2.2. LINKAGE GROUP SELECTION 
In order to map the regions of the genome containing genes conferring the resistance 
phenotypes, a genome wide approach known as Linkage Group Selection (LGS) was carried 
out. This analysis consisted of performing a genetic cross between AS-ATNMF-1 and the 
genetically unrelated AJ clone. The cross progeny obtained here was then selected using four 
different drugs or drug combinations: i) artesunate, ii) mefloquine, iii) the combination of these 
two drugs, and iv) artemisinin. However, these experiments met with limited success, as drug 
treatment seemed to be insufficient to allow the detection of relevant loci.  The data is presented 
in detail in the Appendices section (Appendix II).  
 
II.2.2.3. GENOME-WIDE MUTATION DETECTION  
With the purpose of identifying additional mutations arising after selection for artesunate + 
mefloquine (ATN + MF) resistance, the complete genome sequence of the AS-ATNMF-1 clone 
was investigated. 
The analysis carried out in this work was made using the Illumina/Solexa platform. AS-
ATNMF1 was sequenced using 50 bp paired-end reads and mapped to the reference genome 
(AS-WTSI) using the SSAHA2 and MAQ programs, as described in the Material and Methods 
(Section 3.7.1).  
23,732,208 reads were produced for AS-ATNMF-1, of which 91% (21,816,439 reads) and 
87.2% were mapped to the genome by SSAHA2 and MAQ softwares, respectively. 86% 
(20,423,970 reads) of the total reads were found to map uniquely in SSAHA2 and 84% in 
MAQ. The average coverage of the whole genome was ~50-fold for SSAHA2 and ~49-fold for 
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MAQ. Furthermore, according to SSAHA2 (similar data was not readily available from MAQ), 
43% of the genome had a coverage of at least 40-fold, 92% was covered by at least 10 reads, 
whereas <0.7% of genome was not covered by any read.   
The reads obtained for AS-ATNMF-1 were mapped against the reference genome (AS-
WTSI), and a list of mutations was generated. This list of mutations was then compared to 
similar lists obtained previously for the AS-SENS and AS-50SP clones. Thus, non-clone 
specific mutations were filtered out (see Materials and Methods, section 3.7.1), and as such a 
total of 214 mutations were identified, which consisted of 21 potential SNPs (Appendix III) and 
193 potential indels or CNVs (Appendix IV).  It has to be noted that the quality of the reads was 
not as high as obtained in previous studies (Hunt et al, 2010).  This affected the quality of the 
mutation calls, particularly SNPs. As a consequence, no filtering of SNPs based on quality 
scores could be performed, with all SNPs needing to be treated as potentially genuine mutations 
pending verification by di-deoxy sequencing.  In the case of small and large indels, the vast 
majority is still expected to be false positive calls (Hunt et al, 2010) and limited di-deoxy 
sequencing indeed appears to suggest so (see False positives). 
A sub-set of twenty three mutations was chosen for validation by di-deoxy sequencing or 
Real-Time PCR analysis of AS-ATNMF-1. These included thirteen SNPs, nine indels and one 
CNV.  The criteria used for selecting this sub-set of mutations was the potential biological role 
attributed to the proteins coded by the genes where mutations were present or, in the case of 
intergenic mutations, the role of genes immediately close (either upstream or downstream) to 
the identified mutations. In addition, since the list of mutations present in AS-ATNMF-1 was 
made by comparison with AS-SENS or AS-50SP, di-deoxy sequencing analysis was also 
carried out for the other clones of the AS lineage in order to trace back the origin of each 
mutation. In total, thirteen mutations (nine SNPs, three indels and one CNV) were confirmed by 
di-deoxy sequencing or Real-Time PCR (Appendices V and VI, highlighted in green) and are 
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described in detail in the following sub-sections. Of the rejected SNPs, three were actually 
proxies for large deletions (False positives).   
Furthermore, two additional potential indels that were not verified in this study were 
considered as real mutations due to their size, location and evidence from other sequenced 
clones (see Unverified high-confidence mutations).   
Finally, one previously known deletion was missed by our analysis.  This was due to the 
use of AS-50SP clone, instead of AS-SENS for the identification of large indels, due to 
technical issues.  This is described in detail below. 
Thus, in total, fifteen mutations were considered genuine, of which thirteen were actually 
confirmed directly or indirectly by di-deoxy sequencing or Real-Time PCR. A summary of 
these mutations will be presented in the end of this section, in Figure 16. 
It is important to note that the list of mutations for ATNMF-1 provided here is not yet final 
and more verification is pending, particularly for the remaining eight potential SNP calls 
(Appendix III, highlighted in orange). 
 
VERIFICATION OF MUTATIONS 
In total, twenty three mutations were analysed either by di-deoxy sequencing or Real-Time 
PCR. They consisted of thirteen SNPs, nine indels, and one CNV (Table 3). Each of these 
mutations and their potential biological functions are described in the following sub-sections.  
In total, thirteen mutations were confirmed and ten rejected as false positives. A graphic 
summary of the verified mutations across the AS lineage is presented in Figure 16. 
For all mutations analysed here, the AS-MFATN-5 clone and the parasites AS-15MF36P 
showed the same genotype as its progenitor AS-15MF. Similarly, the uncloned parasites AS-
ATN27P showed the same genotype as AS-ATN. 
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Verified point mutations 
Nine mutations are described below. Seven of them encode non-synonymous substitutions 
while the remaining two are positioned in intergenic regions. 
 
a) G217,047T SNP on chr 2 
A G to T substitution was found on position 217,047 of chr 2 by Solexa in AS-ATNMF-1 
(Table 3). Di-deoxy sequencing confirmed this mutation was also present in AS-ATNMF-1’s 
parental clone, AS-ATN. This mutation falls into the coding region of PCHAS_020720 gene, 
which codes for the pcUBP1 (coding for a deubiquitinating enzyme) enzyme. It was already 
known to be present in AS-ATN (Hunt et al, 2007) and probably appeared in AS-15CQ under 
CQ selection.  It represents a non-synonymous mutation, on aminoacid 2697, where a valine 
was replaced by phenylalanine (V2697F). As previously described, this position is close to the 
protein’s catalytic site and is likely to reduce the activity of the pcUBP1 enzyme (Hunt et al, 
2007). 
No additional mutations were found in the coding sequence of this gene in AS-ATNMF-1. 
 
b) A636,862G on chr 6 
An A to G substitution was identified in position 636,862 on chr 6 by Solexa in AS-
ATNMF-1 (Table 3). Di-deoxy sequencing confirmed this mutation was also present in AS-
ATN. It may have appeared in AS-ATN under ATN selection. This nucleotide substitution falls 
within an intergenic region near the 3’-end of PCHAS_061710 gene. PlasmoDB analysis 
indicated that this gene codes for a seryl t-RNA synthetase which mediates the attachment of a 
serine residue to a specific transfer RNA (t-RNA). Assuming the mutation is placed in what 
could be a regulatory region, it could induce changes in the expression level of 
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PCHAS_061710, thus possibly interfering with the synthesis of other proteins. However, at 
present there is insufficient data to interpret the role of this mutation, if any. 
 
c) G994,546A on chr 7 
A G to A substitution in position 994,546 on chr 7 was found by Solexa in AS-ATNMF-1 
(Table 3). Di-deoxy sequencing confirmed the presence of this mutation in AS-ATNMF-1 and 
also in all preceding clones up to AS-PYR (i.e. only AS-SENS has wild-type allele). As 
described previously, this represents a known mutation, identified in AS-PYR after the 
selection of AS-SENS for pyrimethamine (PYR) resistance (Walliker et al, 1975). This 
nucleotide substitution falls within the coding region of the pcdhfr gene (dihydrofolate 
reductase, PCHAS_072830), coding for the substitution of a serine to an asparagine in residue 
106 (S106N). This mutation is homologous to the S108N substitution observed in P. 
falciparum, and known as underlying PYR resistance (Wang et al, 1997) and is involved also 
with resistance to this drug in P. chabaudi (Walliker et al, 1975; Hayton et al, 2002). 
 
d) G996,332T on chr 11 
A G to T substitution in position 996,332 on chr 11 was found by Solexa in AS-ATNMF-1 
(Table 3). Its presence first appears in AS-3CQ clone under CQ selection.  It was therefore 
expected to be present in AS-ATNMF-1. This mutation falls in the coding region of the 
PCHAS_112780 gene (coding for a putative amino acid transporter, pcaat1), and results in the 
replacement of an alanine to a glutamic acid in aminoacid 173 (A173E). This mutation appears 
to be involved in CQ resistance in P.chabaudi (Modrzynska, 2010). 
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e) A805,658T on chr 13 
An A to T substitution was identified by Solexa in position 805,658 on chr 13 in AS-
ATNMF-1 (Table 3). The presence of this mutation was confirmed by di-deoxy sequencing and 
found to first appear in the AS lineage in AS-15CQ parasites. Di-deoxy sequencing analysis of 
the three clones derived from AS-15CQ revealed that this substitution is also present in AS-
ATN, but not in AS-15MF or AS-30CQ.  
This mutation falls in the coding region of the PCHAS_132020 gene (coding for a 
hypothetical protein), and the prediction of the protein sequence coded by this gene shows that 
this mutation causes the introduction of a STOP codon at position 998 (K998*). This will result 
in a truncated version of the protein, possibly affecting the intracellular processes where it is 
involved.  
However, the function of this protein is unknown and its aminoacid sequence shows no 
similarity to any conserved domains. PROSITE only identified the presence of two asparagine-
rich (ANS-rich) regions (aminoacids 301 to 371; and 1120 to 1335) and one lysine-rich (LYS-
rich) region (aminoacids 538 to 593). In order to find more information, the DNA and protein 
sequences of the P. falciparum orthologue of PCHAS_132020 (PF14_0506) were retrieved 
from PlasmoDB. PF14_0506 gene is described as possibly belonging to a RNI-like superfamily. 
BLAST analysis of the protein coded by PF14_0506 also showed the presence of a 
synthase/transferase motif.  
 
f) A805,659T on chr 13 
An A to T substitution was also found at position 805,659 adjacent to that described in the 
previous section (A805,658T) on PCHAS_132020 gene (Table 3). This mutation appeared 
between AS-ATN and AS-ATNMF-1 and is predicted to ‘rescue’ the previous STOP mutation.  
It encodes a K998L mutation relative to the wild-type allele.  
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The population passaged twenty seven times in absence of drug, AS-ATN27P and the 
other four clones selected by drug pressure with AS-ATNMF-1 (AS-ATNMF-2, AS-ATNMF-
3, AS-ATNMF-4 and AS-ATNMF-5) were also analysed by di-deoxy sequencing. AS-ATN27P 
carried the same allele as AS-ATN, as did two of the four AS-ATNMF clones (AS-ATNMF-4 
and AS-ATNMF-5). Conversely, the other two AS-ATNMF clones (AS-ATNMF-2 and AS-
ATNMF-3) also showed the additional base substitution detected in AS-ATNMF-1. This 
suggests that the second mutation (*998L) was only partially selected (by ATN + MF) in the 
uncloned line, and that therefore the function of this protein is not crucial to parasite survival in 
the untreated or drug-treated lines. 
Further analyses are required in order to determine the importance of these mutations for 
ATN + MF resistance. 
 
g) G1,322,938A on chr 13 
A G to A substitution was identified at position 1,322,938 on chr 13 of AS-ATNMF-1 
(Table 3). Di-deoxy sequencing showed that this mutation was also present in AS-ATNMF-1’s 
progenitor, AS-ATN. This nucleotide substitution is located inside the coding region of 
PCHAS_133430 gene, which encodes a 26S proteasome subunit. 
The translation of the mutated sequence shows that this substitution causes a non-
synonymous mutation in aminoacid 738, where a glutamic acid is replaced by a lysine (E738K), 
thus a polar negatively charged aminoacid is replaced by a polar positively charged one. 
By performing a BLAST search for the aminoacid sequence of this protein, it was possible 
to identify a region homologous to many conserved domains involved in protein transport and 
turnover, and also a proteasome/cyclosome repeat, which is described as an anaphase-
promoting repeat, indicating the involvement of this protein with cell cycle regulation. The 
prediction of these domains in PCHAS_133430 protein sequence is consistent with the function 
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attributed to this gene. The mutation E738K falls into the putative proteasome/cyclosome repeat 
region and this could possibly have an effect on the activity of this protein. Its role in resistance 
to ATN is currently being studied. 
 
h) T936,945G on chr 14 
A T to G substitution was found in position 936,945 on chr 14 of AS-ATNMF-1 (Table 3). 
This mutation was first identified in AS-PYR and for that reason it was also expected to be 
present in AS-ATNMF-1, although it displayed poor read coverage. It falls in an intergenic 
region, close to the 5’-end of PCHAS_142600 gene, which has an unknown function. Analysis 
of PCHAS_142600 protein sequence by HMMTOP indicated the absence of putative 
transmembrane domains. BLAST indicated the presence of a conserved domain in the N-
terminal region of the protein coded by this gene (aminoacids 4 to 125) whose function is still 
unknown. The relation between this intergenic mutation and PYR resistance is still to be 
determined. 
 
i) G1,155,448T on chr 14 
A G to T substitution at position 1,155,448 on chr 14, was found by Solexa in AS-
ATNMF-1 (Table 3) and was confirmed by di-deoxy sequencing as being unique to this clone 
(arising between AS-ATN and AS-ATNMF-1). The parasite population AS-ATN27P carries 
the wild type allele of this gene. Interestingly, di-deoxy sequencing of the other four clones 
selected along with AS-ATNMF-1 revealed that none of them carry this mutation, suggesting 
that the selection on this mutation during passage under ATN + MF treatment was not very 
strong.  
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This nucleotide substitution is placed in the coding region of the PCHAS_143160 gene, 
and the predicted sequence of the mutated protein shows the substitution of an aspartic acid for 
a tyrosine, in position 560 (D560Y). 
As indicated in PlasmoDB, the function of the protein coded by this gene is unknown. 
However, the analysis of its aminoacid sequence by BLAST reveals the presence of 3 putative 
conserved domains. One of them represents a Glycosyl transferase super-family A (GT-A) 
domain (aminoacids 20 to 274) which is involved in the synthesis of oligosaccharides, 
polysaccharides, and glycoconjugates. Another conserved domain identified by BLAST 
belongs to the Left-handed parallel beta-Helix (LbetaH) superfamily (aminoacids 387 to 462), 
and is usually present in enzymes showing acyltransferase activity, and in some cases being 
related to ion transport and translation initiation. The third one consists of a Glutaryl Co-A 
Dehydrogenase (GCD1) domain (aminoacids 266 to 455) which is present in enzymes involved 
in lipopolysaccharide biosynthesis, or in translation and ribosomal structure and biogenesis. In 
addition, PROSITE identified a W2 domain near the N-terminal of the protein (aminoacids 854 
to 1022), and a glutamate-rich (GLU-rich) region (aminoacids 488 to 765) as well as a casein 
kinase II phosphorylation site (aminoacids 558 to 561). HMMTOP identified the presence of 
two putative transmembrane domains (aminoacids 448 to 456 and 894 to 911). 
It is worth noticing that the D560Y mutation is located in the putative casein kinase II 
phosphorylation site contained inside the GLU-rich region, both identified by PROSITE. 
Nevertheless, further analysis still remains necessary to determine the significance of this 
mutation. 
 
 
 
 
 104 
Verified indels/CVs 
Five high confidence indels/CNVs were identified by Solexa in AS-ATNMF-1. Three 
were analysed and confirmed either by di-deoxy sequencing or Real-Time PCR. Each 
confirmed mutation will be described below. 
 
a) 3bp deletion on chr03  
A 3 bp deletion from position 472,273 to 472,275 on chr 3 was identified by Solexa in AS-
ATNMF-1 (Table 3). The presence of this mutation was confirmed by di-deoxy sequencing as 
first appearing in the AS lineage in AS-15CQ, and is also present in two of the three clones 
deriving from it, AS-ATN and AS-15MF, while  being absent in the third one, AS-30CQ. 
The deletion of this triplet (AAT) is placed inside the coding region of PCHAS_031370 
gene. The predicted translation of the mutated protein indicated a deletion of an isoleucine in 
position 103 (I103). 
PlasmoDB describes this gene as a conserved Plasmodium protein, and PlasmoDB and 
HMMTOP indicated the presence of twelve transmembrane domains, with small divergences 
about their precise locations. Additionally the analysis of its predicted translation by BLAST 
search identified a region homologous to a Paraquat Inducible protein A (PqiA) domain 
(aminoacids 52 to 210). This domain is present in proteins belonging to a family of integral 
membrane proteins and its expression is promoted by superoxide radical generating agents. It is 
worth noticing that the I103 deletion falls inside this predicted domain.  
The P. falciparum orthologue of this protein (PFB0675w) is believed to target the 
membrane of the digestive vacuole (P. Moura and D. Fidock, pers. comm.). Additionally, 
another mutation (T707N) in the same gene occurs in AS-30CQ.  This mutation is believed to 
confer high-level CQ resistance (Modrzynska, 2010). 
However, the biological relevance of this mutation still remains to be assessed.  
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b) 60 Kb deletion on chr13 
A 60 Kb deletion spanning from the very beginning of chr 13 to approximately position 
60,867 was identified by Solexa in AS-ATNMF-1 (Table 3). 
As described previously, indels were identified by comparing the coverage between AS-
ATNMF-1 and AS-50SP, both sequenced by 50 bp paired-end reads. The comparative coverage 
between AS-ATNMF-1 and AS-50SP along chr 13 is shown in Figure 13, where an area of 
reduced coverage can be visualised as the peaks in the beginning of the chromosome using the 
Artemis sequence viewing tool. Along the rest of chr 13, a flat line is observed, indicating there 
is no significant difference between the comparative coverage of the two clones in this region.  
 
 Figure 13 – Schematic representation of comparative coverage between AS-ATNMF-1 and AS-50SP clones 
visualised on chr 13 using Artemis Software. Peaks in the beginning of the chromosome (forward and reverse 
strands are represented in grey) indicate a difference in comparative coverage between AS-ATNMF1 and AS-
50SP. In this case the difference indicates drastically reduced coverage, while the flat line indicates no difference 
between the two clones.  Yellow, pink and orange horizontal bars represent different genes along the chromosome.  
 
According to SSAHA2 values, this deletion spans approximately 60Kb and includes 
approximately fifteen genes from PCHAS_130010 to PCHAS_130150, most of which represent 
members of a sub-telomeric gene family, the P. chabaudi interspersed repeats proteins or CIR 
proteins (Table 4). 
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In order to obtain indirect evidence of this deletion, oligonucleotide primers were designed 
for PCR amplification of a fragment of PCHAS_130140 gene, which is located inside of the 
deleted region. A PCR product will be amplified unless the clone under analysis carries a 
deletion of this region. In this case no product will be seen.  
All clones belonging to the AS lineage were investigated. Under the same conditions, 
some samples presented a single band (approximately 500 bp), while other samples presented 
two bands (the previous 500 bp and another one of 400 bp) (Figure 14A and 14B). These results 
were reproducible and each band obtained for each clone was analysed by di-deoxy sequencing 
separately. 
A careful analysis of the sequences obtained for the two different bands was made by 
performing a BLAST search against P.chabaudi genome. This analysis revealed that each band 
corresponded to a different region on the parasite’s genome. The smaller band (~400 bp) 
represented the predicted fragment of the target gene PCHAS_130140, which is present on chr 
13 and codes for a putative Haloacid Dehalogenase (HAD) hydrolase. On the other hand, the 
larger band (~500 bp) represented a fragment of a different gene (PCHAS_144300), present on 
chr 14. PCHAS_144300 codes for a putative Hydrolase/phosphatase protein, which belongs to 
the same superfamily as that encoded by PCHAS_130140. 
Therefore, whenever a clone carried both genes, two regions would be amplified by PCR 
and two bands were observed. On the other hand, clones bearing the deleted fragment on chr 13 
had only one region amplified (on chr 14) and therefore, only a single band would be seen. 
As shown in Figure 14, the deletion seems to be present in AS-ATNMF-1, and seems to 
have first appeared in the AS lineage in AS-15CQ parasites. The deletion also seems to be 
present in AS-ATN. Interestingly, the other two clones derived from AS-15CQ, AS-30CQ and 
AS-15MF carry two bands, i.e. do not have a deletion at the beginning of chr 13.  
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Figure 14 – (A) and (B) PCR products resolved in agarose gel. It is proposed that wild-type clones show two 
bands, whereas clones bearing the 60 Kb deletion in chr 13 only show one band.  
 
 
c) 80 Kb amplification on chr12 
An 80 Kb segment spanning from position 1,382,067 to 1,462,751 on chr 12 seemed to be 
amplified in AS-ATNMF-1 (Table 3).  
By using a similar analysis as the one performed for the identification of differences in 
comparative coverage along chr 13 described in the previous section, it was possible to 
visualise the comparative coverage between AS-ATNMF-1 with AS-50SP along chr 12 (Figure 
15). In this case, however, the peaks correspond to an increase in coverage along a region 
spanning over approximately 80 Kb in AS-ATNMF-1.  
When analysing this region in more detail, it could be verified that it encompasses about 
twenty three genes, from PCHAS_123760 to PCHAS_123980 (Table 5), inclusive. Most of 
these genes code for proteins of unknown function, with a few exceptions. The full list of the 
genes and their proposed functions is presented on Table 5.  
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Figure 15 – Schematic representation of comparative coverage between AS-ATNMF-1 and AS-50SP clones along 
chr 12 visualised using Artemis Software. Peaks indicate a difference in comparative coverage between AS-
ATNMF1 and AS-50SP, in this case, an increase in coverage on a region spanning over approximately 80 Kb. 
Yellow and orange horizontal bars represent different genes along the chromosome. Black arrow indicates gene 
PCHAS_123820, the pcmdr1 gene (yellow bar).  
 
One gene present in this region is PCHAS_123820, coding for pcmdr1 coding for the 
MDR1 ABC transporter. Real-Time PCR analysis carried out in this work confirmed that this 
gene is duplicated in AS-ATNMF-1, whereas its parental AS-ATN only carries one copy 
(Section II.2.2.1, pcmdr1 – copy number variation). This provides an indication that this whole 
segment of chr 12 has been amplified resulting in the duplication of gene pcmdr1 along with 
many other genes. Due to technical constraints, the other four AS-ATNMF clones were not 
inspected for the presence of the mdr1 duplication. 
 
False positives 
Ten out of the twenty three mutations analysed in this study were false positives (four 
SNPs and six indels) (Table 3, highlighted in red).  In one case, SSAHA2 identified position 
566,547 on chr 12 (gene PCHAS_121630, coding for a 40S ribosomal S3A) as heterozygous 
G/A (Table 3). However, di-deoxy sequencing indicated AS-ATNMF1 as showing an A in this 
position, i.e. same as the AS-WTSI reference. Three false positive SNPs were actually found to 
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act as “proxies” for deletions. These were: an A to G substitution in position 876,917 and a C to 
A substitution in position 876,919 both on chr 7, representing proxies for the 34 bp deletion 
previously known to be present in this region (see False negatives, below) and a G to A 
substitution in position 56,840 on chr 13, also a proxy for a large deletion event, the 60 Kb 
deletion described above. 
 
False negatives 
A previously known 34bp deletion from position 876894 to 876927 on chr 7 was not 
detected in AS-ATNMF-1 by Solexa (Table 3, highlighted in blue). This was due to the use of 
AS-50SP as a filter for the identification of indels. This clone also carries the same deletion on 
chr 7. Instead, two SNPs very close to each other were identified (A to G substitution in 
position 876,917 and a C to A substitution in position 876,919), presumed to be deletion 
‘proxies’. It is worth noting that SNP identification was made using AS-SENS as filter, instead 
of AS-50SP, and for that reason, these mutations were identified. 
Di-deoxy sequencing analysis was carried out in order to verify the presence of this 
deletion in AS-ATNMF-1. The alignments of the fragments obtained for AS-ATNMF-1 were 
compared with AS-50SP, AS-PYR, and AS-SENS, showing that of these four clones, three 
carry the deletion, whilst AS-SENS shows the wild type allele (Appendix V).  
This mutation appeared after the exposure of AS-SENS to one dose of PYR (Walliker et 
al, 1975), generating the PYR-resistant clone, AS-PYR. It is thus expected to be present in all 
clones selected from AS-PYR. Indeed this mutation is present in AS-50SP (originated directly 
from AS-PYR) and also in all the other clones of the AS lineage, including AS-ATNMF-1’s 
parental, AS-ATN. 
The presence of this false negative raises the issues of other potential indels having been 
overlooked due to the use of AS-50SP as a filter. However, as referred above, the extensive 
 112 
knowledge of the other clones belonging to the AS lineage minimizes the probability of other 
false negatives. 
 
UNVERIFIED HIGH-CONFIDENCE MUTATIONS 
Two high confidence indels (Appendix IV, highlighted in yellow) identified by the 
analysis carried out here could not be verified: i) a ~2.4 Kb deletion predicted between 
positions 682,682 to 685,106 on chr 5; and ii) a ~30 Kb deletion predicted between position 
305,928 and 339,914 of an artificial chromosome made up of unassigned contigs (“bin”) that 
seems to involve part of contig 11844.   
Although no di-deoxy sequencing analysis was carried out for confirming the presence of 
these two mutations in AS-ATNMF-1, there is strong evidence indicating they consist of true 
mutations. When performing coverage analysis it is possible to note that large deletions leave a 
strong signature. In addition, the deletion on chr 5 was identified as present in other clones of 
the AS lineage in previous work (Hunt et al, 2010). The large deletion on contig 11844, on the 
other hand, may be a continuation of the sub-telomeric 60 kb deletion on chr13, since contig 
11844 contains many features associated with subtelomeric and telomeric chromosomal 
regions.  
 
 
 
 
 
 
 
1
1
3
 
                 
A
S
A
S
-- A
T
2
A
T
2
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 11
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 22
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 33
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 44
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 55
A
S
A
S
--
M
F
A
T
2
5
M
F
A
T
2
5
A
S
A
S
--3
0
C
Q
3
0
C
Q
A
S
A
S
-- A
R
T
A
R
T
A
S
A
S
-- S
E
2
S
S
E
2
S
A
S
A
S
--
P
Y
R
P
Y
R
A
S
A
S
-- 3
C
Q
3
C
Q
A
S
A
S
-- 1
5
M
F
1
5
M
F
A
S
A
S
--
5
0
S
P
5
0
S
P
C
h
r
1
3
 6
0
K
b
 d
e
le
ti
o
n
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
P
C
H
A
S
_
1
3
2
0
2
0
 T
A
P
C
H
A
S
_
1
3
2
0
2
0
T
T
P
C
H
A
S
_
1
3
2
0
2
0
T
T
3
’-
P
C
H
A
S
_
0
6
1
7
1
0
U
B
P
1
-
V
2
6
8
7
F
P
C
H
A
S
_
1
4
3
1
6
0
A
A
T
1
-
A
1
7
3
E
D
H
F
R
-
S
1
0
9
N
C
h
r
1
4
 5
’
-P
C
H
A
S
_
1
4
2
6
0
0
P
C
H
A
S
_
1
3
2
0
2
0
 T
T
P
C
H
A
S
_
1
3
2
0
2
0
T
A
P
C
H
A
S
_
1
3
2
0
2
0
T
A
*
*
A
S
A
S
-- A
T
2
A
T
2
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 11
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 22
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 33
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 44
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 55
A
S
A
S
--
M
F
A
T
2
5
M
F
A
T
2
5
A
S
A
S
--3
0
C
Q
3
0
C
Q
A
S
A
S
-- A
R
T
A
R
T
A
S
A
S
-- S
E
2
S
S
E
2
S
A
S
A
S
--
P
Y
R
P
Y
R
A
S
A
S
-- 3
C
Q
3
C
Q
A
S
A
S
-- 1
5
M
F
1
5
M
F
A
S
A
S
--
5
0
S
P
5
0
S
P
*
2
6
S
 p
r
o
te
a
s
o
m
e
s
u
b
u
n
it
E
7
3
8
K
8
0
 K
b
a
m
p
li
fi
c
a
ti
o
n
in
c
lu
d
in
g
M
D
R
1
C
h
r
1
3
 6
0
K
b
 d
e
le
ti
o
n
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
P
C
H
A
S
_
1
3
2
0
2
0
 T
A
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
A
S
A
S
-- A
T
2
A
T
2
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 11
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 22
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 33
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 44
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 55
A
S
A
S
--
M
F
A
T
2
5
M
F
A
T
2
5
A
S
A
S
--3
0
C
Q
3
0
C
Q
A
S
A
S
-- A
R
T
A
R
T
A
S
A
S
-- S
E
2
S
S
E
2
S
A
S
A
S
--
P
Y
R
P
Y
R
A
S
A
S
-- 3
C
Q
3
C
Q
A
S
A
S
-- 1
5
M
F
1
5
M
F
A
S
A
S
--
5
0
S
P
5
0
S
P
C
h
r
1
3
 6
0
K
b
 d
e
le
ti
o
n
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
P
C
H
A
S
_
1
3
2
0
2
0
 T
A
P
C
H
A
S
_
1
3
2
0
2
0
T
T
P
C
H
A
S
_
1
3
2
0
2
0
T
T
3
’-
P
C
H
A
S
_
0
6
1
7
1
0
U
B
P
1
-
V
2
6
8
7
F
P
C
H
A
S
_
1
4
3
1
6
0
A
A
T
1
-
A
1
7
3
E
D
H
F
R
-
S
1
0
9
N
C
h
r
1
4
 5
’
-P
C
H
A
S
_
1
4
2
6
0
0
P
C
H
A
S
_
1
3
2
0
2
0
 T
T
P
C
H
A
S
_
1
3
2
0
2
0
T
A
P
C
H
A
S
_
1
3
2
0
2
0
T
A
*
*
A
S
A
S
-- A
T
2
A
T
2
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 11
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 22
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 33
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 44
A
S
A
S
-- A
T
2
M
F
A
T
2
M
F
-- 55
A
S
A
S
--
M
F
A
T
2
5
M
F
A
T
2
5
A
S
A
S
--3
0
C
Q
3
0
C
Q
A
S
A
S
-- A
R
T
A
R
T
A
S
A
S
-- S
E
2
S
S
E
2
S
A
S
A
S
--
P
Y
R
P
Y
R
A
S
A
S
-- 3
C
Q
3
C
Q
A
S
A
S
-- 1
5
M
F
1
5
M
F
A
S
A
S
--
5
0
S
P
5
0
S
P
*
2
6
S
 p
r
o
te
a
s
o
m
e
s
u
b
u
n
it
E
7
3
8
K
8
0
 K
b
a
m
p
li
fi
c
a
ti
o
n
in
c
lu
d
in
g
M
D
R
1
C
h
r
1
3
 6
0
K
b
 d
e
le
ti
o
n
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
P
C
H
A
S
_
1
3
2
0
2
0
 T
A
P
C
H
A
S
_
0
3
1
3
7
0
 3
b
p
 d
e
le
ti
o
n
AA
SS
-- 11
55
CC
QQ
  
AA
SS
-- 11
55
CC
QQ
  
AA
SS
-- 11
55
CC
QQ
  
AA
SS
-- 11
55
CC
QQ
  
F
ig
u
re
 1
6
 –
 S
u
m
m
ar
y
 o
f 
th
e 
m
u
ta
ti
o
n
s 
id
en
ti
fi
ed
 b
y
 S
o
le
x
a
 a
n
d
 v
er
if
ie
d
 b
y
 d
i-
d
eo
x
y
 s
eq
u
en
ci
n
g
 a
s 
p
re
se
n
t 
in
 A
S
-A
T
N
M
F
-1
. 
M
u
ta
ti
o
n
s 
ar
e 
in
d
ic
at
ed
 a
s 
th
e
y
 f
ir
st
 a
p
p
ea
re
d
 i
n
 t
h
e 
A
S
 l
in
ea
g
e.
 T
h
e 
th
re
e 
m
u
ta
ti
o
n
s 
fi
rs
t 
ap
p
ea
ri
n
g
 i
n
 A
S
-1
5
C
Q
 a
re
 p
re
se
n
t 
in
 A
S
-A
T
N
, 
d
er
iv
in
g
 f
ro
m
 i
t.
  
O
n
 t
h
e 
o
th
er
 h
a
n
d
, 
th
e 
o
th
er
 c
lo
n
es
 o
ri
g
in
at
ed
 f
ro
m
 A
S
-1
5
C
Q
 a
re
 d
if
fe
re
n
t 
fr
o
m
 t
h
ei
r 
p
ar
en
ta
l:
 *
 A
S
-1
5
M
F
 o
n
ly
 b
ea
rs
 t
h
e 
3
b
p
 d
el
et
io
n
 o
n
 C
h
r3
 (
P
C
A
S
_
0
3
1
3
7
0
),
 a
n
d
 (
*
*
) 
A
S
-3
0
C
Q
 s
h
o
w
s 
n
o
n
e 
o
f 
th
e
m
. 
N
o
n
-c
o
d
in
g
 m
u
ta
ti
o
n
s 
ar
e 
sh
o
w
n
 i
n
 g
ra
y
; 
S
N
P
s 
ar
e 
sh
o
w
n
 i
n
 b
lu
e 
an
d
 i
n
d
el
s 
ar
e 
re
p
re
se
n
te
d
 i
n
 r
ed
. 
 114 
SUMMARY 
By using Solexa whole genome sequencing of AS-ATNMF-1 a total of 214 mutations 
were identified. Further analysis indicated twenty five mutations (nine SNPs, five indels and 
one CNV) which were confirmed to be genuine. 
Ten of these mutations were detected for the first time in this study and will be grouped 
below according to the clone where they were selected: 
a) three mutations were identified as first appearing in AS-15CQ: i) a 3bp deletion on chr 
3, on PCHAS_031370 gene; ii) a A805,658T substitution on chr 13, on PCHAS_132020 gene, 
which causes the introduction of a STOP codon in position 998 of its predicted protein 
sequence; iii) a 60 Kb deletion of the initial segment of chr 13, which may also include the 30 
Kb deletion identified in contig 11844. 
All three mutations identified in AS-15CQ are present in AS-ATN and, on the other hand, 
none of them were observed in AS-30CQ. Only the 3bp deletion on chr 3, on PCHAS_031370 
gene is present in AS-15MF; 
b) two previously unknown mutations appeared in AS-ATN: i) an A636,862G substitution 
near the 3’end of PCHAS_061710 gene, on chr 6; ii) a non-synonymous substitution E738K on 
PCHAS_133430 gene (chr 13) coding for the 26S proteasome subunit.  
c) the following mutations appeared in various clones of the AS-ATNMF population after 
ATN +MF selection: i) an 80 Kb amplification on chr 12, including pcmdr1 among other genes, 
in conformity with the results of the previous section, where the duplication of pcmdr1 gene 
was identified by Real-Time PCR analysis. The other four AS-ATNMF clones were not 
inspected for the duplication of mdr1 gene; ii) a K998L substitution on PCHAS_132020 gene 
(chr 13), replacing the STOP codon present in the progenitor AS-ATN clone (originally found 
in AS-15CQ) for a leucine. This mutation was also observed in AS-ATNMF-2, and -3, but not 
in AS-ATNMF-4 and -5, the other clones selected along with AS-ATNMF-1; and iii) a D560Y 
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substitution on PCHAS_143160, on chr 14, which is found exclusively in AS-ATNMF-1 but 
none of the other AS-ATNMF clones.  
The last novel mutation identified in this work is the ~2.5 Kb deletion on chr 5. The 
presence of this mutation could not be confirmed by di-deoxy sequencing, and as consequence, 
its origin in the AS lineage remains unknown.  
It is important to highlight that the list of mutations discovered in AS-ATNMF-1 presented 
here may not be complete, since only a sub-set of all mutations identified was confirmed or 
rejected by di-deoxy sequencing or Real-Time PCR.  
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SECTION SUMMARY 
The ATN + MF-resistant AS-MFATN-5 and AS-ATNMF-1 clones were analysed in order 
to identify the genetic mutations selected by consecutive rounds of treatment with ATN or ATN 
+ MF, respectively.  
AS-MFATN-5 showed a further amplification of pcmdr1 gene (three copies) when 
compared to its progenitor AS-15MF, previously known as carrying two copies of this gene. In 
addition, consecutive sub-inoculations of AS-15MF clone into mice seems to have caused the 
loss of one of its two pcmdr1 copies, as AS-15MF36P harbours a single copy of pcmdr1. 
Similarly, when compared to its parental AS-ATN, AS-ATNMF-1 has also undergone an 
amplification of the pcmdr1 gene, and carries two copies of this gene. Gene amplification was 
followed by an increase in RNA and protein expression. However, protein levels were 
disproportionally higher (about six-fold) when comparing to gene (two-fold) and RNA 
transcripts (two-to-three-fold).  
Other mutations were found in AS-ATNMF-1 through whole-genome sequencing, and 
were located within genes PCHAS_132020, on chr 13, and PCHAS_143160, on chr 14. 
However, the function of these genes is still unknown.  
Together, these results obtained for AS-MFATN-5 and AS-ATNMF-1 indicate that 
pcmdr1 seems to have a central role in ATN + MF resistance. However, the presence of other 
mutations appearing in AS-ATNMF-1 after selection with ATN + MF suggest that pcmdr1 may 
not be the sole determinant of this phenotype. 
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II.3. DISCUSSION 
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The results obtained in the previous sections of this Chapter will be discussed below. In 
order to facilitate comprehension the different implications of the results obtained here will be 
divided as follows. First, the implications of emergence of parasites which are resistant to 
artesunate and mefloquine (ATN + MF) administered in combination will be discussed under 
the perspective of the advantages and pitfalls of the administration of Artemisinin Combination 
Therapy as antimalarial treatment. 
Secondly the genetic changes accompanying the evolution of resistance to these drugs in 
our model will be discussed. This section will be subdivided as to first present the implications 
of acquisition of an extra copy of mdr1 gene in both ATN + MF-resistant clones selected here. 
Then, overexpression of MDR1 and the possible interaction with other genes (mutated or wild-
type) will be debated, as well as the novel mutations identified in AS-ATNMF-1. 
Finally, other results obtained in this work will also be discussed, such as the implications 
of mutations disclosed by whole-genome sequencing of AS-ATNMF-1, which were identified 
as arising prior to AS-ATNMF-1 selection in the chloroquine-resistant AS-15CQ and 
artesunate-resistant AS-ATN. 
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II.3.1. ARTESUNATE + MEFLOQUINE COMBINATION DOES NOT PREVENT 
EVOLUTION OF RESISTANCE 
At present, widespread drug resistance represents the greatest set-back in the control of 
malaria cases in endemic areas. Indeed, the last standing force against resistant parasites are the 
Artemisinin Combination Therapies, which consist of the administration of an artemisinin 
(ART) derivative in combination with a chemically unrelated antimalarial, such as mefloquine 
(MF). At the time of its implementation, it was believed that administration of combination 
therapy would prevent the evolution of resistance to ART derivatives by malaria parasites. 
However, cases of clinical failure after treatment with ART compounds have already been 
reported, particularly in South-East Asia, where the combination of artesunate (ATN) and MF 
has been used for the past 15 years (Wongsrichanalai and Meshnick, 2008).  
In this context, the main goal of this work was to generate parasites which were resistant to 
the artesunate + mefloquine (ATN + MF) combination, aiming at: i) providing experimental 
evidence that it is biologically possible for a parasite to evolve resistance to ATN + MF and ii) 
identifying genetic mutations associated with the resistant phenotype evolved by these 
parasites, before resistance becomes established in natural P. falciparum populations. In order 
to meet these goals, parasite clones initially resistant to one of the two drugs of the combination 
were exposed to sub-therapeutic drug treatment as follows: i) a MF-resistant Plasmodium 
chabaudi clone was selected with ATN alone and ii) a P. chabaudi clone displaying moderate 
ATN resistance was exposed to ATN + MF combination. Resistance to the combination of the 
two drugs was successfully selected in both cases. 
One important question is whether selection for ATN + MF-resistance could have been 
attempted by using fully sensitive parasites as starting material. This can be argued for, as the 
use of the drug sensitive AS-SENS clone would allow inferring the importance of newly arising 
mutations and their immediate association with resistance to these two drugs administered 
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simultaneously, without the confounding background of the various mutations accumulated 
along time due to repeated passaging through mice or exposure to other drugs, such as 
pyrimethamine and chloroquine (CQ). However, the main goal of this work was not only to 
identify the genetic mutations conferring drug resistance, but also to create a model that could 
help understand the mechanisms of ACT resistance as they would appear in the field. As such, 
the first reason for not choosing AS-SENS as stating material is that currently fully sensitive 
parasites simply do not exist in natural populations. In most endemic areas, resistance to CQ is 
at near-fixation level. In addition, MF-resistant parasites are also widespread, as is the case for 
instance in Western Thailand where MF monotherapy was used for almost 10 years, 
contributing for the emergence of parasites with high levels of resistance to this drug (Carrara et 
al, 2006). Also, ATN monotherapy has been used for almost 30 years in the Thai-Cambodian 
region. This is regarded as being the most important factor contributing for the evolution of 
tolerance to ART derivatives by P. falciparum parasites in this area (Dondorp et al, 2009). Use 
of ACTs for treatment of malaria cases has reached very high cure rates (Nosten et al, 2000). 
However, parasites with previous ATN-resistant or MF-resistant background showed a delayed 
clearance time after ATN + MF combination (Alker et al, 2007; Carrara et al, 2009; Dondorp et 
al, 2009; Noedl et al, 2009), indicating ACT’s efficacy may be waning. Since South-East Asia 
is historically the cradle of resistance to most antimalarial drugs, it is particularly interesting to 
try and model the context of the natural parasite populations of this region. 
For the above reasons, the use of the AS-15MF and AS-ATN clones of the P. chabaudi AS 
lineage for the selection of ATN + MF resistance was an adequate choice. 
The successful selection for ATN + MF resistance shows that even the highly efficacious 
drug artesunate (ATN), when administered in sub-optimal doses may induce resistance (as 
observed for the selection of AS-MFATN-5). Additionally, in case of the administration of 
ATN + MF combination, the quick action of ATN combined with the long-term action of MF is 
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not enough to prevent the appearance of resistant parasites if the two drugs are present in sub-
therapeutic levels (as observed for the selection of AS-ATNMF-1). These results are therefore 
relevant for the application of ACTs for treatment of malaria cases. Indeed, although health 
authorities of each endemic country may apply rigid control over the indiscriminate use of 
ACTs, self-medication is still a reality, as well as counterfeit drugs which contain lower doses 
of one or both of ACT components can also easily be found. As such, parasites would be 
exposed to sub-therapeutic drug doses in the host’s bloodstream increasing the chances of 
selection of resistance. 
One of the premises determined by WHO for malaria treatment is the administration of 
combination therapies involving chemically unrelated drugs as partners of ART derivatives. 
ATN and MF are chemically unrelated and supposedly have two distinct modes of action. This 
would be one of the supposed advantages of the administration of the combination of these two 
drugs. It was postulated that the number of asexual parasite forms present in a single infection 
would not be sufficient to allow enough replication cycles for the appearance of parasites 
harbouring mutations in genes involved in resistance to both drugs (White, 1999). However, the 
evolution of ATN + MF resistance described here may indicate that the mutation rates of the 
parasite have been underestimated, and the appearance of mutations in different genes may be 
more frequent than expected. Moreover, both parasites used as starting material in this work 
already showed a multiple-drug resistant phenotype (AS-15MF is resistant to MF, chloroquine 
(CQ) and pyrimethamine (PYR), and AS-ATN is resistant to ATN, CQ and PYR). Therefore, 
there is a possibility that the progenitor clones used here may have evolved the Accelerated 
Resistance to Multiple Drugs (ARMD) phenotype (Rathod et al, 1997) along the course of 
selection throughout the AS lineage, and this could facilitate the evolution of ATN + MF-
resistance as shown here. Other possiblility is that, pre-existing resistance to one of the partner 
drugs may have facilitated the evolution of resistance to the combination, as a parasite exposed 
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to ATN + MF must only acquire mutation(s) in genes modulating sensitivity to the other partner 
drug, and not to both simultaneously, as postulated previously (White, 1999).  
ACTs are the last standing force against multi-drug resistant malaria and this work 
provides evidence that resistance may evolve in parasites with different genetic backgrounds of 
resistance to one of the two drugs of the combination when exposed to sub-therapeutic doses of 
drug treatment. 
 
II.3.2. GENETICS OF RESISTANCE TO ARTESUNATE + MEFLOQUINE 
Many genes have been previously proposed as involved in resistance to artesunate (ATN) 
and mefloquine (MF) separately. However, no definitive intracellular target has been identified 
to these drugs so far. In addition, the genetic mechanisms behind the delayed clearance time 
after ATN + MF treatment displayed by tolerant parasites have not been identified.  
Genetic analysis targeting the previously proposed ATN resistance pfatpase6 and pcubp1 
genes revealed that, independent of genetic background borne by progenitor clones, no 
mutations have followed the acquisition of resistance to ATN + MF.  
Mutations in the pfatpase6 gene have been implicated in ART resistance in artificial 
models: i) in transfected Xenopus oocytes (Eckstein-Ludwig et al, 2003; Uhlemann et al, 
2005); or ii) in transfected P. falciparum cultured strains (Valderramos et al, 2010). In P. 
falciparum natural populations however, apart from one work (Jambou et al, 2005) no 
mutations in this gene have been further reported as implicated in ART increased tolerance 
(Dahlstrom et al, 2008; Jambou et al, 2010). 
The pcubp1 gene was also investigated. However, the genotype identified corresponded to 
the same as the previously borne by the respective progenitor in case of both ATN + MF 
resistant clones. Mutations in this gene were first identified in P. chabaudi clones selected for 
ATN and ART resistance (Hunt et al, 2007), but no correlation between mutations in pcubp1 
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gene and resistance to artemisinin derivatives have has been reported in the field (Imwong et al, 
2010). 
 
II.3.2.1. MDR1 AMPLIFICATION 
Amplification of mdr1 gene seems to play a determinant role in resistance to ART 
derivatives or MF, as was suggested by many studies using laboratory adapted strains as well as 
parasites from natural populations from different geographic endemic regions. In these studies, 
mdr1 amplification is associated with increased in vitro resistance or delayed parasite clearance 
after treatment with ATN and MF either alone or in combination (Price et al, 1997; Price et al, 
1999; Pickard et al, 2003; Price et al, 2004; Alker et al, 2007; Wongsrichanalai and Meshnick, 
2008; Lim et al, 2009; Rogers et al, 2009; Chaijaroenkul et al, 2010; Chavchich et al, 2010). 
Other studies indicate the locus containing mdr1 gene as being under strong selection. These 
studies attribute this selective pressure to the continued use of ACTs (Nair et al, 2007; Vinayak 
et al, 2010).  
The two different clones selected for ATN + MF resistance, AS-MFATN-5 and AS-
ATNMF-1, harbour a further amplification of pcmdr1 gene. This provides indication that in our 
model, amplification of this gene also plays a central role in resistance to the combination of 
these drugs.  
Additional evidence comes from the AS-15MF clone which was repeatedly sub-inoculated 
into untreated mice for thirty six weeks. These parasites, referred to as AS-15MF36P, seemed 
to be more tolerant to ATN and MF (either administered alone or in combination) than the 
original AS-15MF clone. Interestingly, pcmdr1 gene copy number was decreased in AS-
15MF36P parasites (a single copy instead of the two copies harboured by the original AS-15MF 
clone). Collectively, these results seem to indicate that prolonged in vivo passaging in the 
absence of drugs may lead to a deamplification of pcmdr1 copy number and, as a consequence 
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a decrease in the parasite’s tolerance to ATN and MF either administered alone or in 
combination. 
The instability of the mdr1 gene’s amplification in the absence of drug pressure (Barnes et 
al, 1992; Chen et al, 2010) and the ability of malaria parasites to amplify it presence of drugs 
(Price et al, 1997; Cravo et al, 2003; Price et al, 2004; Alker et al, 2007; Lim et al, 2009; 
Rogers et al, 2009; Chavchich et al, 2010) was already observed in previous studies.  
In addition, great variation has been identified in the size of amplified fragments involving 
mdr1 gene and resistance to drug treatment. The size of the amplified region in AS-ATNMF-1 
clone selected throughout in this work is of approximately 80 Kb, whereas size of the amplicon 
carried by AS-15MF is of 392 Kb (Borges, 2009). Chavchich and colleagues have observed an 
amplification of an approximately 100 Kb locus containing the mdr1 gene, following prolonged 
P. falciparum culturing in presence of the ART derivative artelinin acid (Chavchich et al, 
2010). In field samples, the presence of amplicons containing mdr1 were found to vary between 
15 to 49 Kb, containing two to eleven genes (including mdr1) (Nair et al, 2007). Other study 
has indicated the presence of a locus spanning over more than 100 Kb (Chaiyaroj et al, 1999). 
Some studies indicate that amplifications occur at high rates, occurring once in 10
8
 
parasites in laboratory strains. This rate falls to 1 in 1000 parasites in case of an increase from 
two to three copies of the same region (Preechapornkul et al, 2009). 
In our model, amplification of pcmdr1 gene was observed in three distinct independent 
events: i) AS-15MF; ii) AS-ATNMF-1; and iii) AS-MFATN-5. AS-15MF was selected by 
consecutive sub-inoculation of approximately 10
6
 parasites in each host mouse and drug was 
administered 3 hours later (Cravo et al, 2003). The other two clones were inoculated at a higher 
inoculum (10
7
 parasites were inoculated in each mouse). Mice were treated three days after 
receiving the inoculum, which allowed parasite replication and increased the parasite biomass 
exposed to drug treatment. In all cases, enough parasites were exposed to drug pressure in order 
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to allow the spontaneous appearance of parasites harbouring an amplified locus containing 
pcmdr1 and their subsequent selection by drug pressure. 
The MF-resistant AS-15MF harbours two copies of mdr1 gene and shows some level of 
resistance to ART, without ever being exposed to this drug (Borges, 2009). It could be observed 
here that AS-15MF actually shows increased tolerance to ATN when compared to AS-ATN 
clone, which only carries a single copy of mdr1 gene. This could imply a role of mdr1 
amplification in increased resistance to ATN administered alone. 
In accordance with this idea, AS-ATNMF-1, which has gained an extra copy of mdr1 
gene, shows a slight increase in its level of tolerance to ATN than its progenitor AS-ATN. On 
the other hand, AS-ATNMF-1 parasites are also more resistant to the ATN + MF combination 
and to MF administered alone when compared to AS-ATN and AS-15MF. In AS-15MF the 
presence of two copies of this gene is not enough to confer resistance to the combination of the 
two drugs, only some degree of resistance to ATN and MF separately. This may indicate that 
acquisition of the second copy in AS-ATNMF-1 may not be the only factor conferring 
resistance to the ATN + MF combination.  
Repetitive treatment of AS-15MF with ATN has selected parasites showing ATN + MF 
resistance and an additional copy of pcmdr1. In P. falciparum cultured parasites selection with 
ART derivatives have originated parasites with increased mdr1 copy number (Chavchich et al, 
2010). However, in our model, previous selection with ART and ATN had not resulted in 
parasites harbouring an extra copy of pcmdr1 (Afonso et al, 2006). The acquisition of an extra 
pcmdr1 copy in AS-MFATN-5 was followed by an increase in the levels of tolerance to the 
combination but also to each drug administered separately. On the other hand, loss of an mdr1 
copy in AS-15MF36P has led to increased sensitivity to ATN + MF either alone or in 
combination. This indicates that in a MF-resistant background, drug pressure may dictate the 
status of mdr1 gene (either amplified or not) and that in this case, the acquisition of an extra 
 126 
copy is enough to render these parasites resistant to the combination as well as to the two drugs 
administered alone. 
In our model, amplification of pcmdr1 gene may play the most important role in resistance 
to ATN + MF combination. These findings raise an important issue. Although ATN and MF are 
chemically unrelated and have apparent distinct physiologic modes of action, the evolution of a 
generic mechanism of defence against drugs by the parasite, such as amplification of mdr1 gene 
might render ACTs treatment ineffective. 
 
II.3.2.2. MDR1 OVEREXPRESSION AND ITS POSSIBLE INTERACTION WITH OTHER 
MUTATIONS 
Mdr1 gene codes for an efflux pump present in the parasite’s food vacuole (Cowman, 
1991; Peel, 2001; Duraisingh and Cowman, 2005) and in this case, may be responsible for 
keeping ATN and MF from reaching their respective intracellular targets, through 
overexpression. That mechanism has been widely described in cancer cells, where P-gp1 (the 
human homologue of MDR1) has been shown to mediate the extrusion of chemically unrelated 
drugs. Amplification and/or overexpression of human mdr1 gene in cancer cells have been 
reported to be responsible for high levels of resistance to multiple drugs used in cancer 
chemotherapy (Baker and El-Osta, 2004; Perez-Sayans et al, 2010).  
As mentioned above, AS-ATNMF-1 has a duplication of a segment of approximately 80 
Kb on chr 12, containing the locus of pcmdr1 gene (along with other twenty three genes). In 
addition, the amplification of pcmdr1 gene in AS-ATNMF-1 is followed by an increased 
expression at RNA (two-to-three-fold increase) and protein (about five-to-six-fold increase) 
levels. This disproportional increase in RNA and MDR1 protein levels may reflect some 
particular transcriptional and/or posttranscriptional regulation of this gene. 
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Treatment with ATN can induce an increase in mdr1 transcription in P. falciparum 
cultured strains (Natalang et al, 2008), indicating the existence of a regulatory pathway that can 
alter transcription of this gene upon stimulation. In addition, other study also indicated that 
amplification of a locus containing mdr1 gene and other thirteen genes was shown to influence 
the level of 269 transcripts (Gonzales et al, 2008). As such, the amplification of pcmdr1 gene in 
association with the other genes in the amplified region in AS-ATNMF-1 may be followed by 
some type of constitutive upregulation of transcription of pcmdr1 and other genes throughout 
the genome. 
It was demonstrated in cancer cells that P-gp1 (coded by mdr1 gene in humans) is targeted 
to degradation by the proteasome and that increased ubiquitination results in reduction of P-gp1 
function (Zhang et al, 2004). As mentioned previously, the AS-ATN clone harbours a V2697F 
mutation in pcubp1 gene, which is believed to affect the function of this enzyme, reducing de-
ubiquitination of different proteins, which would probably increase protein degradation via the 
26S proteasome (Hunt et al, 2007). AS-ATNMF-1 has inherited this mutation in pcubp1 gene 
and in case protein turnover in Plasmodium presents the same mechanisms as described for 
cancer cells, it would be expected that reduced function of pcubp1 product would cause an 
increase in MDR1 degradation, therefore, being responsible for a reduction of MDR1 
expression. The almost six-fold increased MDR1 expression following gene duplication 
observed in AS-ATNMF-1 suggests that MDR1 expression may be regulated by an alternative 
pathway.  
In parallel with the selection of AS-ATNMF-1 by ATN + MF drug pressure, the AS-ATN 
clone was consecutively sub-inoculated into mice for twenty seven weeks, resulting in the AS-
ATN27P parasites. Overall, AS-ATN27P shows a slight decrease in its level of tolerance to 
both drugs, either administered alone or in combination, indicating consecutive passaging in 
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absence of drug was responsible for a small reduction in drug-resistance when compared to the 
original AS-ATN. 
AS-ATN27P harbours no mutations when compared to the unpassaged AS-ATN clone. 
Also, although AS-ATN27P showed no changes in pcmdr1 copy number (single copy) or RNA 
levels, it displayed an increased level of expression of MDR1 protein when compared to AS-
ATN. This is an intriguing observation. In case our previous assumptions regarding the role of 
mdr1 amplification and consequent overexpression in drug-resistance are correct, then, AS-
ATN27P should show a slight decrease in its level of sensitivity to ATN and MF treatment. On 
the contrary, AS-ATN27P is less tolerant to treatment with these drugs than AS-ATN. 
Nonetheless, it is important to consider that the increase in MDR1 protein level accompanying 
pcmdr1 gene duplication in AS-ATNMF-1 was about five-to-six-fold, whereas the increase in 
MDR1 observed for AS-ATN27P nears two-fold. Therefore, in order to display high levels of 
resistance to ATN and MF (alone or in combination), it may be necessary a much higher 
increase in expression of MDR1 than what was observed in AS-ATN27P. In this case, the two-
fold increase in MDR1 protein may simply reflect normal fluctuations in intracellular levels of 
this protein, or even an experimental artefact. 
Most studies that describe mdr1 amplification as determining resistance to ATN and MF, 
either alone or in combination had their focus placed exclusively on mdr1 ((Price et al, 1997; 
Price et al, 1999; Gervais et al, 1999; Pickard et al, 2003; Cravo et al, 2003; Price et al, 2004; 
Alker et al, 2007; Lim et al, 2009; Chaijaroenkul et al, 2010; Chavchich et al, 2010). On the 
other hand, the characterisation of pcmdr1 amplification in P. chabaudi AS-15MF clone has 
taken a whole genome approach and, although in this clone a region containing approximately 
one hundred and twelve genes was amplified, linkage analysis has implicated pcmdr1 and its 
duplicated locus as the most influential when parasites were treated with MF or ART (Borges, 
2009). 
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However, it is important to remember that in AS-ATNMF-1 other twenty two genes have 
also been amplified with pcmdr1 and they may be acting in concert with pcmdr1 amplification, 
for instance by influencing the level at which other genes are transcribed (Gonzales et al, 2008).  
In AS-ATNMF-1 apart from the duplication of pcmdr1 locus, two additional SNPs were 
identified: i) the A805,659T substitution on PCHAS_132020 gene in chr 13; and ii) the 
G1,155,448T on PCHAS_143160 gene in chr 14. AS-15CQ harbours the A805,658T mutation 
in the PCHAS_132020 gene. This mutation is also present in AS-ATN and was inherited by 
AS-ATNMF-1. In addition, a second mutation has appeared in AS-ATNMF-1, just next to the 
first mutation borne by these clones (A805,659T). Whereas the first mutation in AS-15CQ and 
AS-ATN result in the introduction of a STOP codon in position 998 of the protein coded by this 
gene (K998*), the second mutation causes another codon change, and in this case, the 998 
codon encodes a leucine (K998L) in AS-ATNMF-1. Whilst the former mutation is very likely 
to result in a truncated version of this protein in AS-15CQ and AS-ATN, the latter mutation 
identified in AS-ATNMF-1 probably restores protein function, either entirely or partially.  
As described above, apart from AS-ATNMF-1, four other clones resulted from the 
exposure of AS-ATN to ATN + MF treatment. By di-deoxy sequencing analysis it was possible 
to determine that the two mutations in PCHAS_132020 gene were present in AS-ATNMF-2 
and AS-ATNMF-3, whereas only the first one was identified in AS-ATNMF-4 and AS-
ATNMF-5. As discussed above, prior to cloning the parasite population selected with 
increasing doses of ATN + MF could survive after treatment with higher doses of the 
combination when compared with the AS-ATN clone used as starting material. After cloning, 
AS-ATNMF-1 has retained its drug-resistant phenotype, and is more resistant to ATN + MF 
than its progenitor. No phenotype analysis was carried out for the other clones, and assessing 
their level of resistance to ATN + MF either in combination or administered separately could 
help in estimating the importance of the acquisition of the second mutation in PCHAS_132020 
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gene for this phenotype. On the other hand, the appearance of a second mutation in 
PCHAS_132020 gene and the consequent recovery of protein function (as speculated above) 
may have some compensatory effect or even interfere with aspects of parasite’s biology, other 
than drug resistance. Other possibility is that PCHAS_132020 gene has no major function in the 
erythrocyte stage of parasite life cycle. As such, mutations in this gene have no major 
consequences in this stage of development and as therefore, no importance for modeling of 
drug resistance, as attempted here. 
The absence of data regarding PCHAS_132020 biological role in PlasmoDB and the 
inability to identify putative conserved domains in its protein sequence by the bioinformatics 
tools used here limit our ability to further speculate any biological function for these mutations 
regarding resistance to drugs and other cellular aspects. 
The T936,945G mutation on chr 14 is placed in the coding region of PCHAS_143160 gene 
and encodes an non-synonymous substitution, in position 560 (D560Y). Bioinformatics analysis 
of the protein sequence coded by gene PCHAS_143160 suggests that the D560Y mutation falls 
in a putative casein kinase II phosphorylation site contained inside a GLU-rich region. In 
mammalian cells casein kinase II catalyses the phosphorylation of at least 307 different 
substrates and is involved in many cellular processes, such as apoptosis and t-RNA and r-RNA 
synthesis (Meggio and Pinna, 2003). In P. falciparum, erythocytic casein kinase II mediates the 
phosphorylation of parasite’s proteins and by doing that participates in the regulation of 
cytoadherence of the infected red blood cells (Hora et al, 2009). In addition, the presence of 
casein kinases has been identified in the P. falciparum’s genome (Holland et al, 2009) 
suggesting different possible regulatory roles for casein kinase II mediated phosphorylation. In 
such context, the presence of the D560Y mutation in the protein coded by gene 
PCHAS_143160 may be affecting its phosphorylation state and therefore, its function.  
 131 
Although the casein linase II phosphorylation site and other putative conserved domains 
were identified by the different bioinformatics tools used here, no function was attributed for 
the PCHAS_143160 gene in PlasmoDB, and again, our ability to predict the consequences of 
the D560Y mutation to ATN + MF resistance is limited.  
Di-deoxy sequencing analysis of the other four AS-ATNMF clones demonstrated the 
D560Y mutation is only present in AS-ATNMF-1, and absent from AS-ATNMF-2, -3, -4, and -
5. Again, phenotypic analysis of the other four clones could shed light on the importance of this 
mutation for ATN + MF resistance. However, considering that prior to cloning the parasite 
population selected under ATN + MF pressure was more resistant to drug treatment than the 
original AS-ATN, the absence of this mutation in the other AS-ATNMF clones may suggest 
that the D560Y substitution in the protein coded by PCHAS_143160 may not play a crucial role 
in resistance to these drugs. 
Nonetheless, the role of the SNPs identified in PCHAS_132020 and PCHAS_143160 
genes should be investigated. Amplification of mdr1 gene has been reported as causing an 
increased biological cost for parasites (Preechapornkul et al, 2009). In such context, maybe the 
mutations identified in PCHAS_132020 and PCHAS_143160 genes could act as compensatory 
mutations, improving the effectiveness of their respective proteins. In addition, no mutations 
were identified in these PCHAS_132020 and PCHAS_143160 genes in AS-MFATN-5. 
Therefore we suggest that these two mutations may be result from a stochastic process where 
random variations in genome sequence are selected by chance and therefore, have no 
consequence in drug resistant phenotype displayed by AS-ATNMF-1. 
 
II.3.2. OTHER ASPECTS INVESTIGATED IN THIS WORK 
Throughout the course of this work, Solexa whole genome re-sequencing was used for 
obtaining the complete genome sequence of the AS-ATNMF-1 clone. Later, the presence of 
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high confidence mutations on AS-ATNMF-1 was confirmed by di-deoxy sequencing analysis. 
Di-deoxy sequencing was also used for determining the presence of these mutations in other 
clones, and as such their origin was traced back in the AS lineage. The only exceptions were 
two high confidence indels which could not be confirmed by di-deoxy sequencing due to 
technical difficulties. However, strong experimental evidence suggests that these two consist of 
genuine mutations. Since no di-deoxy sequencing confirmation was carried out, it was not 
possible to identify the clone in the AS lineage where they were originated, and therefore, it is 
not possible to correlate their presence with drug resistance. 
On the other hand, five verified mutations present in the artesunate + mefloquine (ATN + 
MF)-resistant AS-ATNMF-1, were also present in the ancestral clones, prior to the selection of 
AS-ATNMF-1: i) three appeared after selection for increased chloroquine (CQ) resistance in 
AS-15CQ; and ii) two were selected by artesunate (ATN) pressure which originated AS-ATN. 
 The above mentioned mutations and their putative roles in drug resistance are going to be 
discussed separately in the sub-sections below.  
 
II.3.2.1. MUTATIONS ARISING AFTER SELECTION FOR INCREASED LEVELS OF 
CHLOROQUINE RESISTANCE IN AS-15CQ 
AS-15CQ was selected from AS-3CQ clone, which displays resistance to low doses of 
chloroquine (CQ) treatment. AS-15CQ parasites were later used for the selection of three 
distinct clones: i) AS-30CQ was selected for high-level of CQ resistance; ii) AS-15MF was 
selected for mefloquine (MF) resistance, and iii) AS-ATN was selected for artesunate (ATN) 
resistance.  
In this work, three novel mutations were identified as first appearing in AS-15CQ.  
The first consists of a SNP, where an A805,658T substitution was identified on chr 13. 
This mutation falls in the coding region of PCHAS_132020 gene, which is described by 
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PlasmoDB as coding for a hypothetical protein. The prediction of the mutated protein sequence 
indicates that this mutation introduces a STOP codon at position 998 (K998*). By di-deoxy 
sequencing it was possible to confirm the presence of this mutation in AS-ATN, and its absence 
in AS-15MF or AS-30CQ. 
The second mutation first appearing in AS-15CQ clone is a 3 bp deletion from position 
472,273 to 472,275 on chr 3. This triplet (AAT) is placed inside the coding region of 
PCHAS_031370 gene, and prediction of the protein sequence indicates this mutation results in 
a deletion of an isoleucine in position 103 (I103). BLAST analysis identified a domain which is 
present in proteins whose expression is induced by superoxide radical generating agents. The 
I103 deletion falls inside this putative domain, and as such may affect the function of this 
protein. This deletion is present in AS-ATN and AS-15MF, while being absent in AS-30CQ. 
The third and last mutation identified in AS-15CQ consists of a 60 Kb deletion spanning 
from the very beginning of chr 13 to approximately position 60,867. This region encompasses 
approximately fifteen genes, most of which code for variable surface antigens which belong 
either to the CIR or pc-FAM family. This deletion is present in AS-ATN, being absent in AS-
15MF and AS-30CQ.  
The changes in protein expression and function caused by the three mutations presented 
above should entail drastic changes in parasite cellular machinery. However, the role of these 
mutations in CQ resistance remains elusive. First because most of genes implicated here have 
yet no known function, and it is therefore hard to predict the effect of polymorphisms or non-
expression of the respective proteins on parasite’s biology. Secondly and maybe more 
importantly, AS-30CQ harbours none of these three mutations. Regardless, AS-30CQ shows 
high level of CQ resistance, indicating other loci may be determining resistance, whereas these 
three mutated loci present in the parental AS-15CQ clone are involved with phenotypes not 
related to drug resistance.  
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One very interesting observation resulting from this analysis is that unlike expected, the 
clones deriving from AS-15CQ did not always inherit the mutations borne by this clone. How is 
it possible that AS-ATN has inherited all the mutations identified here as appearing in AS-
15CQ, whilst AS-15MF harbours the 3 bp deletion on chr 03 and AS-30CQ carries none? 
Whilst gene amplification and deamplification are very common events, the reversal of a 
mutated gene (SNPs or deletions) into its wild type version is very unlikely. Therefore, the 
presence/absence of mutations identified in AS-15CQ in the clones derived from it requires an 
alternative explanation. 
 In fact, the genetics of AS-15CQ and the clones deriving from it has a primary intriguing 
feature: AS-ATN carries the V2697F mutation in pcubp1 gene while both AS-15MF and AS-
30CQ harbour the V2728F mutation in this gene. This would have the following implications: 
considering neither of the two above mentioned mutations on pcubp1 gene appeared in AS-
15CQ, this would imply that the V2728F mutation has appeared independently in two different 
clones (AS-15MF and AS-30CQ) which is very unlikely to occur. So, one possibility is that the 
V2728F mutation should be present in AS-15CQ, and then was inherited by AS-15MF and AS-
30CQ. However, in this case, it would mean AS-ATN has reversed the V2728F mutation and 
acquired a new mutation in pcubp1 (V2697F). A third option would then be to consider both 
mutations were present in AS-15CQ prior to selection of AS-ATN, AS-15MF and AS-30CQ. 
And in order to be inherited separately by AS-15CQ progeny two parasite populations should 
be present, i.e. AS-15CQ is not representative of a clonal population.  
The discovery of the three mutations identified in this work adds up to the puzzle. For 
clarity purposes, focus will be placed specifically on the the presence of the 3 bp deletion on chr 
3 (PCHAS_031370 - I103) on AS-ATN and AS-15MF inherited from AS-15CQ, and its 
absence in AS-30CQ. Considering the 3 bp deletion on chr 3 and the two different genotypes of 
pcubp1 discussed above, three haplotypes are present in the clones deriving from AS-15CQ: i) 
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presence of 3bp deletion on PCHAS_031370 and the V2697F mutation on pcubp1 gene, as in 
AS-ATN; ii) presence of 3bp deletion on PCHAS_031370 and the V2728F mutation on pcubp1 
gene, as in AS-15MF; and iii) absence of 3bp deletion on PCHAS_031370 and the V2728F 
mutation on pcubp1 gene, as in AS-30CQ. 
A simple explanation for this mixture of alleles may lie in the selection procedure which 
has generated AS-15CQ. Briefly, AS-3CQ was exposed to treatment with CQ, generating 
parasites that showed increased level of resistance to this drug. These parasites then passaged 
through mosquitoes (Padua et al, 1980). However, inefficient cloning of the newly generated 
resistant parasites may have left a parasite population consisting of a few clones where the 
mutations in PCHAS_132020 gene, the 3 bp deletion in chr 03 and the 60 Kb deletion in chr 13 
were either present or absent. In addition, the two different mutations on pcubp1 gene would 
have appeared also upon AS-15CQ selection, in two distinct events. When passaged through 
mosquitoes, genetic recombination would have generated a multi-clonal population that after 
further selection and posterior cloning would have been converted into three different clones, 
carrying three different haplotypes, as seen in AS-ATN, AS-15MF and AS-30CQ.  
This hypothesis may be not very far-fetched if one considers cloning methodology. 
According to statistics, by inoculating the equivalent of 1 parasite in each mouse, a clonal 
population is obtained in each animal showing parasite growth if at least 37% of all animals 
have no detectable parasitaemia. However, it is not possible to guarantee only one parasite was 
indeed inoculated in the acceptor mouse, or that, although more parasites could have been 
present in the first moment, only a single parasite multiplies in order to form the infecting 
population.  
The appearance of two distinct mutations on pcubp1 gene during the selection of AS-
15CQ might indicate that CQ pressure, rather than ATN or artemisinin (ART), is the major 
factor influencing the evolution of mutations in this gene in our model. Indeed, work carried out 
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by our group has indicated that parasites harbouring pcubp1 mutations are selected by CQ 
treatment (Mordzynska, 2010). Nevertheless, in a genetic cross between AS-15MF and AJ, 
treatment with ART, MF and lumefantrine was also found to select parasites bearing the 
V2728F mutation in pcubp1 (Borges, 2009).  
Elucidation of the role of the pcubp1 gene in regulation of protein expression in drug-
sensitive and drug-resistant parasites of the AS lineage may shed light in these questions. 
Additionally, identifying the functions and the changes imposed by mutations on the other 
genes identified as appearing in AS-15CQ will certainly help to clarify the mechanisms 
underlying the complex genetics of CQ resistance. However, it is important to retain that AS-
15CQ does not consist of a clonal population, and as such, an accurate genetic analysis of these 
parasites may not be possible.  
 
II.3.2.2. MUTATIONS ARISING AFTER SELECTION FOR ARTESUNATE 
RESISTANCE IN AS-ATN 
AS-ATN was selected from AS-15CQ by consecutive sub-inoculations in mice treated 
with stepwise increasing doses of ATN. Genetic analysis of this clone carried out in this work 
have confirmed the presence of the V2697F mutation in pcubp1 gene, whose role in ATN 
resistance has been discussed elsewhere (Hunt et al, 2007) and identified the presence of two 
previously unknown mutations: i) the A636,862G substitution near the 3’-end of 
PCHAS_061710 gene on chr 6; and ii) a mutation in gene PCHAS_133430 on chr13, resulting 
in an E738K substitution in a 26S proteasome subunit.  
As indicated by PlasmoDB, the PCHAS_061710 gene on chr 6 codes for a seryl t-RNA 
synthetase, which is responsible for the attachment of the correct aminoacid to its cognate 
transfer RNA (t-RNA) during protein synthesis (Bhatt et al, 2009). In human cells, untranslated 
regions placed upstream the 3’-end of a gene were described as being involved in translational 
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regulation of this gene (Chatterjee and Pal, 2009). In addition, low complexity regions were 
described in Plasmodium as regulators of folding of the newly synthesized proteins (Frugier et 
al, 2010). Mutations in the upstream region near the 3’-end of gene PCHAS_061710 may 
therefore cause changes in the levels of expression or misfolding of seryl t-RNA synthetase, 
and as a consequence may cause serious effects in parasite protein synthesis machinery.  
 However, as the seryl t-RNA synthetase belongs to a pathway of major importance, there 
is a chance that protein synthesis would be maintained at its normal levels by other proteins 
with similar function. Functional redundancy has been already observed as present in other 
pathways in Plasmodium (Omara-Opyene et al, 2004) and could be responsible for 
counteracting the role of the mutations identified here. 
The second mutation indentified in AS-ATN is a non-synonimous (E738K) mutation in 
gene PCHAS_133430, which codes for a 26S proteasome subunit. The E738K mutation falls in 
the putative proteasome/cyclosome repeat region identified by BLAST analysis of this gene. 
The 26S proteasome is described as involved in degradation of different types of ubiquitin-
tagged proteins (van Leuken et al, 2008). In additon, cell cycle regulatory proteins can also be 
degraded by the 26S proteasome, and it has been indicated that cyclin degradation by the 26S 
proteasome is necessary for cell cycle progression (van Leuken et al, 2008).  
In P. falciparum cultured strains, evolution of ART resistance has been described as 
mediated by a quiescence mechanism, in which ART-tolerant parasites remain arrested at ring 
stage in the presence of ART treatment. When the drug is removed from the medium, the 
parasites re-enter cell cycle, developing into schizonts and undergoing replication (Witkowski 
et al, 2010). In this context, the E738K mutation identified in AS-ATN could be affecting the 
replication machinery of this clone, by causing partial or complete disruption of 26S 
proteasome function. 
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In addition, it is possible that the V2697F mutation in pcubp1 gene is acting in concert 
with the E738K mutation in the 26S proteasome in AS-ATN parasites, since de-ubiquitinating 
enzyme and the 26S proteasome are both part of the protein degradation pathway. Indeed, as 
suggested by Hunt and colleagues, the mutation V2697F would be responsible for a reduction 
in the de-ubiquitinating activity of the protein coded by pcubp1 gene. This would increase 
protein degradation via the 26S proteasome. In this case, the E738K mutation identified in the 
26S proteasome subunit identified here could have one of the two possible roles: i) decreasing 
the 26S proteasome activity, and acting as compensation for the V2697F mutation in pcubp1 
gene; ii) increasing the 26S proteasome activity and in this case, this would have an enhanced 
impact in protein turnover.  
Given the high degree of redundancy identified in cell cycle components in other 
eukaryotes, it is possible, as hypothesized for the mutation in the region near the 3’-end of gene 
PCHAS_061710 above, that the E738K mutation on the 26S proteasome subunit may be 
compensated to some extent by other mechanisms, resulting in little or no effect in overall cell 
cycle progression.  
The role of the two novel mutation identified in AS-ATN regarding ATN resistance needs 
to be further investigated. 
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CHAPTER III 
FITNESS COST OF RESISTANCE TO ARTESUNATE + MEFLOQUINE  
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This Chapter describes the competition assays to which the ATN + MF-resistant AS-
ATNMF-1 clone selected and characterised in Chapter II was subjected. These assays aimed to 
check if the selection procedure has resulted in changes in AS-ATNMF-1 fitness when 
compared to the progenitor AS-ATN. This Chapter will be subdivided in three sections: i) 
Introduction – a brief review of the literature involving parasite fitness and its consequences for 
the spread and maintenance of drug-resistant strains in parasite populations will be presented; 
ii) Results – firstly, optimisation of the protocol for the determination of proportions of 
individual strains in parasite mixtures will be described, and secondly, data relative to the 
within host competitive growth of the ATN + MF-resistant AS-ATNMF-1 and its AS-ATN 
progenitor or the untreated parallel line AS-ATN27P, will be described.; iii) Discussion – the 
results obtained in the previous section will be discussed.  
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III.1. INTRODUCTION 
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III.1.1. FITNESS COST OF DRUG RESISTANCE  
As postulated in Charles Darwin’s classical book The Origin of Species (Darwin, 1859), 
the evolution of a species is directly connected to its ability to survive and propagate in a 
certain environment. In very general terms, this means that individuals must compete not only 
with others belonging to different species (Richardson et al, 2009; Staves and Knell, 2010), but 
also that intra-specific competition shapes the characteristics of a population (Wargo et al, 
2007; Baquero and Lemonnier, 2009; Staves and Knell, 2010; Mackinnon and Marsh, 2010). 
Therefore, in any given circumstance there is a tendency that the less fit individuals are 
displaced from the population by the best adapted ones (Wargo et al, 2007; Richardson et al, 
2009). However, being extremely well adapted to a certain environment does not mean an 
individual is adapted to any environment (Hoffmann, 2010), and in fact, changes in surrounding 
conditions may subvert what was formerly an advantage into a disadvantage (Anderson, 2005; 
Bottger and Springer, 2008). 
The malaria parasite interacts with different environments throughout its life cycle. It goes 
through two different hosts, from the mosquito’s midgut through its haemolymph to its salivary 
glands, and then in the mammalian host from hepatocytes through the blood stream to the 
erythrocyte. Together, all these factors help to shape the parasite’s genome and, consequently, 
its phenotype (Mackinnon and Marsh, 2010).  
With regards to the mammalian host bloodstream only, it is clear that the malaria parasite 
has to face many obstacles in order to establish and maintain a successful infection. The most 
obvious challenge for the parasite’s survival is the host’s immune system, against which the 
parasite has developed a very efficient evasion strategy. Another aspect of parasite’s adaptation 
would be its intrinsic ability to invade, explore, proliferate, and develop within the erythrocyte. 
Finally the parasite’s investment in sexual stages can also be a determinant of fitness, as it 
allows the parasites to undergo genetic recombination and also explore new hosts.  
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III.1.1.1. EMERGENCE OF RESISTANCE: AN INCREASED BURDEN 
In most cases, symptomatic malaria patients are treated with drugs (Luxemburger et al, 
1997). As mentioned previously, intensive use of antimalarials has led to the appearance and 
dispersal of parasites harbouring increased tolerance and even high levels of resistance to one or 
multiple drugs. In some areas, parasite strains harbouring either drug sensitive or drug resistant 
alleles can be observed. Depending on the strength with which a drug was used in this 
population or the transmission intensity of the region (Mackinnon, 1997), the resistant allele(s) 
may be at very high frequency or close to fixation in the parasite pool (Price et al, 1999; Lopes 
et al, 2002; Price et al, 2004; Anderson et al, 2005). 
Studies in many different organisms have shown that the acquisition of mutations 
conferring drug resistance is frequently deleterious in absence of drug pressure, being 
accompanied by a reduction in the ability of the resistant strain to compete with a sensitive one 
in untreated hosts (Anderson, 2005; Bottger and Springer, 2008). This is known as fitness cost 
and was largely described in bacteria (Gagneux, 2009; Andersson and Hughes, 2010). 
Many groups have investigated the fitness cost of resistance in malaria parasites. In 1994, 
one study found that in the rodent malaria parasite Plasmodium berghei a pyrimethamine 
(PYR)-sensitive strain had transmission advantage over a PYR-resistant one (Shinondo et al, 
1994). This finding is in accordance with previous work on another rodent model, P. chabaudi 
(Rosario et al, 1978). In this work a PYR-resistant strain was outgrown by its sensitive 
progenitor in two out of three experiments. In the same study the cost incurred by chloroquine 
(CQ)-resistant parasites was also investigated, by using a similar approach. However, in this 
case, the sensitive strain was outgrown by the resistant parasites indicating resistance may not 
always be followed by reduction in fitness of a parasite strain (Rosario et al, 1978). 
In in vitro cultured P. falciparum strains, Hayward and colleagues (2005) have identified 
that polymorphisms on the pfmdr1 gene that confer resistance to CQ can be deleterious in the 
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absence of drug pressure. Similarly, in a mefloquine (MF)-resistant strain, the amplification of 
pfmdr1 was associated with a decrease in fitness when compared to the sensitive counterpart. In 
this study, additional increase in copy number was associated with increased detrimental effects 
on parasite’s survival (Preechapornkul et al, 2009).  
In addition to studies using laboratory strains, field analysis also indicates that in the 
absence of drug pressure, the frequency of mutated alleles related with drug resistance tends to 
decrease in a geographic region (Thaithong et al, 1988; Schwenke et al, 2001; Nair et al, 2003; 
Abdel-Muhsin et al, 2004; Ord et al, 2007; Babiker et al, 2009). The most important field study 
corroborating fitness cost of resistance is the case of CQ use and its subsequent withdrawal in 
Malawi (Laufer et al, 2006). In this country, CQ was used as first line therapy against P. 
falciparum malaria, and cases of resistance were first reported in the 1970’s. In 1993, clinical 
failure after CQ therapy reached about 50%, accompanied by an 85% prevalence of the 
mutation K76T in the pfcrt gene (Kublin et al, 2003). CQ was then replaced by sulphadoxine + 
pyrimethamine (SP) as the first-line treatment. Over time, reports indicated that the presence of 
the mutated pfcrt K76T marker in the parasite population decreased to about 17% in 1998, and 
finally to 2% in 2000 (Mita et al, 2003). Clinical trials were carried out and the resurgence of 
CQ sensitivity was reported (less than 1% clinical failure in 2005) (Laufer et al, 2006).  
The re-emergence of CQ sensitivity in Malawi was shown to have taken place due to the 
re-emergence of sensitive parasite populations, reflected by the re-expansion of parasites 
carrying pfcrt sensitive alleles, rather than by back-mutation in this gene (Mita et al, 2004). 
This provides strong indication that CQ-sensitive parasites were fitter than resistant ones, and 
therefore when CQ pressure was removed, resistant parasites were slowly removed from the 
parasite pool.  
The case of Malawi might have serious implications for therapy policy in the field: the 
reversal of CQ resistance reported in Malawi provid
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abandoned drugs, such as CQ, could be re-introduced in case of emergence of resistance to 
currently used therapies. 
However, the case of reversal of CQ resistance in Malawi is so far unique. In Kenya, the 
substitution of CQ for SP, led to a decrease in the prevalence of the K76T mutation from 94% 
in 1993 to 63% in 2006, but not the elimination of the mutated allele, which remained 
correlated with low susceptibility to CQ in vitro (Mwai et al, 2009). Also, in Gabon there was a 
decrease in in vitro CQ resistance from 100% in 1992 to 45% in 1996 (Schwenke et al, 2001). 
However, in vivo studies showed 100% clinical failure after CQ therapy and the presence of 
K76T mutated pfcrt in all samples analysed (Borrmann et al, 2002).   
 It is important to reinforce the idea that successful reintroduction of a drug would only be 
possible if resistance to this drug imposes a burden to parasite’s survival in the absence of drug 
pressure. Additionally, treatment with the drug must be completely ceased, and the newly 
deployed treatment cannot be based on drugs that share mechanisms of action with the replaced 
drug. Finally, it is also crucial that the resistant allele has not reached near-fixation levels, i.e, 
enough sensitive parasites must remain in the population so they can compete and displace the 
resistant ones (Hayward et al, 2005). 
 
III.1.1.2.  COMPENSATORY MUTATIONS 
In some cases, the acquisition of resistance is accompanied by subsequent mutations that 
compensate for the burden caused by the changes conferring a disadvantageous phenotype. 
These “compensatory mutations” can then restore parasite’s fitness either partially or 
completely, allowing resistant parasites to remain in the population even in the absence of 
selective pressure. This phenomenon has been reported in bacteria, where compensatory 
mutations can occur either in the gene where previous mutations have led to the acquisition of 
drug resistance or in a different one (Maisnier-Patin and Andersson, 2004; Nilsson et al, 2006). 
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In bacteria, some studies describe the appearance of compensatory mutations after serial 
passages of the resistant strain in the absence of drug pressure (Kugelberg et al, 2005; Nilsson 
et al, 2006). 
In malaria parasites it is also possible that consecutive passaging through mice may 
increase parasite fitness. For instance, in a study carried out in P. chabaudi, a low-fitness 
(relative to the sensitive progenitor) PYR-resistant clone underwent consecutive passages 
through mice and then through mosquitoes in absence of drug. This clone eventually outgrew 
its sensitive progenitor in untreated hosts (Walliker et al, 2005). As the increased fitness shown 
by the passaged parasites was not reverted by transmission through mosquitoes, it is possible 
that consecutive sub-inoculations into mice was responsible for the appearance of mutations 
(genetically stable changes, which can be therefore transmitted through mosquitoes), and that 
these mutations may act as compensation for the deleterious effects of PYR resistance, 
increasing parasite’s fitness in absence of drug. 
In fact, other studies have shown that, some mutations were implicated as playing a role in 
compensating for the burden imposed by the acquisition of drug resistance in malaria parasites. 
Amplification of the pfgch1 gene, coding for the GTP-cyclohydrolase I, was reported to be 
prevalent in field samples from areas where high levels of anti-folate drugs were used (Nair et 
al, 2008). This enzyme is involved in folate metabolism (Dittrich et al, 2008) and the 
amplification of this gene, and consequently increased protein expression, is believed to 
function as compensation for the mutations in pfdhfr and pfdhps genes in pyrimethamine 
(PYR)-resistant parasites (Nair et al, 2008). Osman and colleagues (2007) described that 
multiple mutations in genes associated with resistance to chloroquine (CQ) and PYR impose a 
high fitness cost, expressed as lower parasite density in the host blood. However, this trait was 
accompanied by an increased gametocyte production, which the authors believe to act as 
compensation for the reduction in asexual forms.  
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The presence of compensatory changes in expression pattern of different transporters has 
also been described as adaptation to CQ resistance conferred by the K76T mutation in the pfcrt 
gene (Jiang et al, 2008). 
 
III.1.2. AIMS 
In this chapter, results assessing the potential fitness cost associated with the acquisition of 
resistance to the ATN + MF are presented. As described in Chapter II, the ATN + MF-resistant 
AS-ATNMF-1 clone was selected after serial sub-inoculation into host mice treated with the 
ATN + MF combination. The AS-ATN clone was used as starting material for the selection of 
AS-ATNMF-1 and was also passaged through mice in the absence of drug treatment, 
generating the A-ATN27P parasite line.  
We have then performed experiments to evaluate how the within-host growth of parasites 
resistant to combination treatment compares to that of sensitive ones. Thus the next section will 
outline competition assays designed to determine the biological cost of the acquisition of 
resistance to ATN + MF by AS-ATNMF-1. This clone was grown in competition with the 
original parental AS-ATN and also with AS-ATN27P. 
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III.2.1. COMPETITION ASSAYS 
Increased resistance to a drug is commonly associated with reduced growth of resistant 
parasites when compared with drug-sensitive ones in the absence of drug pressure (Rosario et 
al, 1978; Shinondo et al, 1994; Peters et al, 2002). This biological cost (or fitness cost) could 
therefore grant the sensitive parasites adaptive advantages over the resistant ones when co-
infecting the vertebrate host. In such context, the impact of the evolution to an ATN + MF-
resistant phenotype undergone by AS-ATNMF-1 was assessed. AS-ATNMF-1 was grown 
within the same host together with its original progenitor AS-ATN in mixtures containing 
different initial proportions of the two clones. 
It has been observed that changes in parasite fitness can also occur due to repeated sub-
inoculations into mice (Mackinnon and Read, 1999; Walliker et al, 2005). Since the selection of 
ATN + MF-resistance was made by consecutive sub-inoculations in mice under drug treatment, 
the fitness of AS-ATNMF-1 clone was also assessed when in competition with AS-ATN27P, 
the untreated parasites passaged twenty seven times in parallel with AS-ATNMF-1. 
It is important to highlight that accurate estimates of Plasmodium parasites’ fitness should 
take into account the ability of one strain to outcompete a different one throughout each phase 
of the parasite’s life cycle.  However, in this work, competition assays will only assess parasite 
growth in the mammalian host’s bloodstream.  
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III.2.1.1. VALIDATION OF THE COMPETITION ASSAYS 
As described in Chapter II, a G to T substitution in position 1155448 on chr 14, in the 
PCHAS_143160 gene is exclusive to the AS-ATNMF-1 clone. By using proportional 
sequencing analysis targeting this mutation, it is possible to estimate the relative proportion of 
AS-ATNMF-1 parasites present in a mixture with parasites displaying the wild-type form of 
this genotype. However, prior to determining parasite proportions in unknown mixtures, it was 
crucial to verify whether the accuracy of quantifying parasite proportions using this method was 
satisfactory for analysing unknown mixtures. For this purpose artificial mixtures with known 
proportions of AS-ATNMF-1 and AS-ATN27P parasites were prepared and analysed, as 
described in the Material and Methods, Section 4. The amplified fragments were analysed for 
each sample in both forward and reverse directions and, subsequently, peak heights were 
measured in the genetically polymorphic position. These were then used to calculate the relative 
proportions of each parasite.  
Overall, there was a good correlation between the observed and expected values, reflected 
by a linear pattern in both the forward and reverse directions (Figure 17).  However, it was 
verified that the use of the reverse primer produced slightly more accurate results, as reflected 
in the observation that the expected and observed values were more correlated to each other 
than those produced using the forward assay (Figure 17). The assay was subsequently used to 
estimate parasite proportions in the competition experiments described below. 
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(%) forward sequence 
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  100  100   100 
  99   100   100 
  90   91.4   91.7 
  75   78.5   76 
  50   56.4   52 
  25   33.6   29.2 
  10   14.5   15 
  1   4.5   
4.3 
  0   0   0 
 
 
Figure 17 – Validation of proportional sequencing method. DNA present in artificial mixtures of AS-ATNMF-1 
and AS-ATN27P parasites was analysed for the detection of a G to T substitution in position 1155448 on chr 14. 
Analysis of electropherograms resulted in the observed proportion of the sensitive allele calculated for both 
forward and reverse sequences that are shown in table. The values from both forward (black diamonds) and reverse 
sequences (black squares) were plotted against the expected values, as depicted in the graph. In addition, the 
calibration curve is shown (gray triangles and line).  
 
III.2.1.2. WITHIN-HOST COMPETION ASSAYS USING AS-ATN + AS-ATNMF-1 
In order to determine if the evolution of resistance to ATN + MF may have caused any 
impact on the fitness of the AS-ATNMF-1 clone relative to its progenitor AS-ATN, five groups 
of mice were inoculated with mixtures of the two parasites in different proportions 100:0, 
90:10, 50:50, 10:90, and 0:100 (AS-ATN:AS-ATNMF-1). Absolute parasitaemias and 
proportions of each clone were analysed for each animal along time, as described below. 
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EVOLUTION OF ABSOLUTE PARASITE GROWTH ALONG TIME 
In order to gain an initial insight into the overall parasite growth, absolute percentage 
parasitaemias were followed over time in mice infected with the above inocula. Mice inoculated 
with AS-ATN parasites alone (100:0) showed peak parasitaemia of about 38% on Day 10 post-
inoculum (pi). In the group of mice inoculated only with AS-ATNMF-1 (0:100), parasites grew 
faster, and reached higher levels of parasitaemia than AS-ATN (near 63% on Day 8 pi) (Figure 
18).  
Mice inoculated with unequal proportions of AS-ATN and AS-ATNMF-1 (10:90 and 
90:10) showed similar parasite growth as animals inoculated with AS-ATNMF-1 alone (0:100). 
These mice showed peak parasitaemias of about 50-55% on Day 8 pi. However, after reaching 
peak parasitaemia, mice inoculated with higher proportion of AS-ATN (90:10) appeared to 
have a much smoother decrease in parasite numbers when compared to animals inoculated with 
higher proportion of AS-ATNMF-1 (10:90) or AS-ATNMF-1 alone (0:100) (Figure 18).  
A biphasic shape was observed in the curve representing parasite growth of animals 
inoculated with equal proportions of AS-ATN and AS-ATNMF-1 (50:50). In this group, the 
first day of detection of parasites in the blood smears differed greatly when comparing the three 
mice. This indicated a difference in the initial absolute number of parasites inoculated in each 
animal, most likely due to a technical shortcoming, although inherent biological variations 
cannot be excluded. Therefore, the biphasic shape of the parasite growth curve does not 
probably reflect changes in the growth pattern of parasites due to competition within the host. 
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Figure 18 – Percentage (%) parasitaemias were determined along time for animals inoculated with different 
proportion of the artesunate + mefloquine-resistant AS-ATNMF-1 clone and its progenitor, AS-ATN. Legend 
indicates initial percentage of AS-ATN clone. 
 
EVOLUTION OF PARASITE PROPORTIONS ALONG TIME 
In addition to determination of absolute parasite growth by analysis of percentage 
parasitaemias along time, the proportion of each clone in the blood of each mouse was 
measured every two days. This was made by PCR amplification of a fragment of 
PCHAS_143160 gene containing a G to T mutation in AS-ATNMF-1, and by assessing the 
peak heights of chromatograms obtained from sequencing each amplified sample.  
DNA samples were first obtained from blood mixtures which were later inoculated into 
mice. Thus, the initial proportions of AS-ATN and AS-ATNMF-1 inoculated in each mouse 
were determined (Day 0, Figure 20). It was possible to verify that mice inoculated with a higher 
proportion of AS-ATN (90:10) appeared to have received a smaller proportion of AS-ATN than 
expected (about 79% of the wild-type allele in the mixture). Conversely, samples obtained from 
the inoculum where equal proportions of the two clones were injected into mice consisted of a 
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higher proportion of AS-ATN, as approximately 60:40 was observed instead of 50:50 (AS-
ATN:AS-ATNMF-1). Finally, the proportions of each clone in the initial inoculum of the group 
of mice that received a higher proportion of AS-ATNMF-1 (10:90) seem to be consistent with 
the expected values (Figure 19). 
Regardless of the initial proportion of each parasite in the initial inoculum, when observing 
the samples obtained from each mouse along time, the presence of the wild-type allele 
(representing AS-ATN clone) decreased along time.  In fact, when observing the animals 
inoculated with higher proportions of the wild-type AS-ATN clone (90:10) this decrease 
appeared to be almost linear along time, and from Day 8 AS-ATNMF-1 proportions have 
increased when compared to the initial proportion inoculated in each mouse in this group (on 
around 32% on Days 8 and 10, p<0.005; around 40% on Day 12 and 61% on Day 14, 
p<0.0004) (Figure 19).  
Similarly, in mice initially inoculated with similar proportions of each clone (nominally 
50:50, but in reality 60:40), the proportion of the AS-ATN allele decreased from its initial value 
(60%) to Day 4 (30%, p<0.0004), with a further reduction from Day 4 to Day 6 (20%, 
p>0.0004). However, from Day 6 onwards, the proportion remained unchanged up to Day 14, 
when a further reduction in the wild-type allele was observed (12%, p>0.0004) (Figure 19). 
Samples obtained from mice inoculated with higher proportions of AS-ATNMF-1 (10:90) 
also showed a decrease in the proportion of the wild-type allele (AS-ATN), with the reduction 
of the AS-ATN clone below detection by Day 10 (Figure 19). 
The parasite proportions of in blood samples from mice inoculated with only AS-ATN 
(100:0) or AS-ATNMF-1 (0:100) were also calculated and served as controls. No changes in 
the initial proportion were found along time in these two groups of mice.  
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Figure 19 - Competition assays carried out using the artesunate + mefloquine-resistant AS-ATNMF-1 clone and its 
progenitor, AS-ATN. Bars represent the mean of two animals. Gray bars represent AS-ATNMF-1 (mutant) allele 
and black bars represent AS-ATN (wild type) allele. Day 0 corresponds to samples obtained from the blood 
mixture used to inoculate each mouse. From Day 4 onwards, samples were obtained from each animal in each time 
point. Statistical analysis was made comparing the obtained proportions along time against the proportion 
inoculated into mice: * p<0.005; ** p<0.0004. 
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III.2.1.3. WITHIN-HOST COMPETION ASSAYS USING AS-ATN27P + AS-ATNMF-1 
As observed in the previous section, the artesunate + mefloquine (ATN + MF)-resistant 
AS-ATNMF-1 clone seems to outgrow its sensitive progenitor AS-ATN when in competition 
within the same host in absence of drug treatment.  
In order to determine if consecutive passaging through mice would be responsible for any 
changes in parasite fitness, the growth of AS-ATNMF-1 was assessed when in competition 
within the same host with AS-ATN27P, the uncloned parasites passaged twenty seven times in 
absence of drug treatment. In that context, parasite mixtures were prepared in different 
proportions 100:0, 90:10, 50:50, 10:90, and 0:100 (AS-ATN27P:AS-ATNMF-1) and injected 
into mice. Absolute parasitaemias and parasite proportions were determined along time. 
 
 EVOLUTION OF ABSOLUTE PARASITE GROWTH ALONG TIME 
In a similar fashion as the competition assays performed using AS-ATNMF-1 and AS-
ATN clones, the absolute percentage parasitaemia was analysed in mice receiving the different 
parasite inocula. 
Mice inoculated only with AS-ATN27P (100:0) showed similar parasite growth as 
observed for mice inoculated only with AS-ATNMF-1 (0:100). AS-ATN27P (100:0) showed 
peak parasitaemias of 79% and AS-ATNMF-1 (0:100) showed peak at 61%, both on Day 8 pi. 
However, the slope of the AS-ATN27P growth curve was higher than the one observed for AS-
ATNMF-1, which may indicate a slight difference in growth of the two parasites, with AS-
ATN27P having a slightly higher growth rate (Figure 20). 
Differences in slope could also be observed when calculating the parasitaemias of mice 
inoculated with mixtures of the two parasites. The parasite growth curve shown by mice 
inoculated with higher proportion of AS-ATN27P (90:10) had a steeper slope when compared 
with the curve of mice receiving a higher proportion of AS-ATNMF-1 (10:90) (Figure 20). 
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When examining the animals which received equal proportions of AS-ATNMF-1 and AS-
ATN27P (50:50), a considerably smoother parasite growth curve could be observed. 
However, parasite growth in the three groups of animals receiving the mixtures of the two 
parasites in different proportions (90:10, 50:50, and 10:90) seemed to be very similar. All 
groups of mice showed peak parasitaemias on Day 8, ranging from 50-to-63% (Figure 20).  
 
 
0.0
20.0
40.0
60.0
80.0
100.0
4 6 8 1 1 1
0
10
50
90
100
 
 
Figure 20 – Percentage (%) parasitaemias shown by mice inoculated with different proportion of the artesunate + 
mefloquine-resistant AS-ATNMF-1 and the parasites passaged twenty seven times in the absence of drug pressure, 
AS-ATN27P. Legend indicates initial percentage of AS-ATN27P parasites. 
 
 
EVOLUTION OF PARASITE PROPORTIONS ALONG TIME 
In order to assess the growth of AS-ATN27P and AS-ATNMF-1 in competition within the 
same host, the parasite proportions in the blood of mice injected with the different mixtures of 
parasites was analysed in a similar fashion as described above. 
Firstly, a sample of the blood mixture used to inoculate each group of mice was analysed, 
in order to determine the actual proportions initially inoculated in each group of mice (Day 0, 
Time (days pi) 
%
 P
ar
as
it
ae
m
ia
 
AS-ATN27P + AS-ATNMF-1 
 158 
Figure 21). In all cases, the proportion of wild-type and mutant alleles (representing AS-
ATN27P and AS-ATNMF-1, respectively) corresponded approximately to the expected values.  
After the inoculum, blood samples were extracted from each mouse every two days (from 
Day 4 onwards) and then analysed.  
The group of mice which received an inoculum containing a higher proportion of AS-
ATN27P (90:10) showed a slight increase in the proportion of the wild-type allele (representing 
AS-ATN27P) along time, from 90% on Day 4 to about 93% on Day 10. From Day 12 onwards, 
however, the proportion of the wild-type allele started to decrease, reaching 89% on day 14 
(Figure 21). 
The same pattern could be observed in mice which were inoculated with equal proportions 
of the two parasites (50:50). However, this pattern was more pronounced than in mice 
inoculated with a higher proportion of AS-ATN27P (90:10). Thus, there was an increase in the 
proportion of the AS-ATN27P allele from about 53% on Day 4 to almost 70% on Day 8 
(p<0.001). On Day 10, the proportion began to decrease and reached about 50% on Day 14 
(Figure 21). 
Mice inoculated with higher proportions of AS-ATNMF-1 (10:90) showed the same 
pattern of increase of the wild-type allele (AS-ATN27P) along time, however, with some delay. 
Thus, the proportion of AS-ATN27P appeared stabilise around 10% up to Day 6. On Day 8 it 
started to increase, reaching about 25% on Day 12 (p<0.0001). On Day 14, however, there was 
a decrease to about half the value measured on Day 12 (about 13%) (Figure 21).  
The proportions of each parasite were also calculated in samples extracted from mice 
inoculated only with AS-ATN27P (100:0) or AS-ATNMF-1 (0:100), and served as control. No 
differences were found in the initial inoculum and the expected values. In addition, no changes 
in the percentages of each allele were found along time in these two groups.  
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Figure 21 – Competition assays carried out using the artesunate + mefloquine-resistant AS-ATNMF-1 clone and 
the parasites passaged twenty seven times through mice in absence of drug, AS-ATN27P. Bars represent the mean 
of two animals. Gray bars represent AS-ATNMF-1 (mutant) allele and black bars represent AS-ATN27P (wild 
type) allele. Day 0 corresponds to samples obtained from the blood mixture used to inoculate each mouse. From 
Day 4 onwards, samples were obtained from each animal in each time point. Statistical analysis was made 
comparing the obtained proportions along time against the proportion inoculated into mice: * p<0.02; ** p<0.002; 
*** p<0.006; † p<0.0001. 
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CHAPTER SUMMARY 
The growth of artesunate + mefloquine (ATN + MF)-resistant AS-ATNMF-1 clone was 
compared with the progenitor AS-ATN in the absence of drug treatment within the same host. 
This competition assay provided an indication that the acquisition of resistance to ATN + MF 
by AS-ATNMF-1 seems to confer no biological disadvantage when in competition with its 
sensitive progenitor AS-ATN.  
In order to assess if consecutive sub-inoculations could be responsible for the changes in 
fitness observed on the selected AS-ATNMF-1 clone, the growth of this clone was compared to 
those of AS-ATN27P parasites in absence of drug treatment within the same host.  
A slight difference between the ATN + MF-resistant AS-ATNMF-1 clone and the drug-
sensitive AS-ATN27P parasites is expressed as an initial increase in AS-ATN27P proportions 
in relation to AS-ATNMF-1. However, this increase is followed by a reduction in the AS-
ATN27P proportions, which tend to return to the initial level. This result seems to indicate that 
there may be a small fitness cost associated with ATN + MF-resistance in AS-ATNMF-1. 
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III.3. DISCUSSION 
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A clone showing moderate level of resistance to artesunate (ATN), AS-ATN was used for 
the selection of resistance to artesunate + mefloquine (ATN + MF), originating the AS-
ATNMF-1 clone. Previous studies have indicated that an increase in drug resistance may cause 
a decrease in parasite fitness in absence of drug treatment (Rosario et al, 1978; Shinondo et al, 
1994; Peters et al, 2002). Sometimes this decrease in fitness is directly related to the 
mechanism evolved by the parasite to escape the toxic effects exerted by drug treatment 
(Rosario et al, 1978; Walter, 1986). 
In order to estimate if ATN + MF resistance could have caused a decrease in fitness of AS-
ATNMF-1, this clone was inoculated in the same host together with its progenitor AS-ATN in 
different initial proportions. In all cases, AS-ATNMF-1 appeared to outgrow its sensitive 
progenitor, which suggests that AS-ATNMF-1 is fitter than AS-ATN. This result contradicts 
the above mentioned assumption. In fact, by observing the growth of each parasite alone, AS-
ATN seems to have a slower growth rate than AS-ATNMF-1. Thus, through these initial 
observations, it could be expected that when grown within the same host AS-ATNMF-1 would 
outcompete AS-ATN.  
Other studies have also showed that increased drug-resistance may not always be followed 
by reduced fitness when compared to the respective sensitive progenitor, as demonstrated in a 
chloroquine (CQ)-resistant P. chabaudi clone (Rosario et al, 1978). In addition, there is also 
evidence that in P. falciparum natural populations resistance may not always cause increased 
fitness cost to parasites, as in some regions CQ withdraw caused a reduction in frequency but 
not the complete removal of resistant parasites from the population (Borrmann et al, 2002; 
Mwai et al, 2009). A possible explanation to such trend may be that in some cases, evolution of 
resistance is accompanied by acquisition of secondary mutations that compensate for fitness 
loss induced by the mutation directly responsible for drug resistance (Nair et al, 2008; Jiang et 
al, 2008). As discussed in Chapter II, AS-ATNMF-1 has acquired three mutations when 
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compared to AS-ATN: i) amplification of the mdr1 gene; ii) a non-synonymous point mutation 
in the PCHAS_132020 gene; and iii) a non-synonymous point mutation in the PCHAS_143160 
gene. Amplification of mdr1 has been previously described as responsible for increased drug 
resistance (Price et al, 1997; Price et al, 1999; Pickard et al, 2003; Price et al, 2004; Alker et al, 
2007; Wongsrichanalai and Meshnick, 2008; Lim et al, 2009; Rogers et al, 2009; Chaijaroenkul 
et al, 2010; Chavchich et al, 2010) but, on the other hand, is also associated with reduced 
fitness of mutant parasites (Preechapornkul et al, 2009). As discussed in Chapter II, it is 
possible that the amplification of mdr1 gene is the most relevant genetic change for the 
expression of the ATN + MF resistance phenotype displayed by AS-ATNMF-1. Conversely, 
the role of the additional two mutations disclosed is unknown. It is possible that the mutation in 
PCHAS_132020, replacing a STOP codon (present in AS-ATN) for a leucine in position 998, 
may restore protein function and that the D560Y mutation in PCHAS_143160 may affect its 
phosphorylation state. Although an extra copy of mdr1 is very unlikely to contribute for the 
increased fitness showed by AS-ATNMF-1, there is a chance that the SNPs present in 
PCHAS_132020 and PCHAS_143160 could be acting as compensatory mutations, and 
therefore be associated with higher fitness of AS-ATNMF-1 when compared with AS-ATN. 
However it is important to retain that no functional analyses have been performed, and 
therefore the attribution of a role for these mutations in parasite fitness is merely speculative.  
As such, it would be interesting to analyse the role of each individual mutation described 
as arising in AS-ATNMF-1 after selection of ATN + MF resistance. This could be done by 
introducing the mutated allele of each gene (or an extra copy in case of mdr1) in AS-ATN 
separately, generating three mutant clones that could then be compared to the original AS-ATN 
in within-host competition assays in untreated (and maybe also in treated) mice along time. 
Another means to assess the contribution of each mutation for fitness cost associated with drug 
resistance would be by performing genetic crosses between the AS-ATNMF-1 and AS-ATN, 
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and analyse the clones of the resulting cross-progeny regarding: i) response to drug-treatment 
and growth rate, and ii) the relation between phenotype and the mutations carried by the various 
clones generated. 
There are reports indicating that in bacteria, compensatory mutations may arise in resistant 
laboratory strains undergoing repeated culturing or several sub-inoculations in mice (Kugelberg 
et al, 2005; Nilsson et al, 2006). In malaria parasites an increase in parasite fitness when 
compared with the respective progenitor was also observed after subjecting parasites to 
consecutive sub-inoculations through mice followed by transmission through mosquitoes 
(Mackinnon and Read, 1999; Walliker et al, 2005). We note that AS-ATNMF-1 was generated 
by repetitive sub-inoculations in presence of drug pressure, and these consecutive rounds of 
selection could have been responsible for the increase in fitness observed in these parasites 
when compared to the original AS-ATN clone. In order to test this hypothesis, the AS-ATN 
clone was passaged through untreated mice twenty seven times, generating the AS-ATN27P 
parasites. Subsequently, competition assays were performed between the ATN + MF-resistant 
AS-ATNMF-1 and AS-ATN27P. The pattern observed here is not as clear as the one observed 
for the competition assays performed using AS-ATNMF-1 and the original AS-ATN clone. AS-
ATN27P seems to increase in proportion as parasitaemias grow. However, this tendency seems 
to disappear at the post-peak phase, and proportions of AS-ATNMF-1 and AS-ATN27P tend to 
return to initial levels. It could be argued that this may be an indication that AS-ATN27P is 
slightly fitter than AS-ATNMF-1 and this could be justified by the mutations present in AS-
ATNMF-1, which are absent in AS-ATN and AS-ATN27P (such as mdr1 amplification). On 
the other hand, the recovery of AS-ATNMF-1 after peak parasitaemia may point towards the 
opposite, i.e. there is no actual difference between AS-ATNMF-1 and AS-ATN27P. 
Collectively, these results seem to suggest that there may be a small fitness cost associated with 
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ATN + MF-resistance in AS-ATNMF-1, and that this fitness cost may be compensated by other 
factors. 
One important consideration worth mentioning is that it is possible that AS-ATN27P does 
not consist of a clonal population. As such, there is a chance that the many parasites 
constituting this population show different growth rates and this could be contributing to the 
contrasting evidence observed when comparing AS-ATNMF-1 and AS-ATN27P proportions 
along time. 
When observing the growth of AS-ATNMF-1 and AS-ATN27P separately, they seem to 
grow at similar rates. This implies that AS-ATN27P also has a higher growth rate than the 
original AS-ATN clone. In such context, it is important to highlight that the three mutations 
mentioned above as appearing in AS-ATNMF-1 after selection for ATN + MF resistance are 
not present in the AS-ATN27P, there being no difference between AS-ATN27P and the original 
AS-ATN. However, it is possible that other mutations have emerged after the twenty seven 
rounds of sub-inoculation that generated AS-ATN27P, and these could be responsible for the 
increase in growth capacity observed here when compared with AS-ATN.  
The results presented here are representative of a single experiment and therefore 
additional assays would be necessary in order to fully understand the dynamics of within-host 
competition of the ATN + MF-resistant AS-ATNMF-1 and the ATN + MF-sensitive AS-ATN 
and AS-ATN27P parasites. Furthermore, the within-host competition assays described here 
focused solely on the erythrocytic asexual phase of parasite life cycle. However, there are other 
aspects that were not embraced, such as gametocyte production and transmission efficiency. It 
has been observed in P. falciparum natural populations that increased resistance to CQ and 
sulphadoxine-pyrimethamine (SP) is associated with lower density of asexual parasite forms in 
the host bloodstream when compared to what is observed for sensitive strains (Osman et al, 
2007). On the other hand, in the same study, the drug-resistant parasites produced higher 
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number of gametocytes. This could result in compensation for the cost of drug-resistance shown 
by asexual blood forms, as it increases the chance of these parasites being transmitted by 
mosquitoes. However, the efficiency of gametocytes in generating viable offspring may also 
limit parasite spread and establishment in the population.  
Very few studies focused on the effects of evolution of drug resistance on the transmission 
potential. This cannot be experimentally assessed in P. falciparum natural parasite populations 
due to ethical constraints. Also, there is a paucity of studies using rodent models for assessing 
this matter, and in addition results seem confounding. For instance, Shinondo and colleagues 
(1994) have shown that a PYR-resistant P. berghei mutant had similar growth in mice as its 
sensitive progenitor and, when in mosquitoes, the resistant clone showed delayed production of 
sporozoites when compared to its sensitive counterpart. On the other hand, in another study 
mosquitoes were fed with mixed infections of a P. chabaudi PYR-resistant clone and its 
sensitive progenitor. The proportion of the mutated and wild-type allele of pcdhfr (where the 
S106N mutation is responsible for PYR resistance) was assessed in oocysts carried by these 
mosquitos. The results were not consistent: the wild-type allele increased along time in two 
experiments, whereas the inverse was observed in the third experiment (Walliker et al, 2005).  
In the above contexts, it would be interesting to compare the evolution of AS-ATNMF-1 
in competition with AS-ATN or AS-ATN27P also taking into account the proportions of 
gametocytes produced, the sporogonic cycle and also perform a genetic cross between the drug-
resistant and one of the drug-sensitive clones and then determining the percentage of the 
parasites in the resulting cross-progeny which would carry resistant alleles. 
Fitness cost of drug-resistance may be an important determinant of spread of drug-resistant 
parasites, and as a consequence drug treatment useful life. Also, estimating fitness cost of 
resistance to a given drug may help in better shaping drug policies in order to minimise the 
factors that would contribute to the maintenance of resistant parasite sub-populations. This 
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subject was intensively debated in many studies (Walliker et al, 2005; Hastings and Donnelly, 
2005). Most of them agree that the establishment of drug-resistant mutants in the parasite 
population is directly dependent on the drug pressure exerted over this population. In addition, 
considering a region where one drug has been used for long periods, and resistance is already 
established, it has been postulated that one advantage of the use of combination therapies is that 
if the cost of mutations conferring resistance to the first drug is up to a certain magnitude in 
absence of treatment, the administration of this drug as partner in a combination would reduce 
the effect of the pressure exerted by the first one and thus, result in the gradual removal of 
resistant strains from the population (Hastings and Donnelly, 2005). 
Other factors may play an important role in maintenance and spread of drug resistance. 
One of them is transmission rate of a given area. In a high transmission setting, the host 
population usually shows high levels of immunity which implies: i) host immunity eliminates 
parasites regardless of their drug-resistant or sensitive status; ii) in places where hosts show 
high levels of immunity the occurrence of asymptomatic infections is frequent. As 
asymptomatic infections are rarely treated, drug selective pressure is therefore weak. In 
addition, untreated hosts consist of a reservoir of sensitive strains. In high transmission areas, 
most malaria cases consist of polyclonal infections (Arnot, 1998), and as such, parasites are 
subjected to constant competition with other (more sensitive) strains. Finally, in high 
transmission settings, frequent recombination in mosquitoes may break haplotypes apart, i.e. 
the reassortment of genetic material may separate mutations determining drug-resistance from 
the compensatory mutations required for reducing the biological cost of resistance. Together, all 
these factors seem to indicate that in high transmission settings, spread of drug-resistant parasite 
strains would be considerably slowed down. In addition, withdrawal of a failing treatment to 
which resistance is well established, could result in removal of the resistant strains from the 
parasite pool by the sensitive ones, in a similar fashion as observed for CQ resistance in Malawi 
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(Kublin et al, 2003; Mita et al, 2003; Laufer et al, 2006). Conversely, in low transmission 
settings, monoclonal infections are more frequent, and as such, an emerging mutant has higher 
chance of establishing an infection and consequently has higher chances of being transmitted to 
other hosts. In addition, most malaria cases are symptomatic, and therefore treated. This 
increases the advantage of drug-resistant strains over sensitive ones. Finally, due to the low rate 
of recombination, there is not much genetic diversity, and as consequence, there is smaller 
chance of advantageous mutations being separated by recombination with more sensitive 
strains. Resistant parasites which appear in these settings could not be removed from the 
parasite pool upon drug withdrawal, since there are no sensitive strains to outcompete them. 
In this context, our model may be defined as best representing the evolution of drug 
resistance as described in low transmission areas: AS-ATN parasites were allowed to grow as 
monoclonal infections, where parasites were subjected to intensive drug pressure (repetitive 
treatment, even if in sub-therapeutic levels). No genetic recombination with drug-sensitive 
strains occurred along the course of selection. The parasites obtained using this approach seem 
to have little or no reduction in fitness when in competition with sensitive counterparts. In case 
P. falciparum natural populations were to follow this trend, it is possible that resistant parasites 
would persist in the parasite pool even if ATN + MF combination use was abolished. Still, it is 
important to consider that P. falciparum natural populations are highly complex and the factors 
presented above may consist of a simplification, since they do not fully account for the 
exposure of parasites to sub-therapeutic levels of drug, the stage of parasite life cycle at which 
resistance would emerge, etc (White et al, 2009).  
The results obtained here consist of a preliminary analysis of within host competition 
between laboratory selected P. chabaudi clones. As such they may fail to completely replicate 
the complexity of P. falciparum natural populations. Nonetheless, they are the first to provide 
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insights on the within-host dynamics of ACT-resistant and sensitive parasite strains, and alert 
for the importance of rational design of treatment policies in endemic countries.   
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APPENDIX I 
SELECTION OF ARTESUNATE + MEFLOQUINE RESISTANCE BY 
GENETIC RECOMBINATION 
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As mentioned in Chapter I, Section I.2, the sexual phase of Plasmodium life cycle takes 
place into the mosquito’s midgut after the parasite’s gametocytes are ingested during the blood 
meal. It is in this stage that the exchange of genetic material between two parasites may occur. 
This may lead to the emergence of new parasites bearing characteristics deriving from both 
parentals. 
Assuming resistance to artesunate (ATN) and mefloquine (MF) happens separately in two 
different events (also assuming that resistance to each drug is associated with different genetic 
determinants), two different parasite populations would exist: one which is resistant to ATN 
and another one resistant to MF. If the genetic material of these parasites were to recombine in 
mosquitoes, this could lead to the emergence of parasites bearing genetic traits conferring 
resistance to both drugs in combination, without ever being exposed to the two drugs 
simultaneously. 
As an attempt to test this hypothesis, a genetic cross between the parasites AS-ATN and 
AS-15MF was performed. As described in Material and Methods, Section 2.2, mice were 
inoculated with a mixture in equal proportions of the two clones, and used to feed Anopheles 
stephensi female mosquitoes. As controls, each clone was inoculated separately into two groups 
of mice and used to feed two other groups of mosquitoes. Due to its ability to be easily 
transmitted and in order to control the experimental conditions, the AJ clone was injected in a 
group of mice that were used to feed an additional group of mosquitoes. 
On Day 9 after the blood meal ten mosquitoes from each group were dissected and 
inspected for the presence of oocysts in their midguts. It was possible to find oocysts in all 
midguts of the mosquitoes that fed on mice infected with the AJ clone. The mosquitoes that fed 
on mice carrying the AS-ATN clone also had oocysts in their midguts, although in a smaller 
amount (only 20% of the midguts analysed showed oocysts). No oocysts were found in the 
mosquitoes that fed on mice infected with the AS-15MF clone. The mosquitoes that fed on 
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mice carrying the mixture of AS-ATN and AS-15MF, showed the presence of oocysts in 40% 
of midguts analysed.  
Regardless of the detection of oocysts in the midguts analysed, all groups of mosquitoes 
were allowed to feed on uninfected mice in order to transmit the infection. These mice had their 
blood inspected for the presence of parasites for up to nine days after transmission.  
As expected, AJ was successfully transmitted. On the other hand, in spite of the detection 
of oocysts, the AS-ATN clone was not. The MF-resistant AS-15MF clone was also not 
transmitted to new mice. This was not surprising, since no oocysts were detected in the 
mosquitoes’ midguts. 
Importantly, the mosquitoes that fed on mice carrying the mixture of AS-ATN and AS-
15MF clones were able to transmit the infection to new animals. The parasites borne by those 
mice (SAMPLE 1, Table 6) could represent the progeny resulting after a recombination event 
between the two parental clones. In order to verify that, the parasites were investigated for the 
presence of two genetic markers originating in each of the parental clones used for the genetic 
cross.  
One of these markers is in pcubp1 gene (PCHAS_020720), and is associated with 
resistance to ART derivatives. A mutation in this gene (G8089T) was identified as exclusive of 
the parental AS-ATN (Afonso et al, 2006), whereas the parental AS-15MF carries a different 
mutation, at a very close position (G8182T). 
When analysing the parasite population transmitted through mosquito, the parasites 
showed the mutation G8089T, indicating these parasites carry the AS-ATN parental allele of 
this gene. 
The other marker analysed was the lysine decarboxylase gene (PCHAS_100330), where a 
mutation A2467C is exclusive of the MF resistant parental AS-15MF. The parasite progeny 
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transmitted through mosquito bear the wild type version of this gene, indicating they also carry 
the AS-ATN parental allele of this gene (SAMPLE 1, Table 6).  
No marker belonging to the AS-15MF parental was identified in the progeny resulting 
from the genetic cross. One explanation could be that the parasites bearing the AS-15MF alleles 
are underrepresented in the cross-progeny when compared to the ones carrying AS-ATN alleles 
for the genes investigated. If this was the case, treatment with either ATN, or MF, or both could 
eliminate the sensitive parasites of the progeny, and could allow the emergency of other 
parasite populations. 
For that purpose, the parasite progeny transmitted through mosquitoes was further 
inoculated into a group of uninfected mice divided in four groups. Each group received drug 
treatment as follows: SAMPLE 2) DMSO vehicle; SAMPLE 3) 20 mg/kg/day of ATN, 
SAMPLE 4) 2 mg/kg/day of MF, and SAMPLE 5) 1 mg/kg/day of MF in combination with 7.5 
mg/kg/day of ATN. The parasites were allowed to grow and were analysed for the same 
markers as the unselected progeny. 
Regardless of drug treatment (or the absence of it, as in the DMSO treated group), all the 
parasites selected here carried the AS-ATN parental allele of both pcubp1 and lysine 
decarboxylase genes (Table 6). 
Due to the inability to confirm that the parasites generated here are recombinants, the 
experiments involving the progeny resulting from the AS-ATN x AS-15MF crossing were 
discontinued. 
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pcubp1 lys decarboxylase 
SAMPLE NAME ORIGIN 
PCHAS_020720 PCHAS_020720 PCHAS_100330 
    
pos. 8089 pos. 8182 pos. 2467 
REFERENCE   G G A 
SAMPLE 1 AS-15MF X  AS-ATN * T G A 
SAMPLE 2 AS-15MF X  AS-ATN (NT)  T G A 
SAMPLE 3 AS-15MF X  AS-ATN (20 ATN) T G A 
SAMPLE 4 AS-15MF X  AS-ATN (2 MEF) T G A 
SAMPLE 5 AS-15MF X  AS-ATN (1 MEF+ 7.5 ATN) T G A 
          
PARENTAL AS-ATN T G A 
PARENTAL AS-15MF G T C 
 
 
Table 6 – Analysis of the progeny transmitted through mosquitoes for mutations present in genes pcubp1 and 
lysine decarboxylase, implicated in the expression of resistance to artesunate (ATN) and mefloquine (MF), 
respectively. Sample 1, parasite progeny after transmission through mosquitoes was passaged into further mice 
treated as follows: Sample 2, DMSO vehicle; Sample 3, 20 mg/kg/day of ATN; Sample 4, 2 mg/kg/day of MF; and 
Sample 5, 1 mg/kg/day of MF in combination with 7.5 mg/kg/day of ATN. The genotypes of the parental clones 
AS-ATN and AS-15MF used for the genetic cross are also indicated. 
 
One possible explanation for the absence of AS-15MF alleles in the parasites resulting 
from AS-ATN x AS-15MF crossing is that genetic recombination did not take place. In this 
case, in spite of being fed on mice carrying a mixture of the two clones (AS-ATN and AS-
15MF), and showing oocysts in their midguts, the mosquitoes carried oocysts resulting from 
self-mating of AS-ATN gametes. Indeed, the inability of the AS-15MF clone to be transmitted 
through mosquitoes has been previously observed (Pedro Cravo, personal communication), 
indicating a possible reproductive fitness cost associated with the acquisition of MF resistance 
in this particular clone. 
On the other hand, it is possible that genetic recombination between AS-ATN and AS-
15Mf did take place. In this case, even after drug treatment, the AS-15MF alleles of the two 
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genes analysed here may still be underrepresented in the cross-progeny and for this reason, 
were not detected by PCR analysis.  
Alternatively, in case genetic recombination has occurred, it is possible that for these two 
particular markers no parasites harbouring AS-15MF alleles were present in the cross-progeny. 
In fact, in order to determine the outcome of the crossing experiment, only two genes were 
investigated and in both cases, the identified allele represented the ATN-resistant parental 
clone. Other loci could be investigated in an attempt to confirm whether the ATN-resistant 
parental was the sole contributor to the production of the cross progeny. It is important to bear 
in mind that the two clones used here are isogenic, differing only for mutations arising upon 
each step of selection (see AS lineage). In this work, many mutations were identified in AS-
ATN clone which could serve as additional markers for identifying the contribution of each 
parental. However, by the time the genetic cross was performed, the Solexa whole genome re-
sequencing of AS-ATNMF-1 (which than allowed the detection of mutations and their origin in 
each clone of the AS lineage) was still not but a plan.  
As future analyses, it would be interesting to investigate the above mentioned novel 
markers identified as first appearing in AS-ATN, for which AS-15MF bears the wild-type 
allele. In addition, it could be interesting to assess if any of the parasites in the cross progeny 
carries a duplicated copy of pcmdr1, another marker representative of the AS-15MF parental 
clone (in this context).  
In case of any AS-15MF markers were identified in the AS-ATN x AS-15MF cross 
progeny, this would at least confirm the possibility of the biological concept where mating 
between two parasite clones resistant to ATN and MF, respectively, would be capable of 
generating viable progeny. Then, further investigation would be required in order to ascertain 
the level of resistance to treatment with ATN and MF administered alone or in combination 
shown by the cross progeny (as a whole or each of its component clones).  
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1. AS-ATNMF-1 x AJ GENETIC CROSS 
The genome of the Plasmodium sp. is constituted by more than 5,500 genes. This 
represents a vast ground to be covered when searching for genetic modifications such as 
random mutations selected by drug pressure, as is the case of the AS-MFATN-5 and AS-
ATNMF-1 clones selected here. In addition, genome sequencing and identification of mutations 
of drug-resistant parasites may provide clues on how drug pressure may affect evolution of the 
genome of the parasite, however, little can be inferred about the roles of these mutations in 
determining drug-resistant phenotype. Linkage Group Selection (LGS), on the other hand, 
provides an overview of the parasite’s whole genome, and the influence of each locus in the 
expression of the phenotype of interest. 
Therefore, in order to search the whole genome of the parasite for loci which are relevant 
for the expression of drug resistance, a genetic cross between the ATN + MF-resistant AS-
ATNMF-1 and the genetically unrelated and drug sensitive AJ was performed.  
So, as described in Material and Methods, Section 3.8.1, five mice were inoculated with 
mixed infections containing equal proportions of AS-ATNMF-1 and AJ clones and used to feed 
female mosquitoes divided into five groups. In addition, two groups of mosquitoes were 
allowed to feed on mice carrying each parental clone as controls for the experimental 
conditions. Mosquitoes’ midguts were dissected in order to check for the presence of oocysts. 
Oocysts were found in the group that fed on the mouse carrying AS-ATNMF-1 parental, and in 
mosquitoes from three out of the five cages fed on mice carrying the AS-ATNMF-1 + AJ 
mixture. Mosquitoes that fed on AJ infected mouse did not show oocysts in their midguts.  
DNA was then extracted from oocysts and analysed for polymorphisms present in gene 
pcubp1. Only the AS allele of this gene was found in oocysts dissected from mosquitoes that 
fed on the mouse carrying the AS-ATNMF-1 parental. On the other hand, and in spite of the 
inability of the AJ parental to produce oocysts when transmitted alone, the oocysts resulting 
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from the mixed infection showed a mixture of alleles from both parentals. This provided 
evidence that the cross between AS-ATNMF-1 and AJ was successful, i.e. the parasites 
transmitted through mosquitoes represented the progeny resulting from the genetic cross AS-
ATNMF-1 x AJ (Table 7).  
 
AS AJ AS AJ AS AJ AS AJ
T G A G C T A G
AS-ATNMF1 100.00 0.00 100.00 0.00 100.00 0.00 100.00 0.00
AS-ATNMF1xAJ 73.40 26.60 73.30 26.70 72.06 27.94 74.62 25.38
AS-ATNMF1xAJ 65.79 34.21 67.04 32.96 62.76 37.24 67.35 32.65
AS-ATNMF1xAJ 89.04 10.96 100.00 0.00 92.81 7.19 92.66 7.34
Polymorphism
144 149 245 293
 
 
Table 7 – Proportional sequencing analysis of polymorphisms in pcubp1 gene between AS and AJ parental.  
 
2. SELECTION OF UNCLONED PROGENY 
Mosquitoes showing oocysts in their midguts were allowed to feed in uninfected mice in 
order to transmit the infection. All mice used here showed detectable parasitaemias and on Day 
10 after the transmission. The uncloned progeny resulting from AS-ATNMF-1 x AJ cross was 
propagated and subsequently inoculated into several mice, divided into six groups. Each group 
received distinct treatment as follows: A) 2 mg/kg/day of MF; B) 100 mg/kg/day of ART; C) 25 
mg/kg/day of ATN; D) 40 mg/kg/day of ATN; E) 2 mg/kg/day of MF in combination with 20 
mg/kg/day of ATN; and F) DMSO vehicle. The proportion of the sensitive allele in the samples 
was determined by Pyrosequencing™ for approximately 150 markers distributed along the 
whole genome of the parasites. A comparative index (CI) between the AS and AJ allele for 
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each polymorphic position was calculated for each treatment relative to the untreated control 
and the results were plotted as shown in Figure 22.  
The results obtained by this methodology seem to indicate that the drug selection of the 
progeny was not sufficient to reduce the amount of sensitive alleles present in the mixture, in 
order to reveal the loci involved in resistance for each drug in AS-ATNMF-1 clone. Therefore, 
as shown in Figure 22, for every drug treated group, no dominant selection valley could be 
seen.  Instead many small peaks and troughs were observed.  
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Figure 22 – Linkage Group Selection analysis of the cross-progeny resulting from AS-ATNMF-1 x AJ cross. The 
parasites were inoculated into six groups of mice, treated with different drugs as follows: A) 2 mg/kg/day of 
mefloquine (MF); B) 100 mg/kg/day of artemisinin; C) 25 mg/kg/day of artesunate (ATN); D) 40 mg/kg/day of 
ATN; and E) 2 mg/kg/day of MF in combination with 20 mg/kg/day of ATN. The last group was treated with the 
DMSO vehicle (non-treated control). The results for each marker along the genome were plotted as the proportion 
of AJ (sensitive) allele in each treatment, normalised against the non-treated control.  
 
When comparing the drug doses used here and those used for the drug sensitivity test 
experiments, the absence of selection valleys in the LGS experiment is not at all surprising. All 
drug doses used for the selection of the cross-progeny obtained after AS-ATNMF-1 x AJ 
crossing are at least half of the ones used for the drug sensitivity tests, where AS-ATNMF-1 
have always shown quick recovery and reached high parasitaemias. 
The choice of the drug treatment used for the selection of the progeny resulting from a 
cross between a drug-resistant and a drug-sensitive parasite must indeed be made with caution. 
The drug selective pressure here must be low enough in order to maintain parasite sub-
populations carrying sensitive alleles, however high enough in order to eliminate the most 
sensitive parasites from the population. In this sense, competition experiments where mice 
infected with mixtures of the sensitive and resistant parasites are subjected to treatment with 
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several drug doses are of great help in the optimisation of the drug dose for treating a progeny 
resulting from crossing these two clones.  
Performing new LGS assays may help in determining the relevance of the mutations 
identified as appearing in AS-ATNMF-1 in drug resistance, as well as the possible contribution 
of other mutations already present in the parental AS-ATN which were inherited by AS-
ATNMF-1.  
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MATERIAL AND METHODS 
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1. GENERAL PROCEDURES 
1.1. SUBSTANCES AND SOLUTIONS 
Citrate saline solution 
0.9% (w/v) NaCl 
1.5% (w/v) Sodium Citrate 
pH 7.2 
 
Deep Freeze solution 
28% (v/v) Glicerol 
3.0% (v/v) Sorbitol 
0.65% (v/v) NaCl 
(sterilised by filtration) 
 
Erythropoietin (10 µg/ml stock solution) 
10 µg Mouse Erythropoietin (Sigma) 
1 ml PBS (Sigma) + 0.1% Bovin Serum 
Albumin (Sigma) 
(sterilised by filtration) 
 
Hypotonic Amonium Chloride Solution 
50 mM NH4Cl 
2 mM EDTA 
5 mM Hepes-Na, pH 7.4 
1% protease inhibittor cocktail (Sigma) 
(sterilised by filtration) 
Loading Buffer 
250 mM Tris-HCl, pH 6.6 
3% SDS 
20 % Glicerol 
 
Parasite Lysis Buffer 
150 mM NaCl 
25 mM EDTA 
0.25% SDS 
 
TAE Buffer (50x stock solution) 
242 g Tris 
57.1 ml Glacial Acetic Acid  
37.2 g Na2EDTA.2H2O 
(final volume 1 litre) 
 
TE buffer 
10 mM Tris-HCl 
0.1 mM EDTA 
 
Xanthurenic Acid (20 mM stock solution) 
41 mg Xanthurenic Acid (Aldrich) 
10 ml PBS (Sigma) 
(adjust pH 7.4) 
 
 
 
1.2. PARASITES AND HOSTS  
Malaria parasites belonging to the rodent infecting species P.chabaudi chabaudi were used. These 
parasites were originally isolated from the blood of a shiny thicket rat (Thamnomys rutilans) from 
the Central African Republic (Landau and Chabaud, 1965). For this work, two lines were used, AS and 
AJ. 
The AS lineage (as described in Chapter II, Section II.1.2.1) consists of an isogenic line of clones 
obtained along time after many steps of selection with different anti-malarials. All these clones share a 
common precursor, the drug-sensitive clone, AS-SENS (Table 8). 
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      PARENTAL 
 
    CLONE NAME 
 
  RESPONSE TO DRUG TREATMENT 
Natural host AS-SENS 
 
sensitive 
AS-SENS  AS-PYR resistant to PYR 
AS-PYR AS-50SP resistant to sulphadoxine 
AS-PYR AS-3CQ resistant to low doses of CQ 
AS-3CQ AS-15CQ resistant to intermediate doses of CQ 
AS-15CQ AS-15MF resistant to and MF 
AS-15CQ AS-ATN resistant to and ATN 
AS-15CQ AS-30CQ resistant to high doses of CQ 
AS-30CQ AS-ART resistant to ART 
 
 
Table 8 – P.chabaudi AS lineage. Nine parasite clones used in this work, their respective parentals and response to 
drugs are represented.  
 
The other parasite line used here is the drug-sensitive AJ clone. This clone is genetically non-
related to AS, differing in a great number of known genetic markers throughout the genome. 
The parasites were maintained in different strains of mice (Mus musculus). Six-to-eight weeks old 
female CBA and C57BL/6 mice were used mainly for the genetic cross between the ACT-resistant clone 
selected here and AJ. Six-to-eight weeks old male CD1 mice were used for the remaining procedures.  
 Mice were kept in polypropylene cages, and sawdust was used as bedding. 41B mouse 
maintenance diet (Harlan-Teklad, UK) and 0.05% p-Aminobenzoic Acid (Sigma) supplemented water 
were available ad libitum. The room temperature ranged from 14ºC to 26ºC with light periods of 12 
hours per day. 
 
 
1.3. MOSQUITO MAINTENANCE CONDITIONS.  
Anopheles stephensi mosquitoes were kept in groups of up to 200 mosquitoes (both male and 
female). Inside of the cages, 10% Glucose solution supplemented with 0.05% p-Aminobenzoic Acid 
was available to the mosquitoes ad libitum. The room was maintained at 24-to-26ºC, the air humidity 
was kept above 60%, and had light-dark cycles of 12-12 hours.  
 
 
1.4. PARASITAEMIA COUNT 
A drop of blood was extracted by a small puncture on the mouse tail vein and used to make a thin 
smear on a glass slide. The blood was fixated with pure methanol and subsequently stained using a 20% 
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Giemsa solution during approximately 20 minutes. The slides were washed with water and read under 
optical microscopy. The number of parasitized Red Blood Cells (pRBC) and total RBC present in a 
particular microscopic field were counted for at least 5 different fields. These values were entered into 
an equation to calculate the percentage Parasitaemia (%P) as follows: 
 
%P = (pRBC / total RBC) x 100 
 
 
 
1.5. PARASITE PASSAGING, PREPARATION AND STORAGE OF PARASITE STOCK 
VIALS 
Frozen parasite-infected blood was thawed on ice after which uninfected mice were injected 
intraperitoneally with 0.1ml of infected blood using a 1.0 ml seringe with a 27G x 1/2” needle. 
Percentage parasitaemias in individual mice were then followed from day 4 post-inoculum (pi) onwards. 
After reaching the desired parasitaemia values (at least above 10%), 5 µl of blood collected from the 
above donor mice, in a glass capillary, was diluted into 195 µl of Citrate Saline Solution and RBC 
density was determined using a Abacus Junior haemocytometer (Diatron, Hungary). Subsequently, 
parasite density was determined by multiplying the RBC density by the parasitaemia and the dilution 
factor (40x). Consequently, blood was diluted such that 0.1 ml would contain the desired amount of 
pRBC to be inoculated into each acceptor mouse. 
The donor mice were then anaesthetised by an intra-muscular (im) injection of a mixture of 1:2 
xylasine:ketamine and then exsanguinated under general anaesthesia by a puncture on the brachial 
artery. Blood was collected using a micropipette and mixed with ice cold Citrate Saline Solution, 
according to the calculations of parasite density. The blood would then be inoculated into uninfected 
mice, starting a new infection.  
Alternatively, in order to store and preserve the parasites, the mixture of blood and Citrate Saline 
Solution was immediately centrifuged at 3000 rpm for 5 minutes at room temperature and the 
supernatant was discarded. The volume of the pellet was estimated and mixed gently with 2,5x volume 
of Deep Freeze Solution, which prevents the formation of crystals and the consequent disruption of the 
RBCs. 300 µl aliquots were made and kept in liquid nitrogen. In order to start a new infection, these 
aliquots were removed from liquid nitrogen and upon thawing on ice 0.1 ml was injected 
intraperitoneally into donor mice, as described in the beginning of this section. 
 
 
1.6. ANTI-MALARIAL DRUGS: DILUTION AND ADMINISTRATION 
All antimalarials used in this work were available as powder and were diluted into pure DMSO 
(Merk). Artesunate (ATN) and artemisinin (ART) were donated by Daphra Farma. Mefloquine (MF) 
hydrochloride powder was purchased from Roche Farmaceutics. The concentrations were adjusted 
according to body weight so the volume given to each animal would range from 0.06 ml to 0.12 ml. The 
drug was then administered orally by gavage. 
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The diluting vehicle DMSO was administered to mice used as untreated controls, in order to 
certifify that neither DMSO alone nor the stress caused by the procedure would interfere with the 
observed parasite growth. 
 
 
2.  SELECTION OF PARASITES RESISTANT TO ARTESUNATE AND MEFLOQUINE IN 
COMBINATION 
2.1. SELECTION OF RESISTANT PARASITES BY DRUG PRESSURE 
Our objective was to generate resistance to the artesunate (ATN) + mefloquine (MF) version of 
ACT. The strategy to achieve resistant parasites was based on the prolonged exposure of parasites to 
consecutive small increments in drug doses in treated mice over many generations. To achieve this goal, 
two parasite clones were used as the starting biological material, as follows: i) parasites resistant to a 
low level of artesunate (P. chabaudi AS-ATN) which were exposed to a combination of ATN and MF 
and ii) mefloquine-resistant parasites (P. chabaudi AS-15MF) which were exposed to ATN. Thus, blood 
containing each of parental clones above was thawed and inoculated intraperitoneally into two CD1 
mice. When these mice reached peak parasiteamia, donor blood was extracted to inoculate 10
7
 pRBC, 
diluted in citrate saline, into two groups of two mice each. One group was left untreated and parasites 
were sub-inoculated every seven days into two uninfected mice in the absence of treatment and in 
parallel with the treated group. The remaining two mice were treated with drugs dissolved on DMSO on 
days 3, 4 and 5 post-inoculum by gavage. Infection progression in individual mice was monitored from 
day 3 onwards by counting the percentage parasitaemia in Giemsa-stained thin blood smears. The 
treated mouse containing the highest parasitaemia on day 7 post-inoculum, was then exsanguinated by 
section of the brachial artery under general anesthesia and served as donor for the next round of drug 
selection. The starting drug-selecting dose was of 1 mg/kg/day of MF administered together with 5 
mg/kg/day of ATN for AS-ATN and 10 mg/kg/day of MF for AS-15MF, and it was increased whenever 
parasitaemias reached above 2% on day 7, under drug treatment. On the other hand, when the parasites 
were not able to grow beyond this value, the dose was maintained. The dose was reduced only as an 
extreme measure, to avoid losing the parasites, in cases when the parasitaemias were nearly 
undetectable. After a number of rounds of drug selection, when a satisfactory degree of resistance was 
achieved, parasites under drug pressure were cloned by limiting dilution. Over the selection course, 
aliquots of parasites were frozen down in order to prevent the loss of the parasites under selection, in 
case the next round of treatment would eradicate the parasites from the host mice. This would also 
provide a useful tool for the analysis of the gradual acquisition of tolerance by these parasites, during the 
course of reaching high levels of resistance.  
 
2.2. CLONING 
At the end of the last round of selection, the resistant parasites population selected as described 
above was cloned by limiting dilution (Rosário, 1981). Thus, mice harbouring the resistant parasite 
populations were exsanguinated by puncture of the brachial artery and blood was diluted in Citrate 
Saline Solution. Serial dilutions were prepared and inoculated into uninfected mice as follows: forty 
CD1 mice were sub-divided into two groups of twenty animals each. The first group was inoculated 
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with the equivalent of 1 pRBC and other twenty animals received the equivalent of 0.5 pRBC. Since the 
parasite inoculum consists of a suspension of cells, the probability of each mouse receiving the exact 
amount of parasites as calculated follows a Poisson distribution. In this case, this means that, for 
instance, of all mice inoculated with the equivalent of one parasite, the mice showing detectable 
parasitaemias are assumed as carrying a clonal population if at least 37% of the mice show no detectable 
parasitaemias. 
Additionally in order to control parasite growth, ten mice were subdivided into three groups of 
three animals and were inoculated with the equivalent of 10
3
 pRBCs, 10
2
 pRBCs, and 10 pRBCs. The 
last animal was inoculated with the equivalent of 10
6
 pRBC. Parasitaemias were followed for at least 
fifteen days.  
The animals showing detectable parasitaemias were exsanguinated and the blood of each animal 
was processed separately. The samples were subsequently stored into liquid nitrogen.  
In this work, the clones with the fastest growth rate were used for further analysis.  
 
 
2.3. DRUG SENSITIVITY TEST 
Two different artesunate + mefloquine (ATN + MF)-resistant parasite populations resulted after 
selection as described in Section 2.1. These populations were cloned (Section 2.2), and the clone 
displaying the fastest growth rate from each of population was further inspected in the course of this 
work. Therefore, two clones were analysed, one of which was named AS-MFATN-5 and was derived 
from the mefloquine (MF)-resistant clone, AS-15MF. The second was named AS-ATNMF-1 and was 
obtained using the artesunate (ATN)-resistant AS-ATN clone as parental.  
In order to assess the degree of resistance obtained by the clones, different drug sensitivity tests 
were performed. For the first one, the clones used were: i) the AS-MFATN-5 clone, ii) its MF-resistant 
parental AS-15MF, iii) AS-ATN clone, which shows some degree of resistance to ATN, iv) AS-3CQ, 
which shows low levels of resistance to CQ, and is sensitive to ATN and MF. Thus, CD1 mice were 
divided into four groups of nineteen animals and were inoculated with 10
7
 pRBC of each of the clones 
mentioned above. Each group was sub-divided into three groups of five mice that were treated with the 
following anti-malarials: ATN, MF or ATN in combination with MF. The remaining two mice received 
only the DMSO vehicle (non-treated control). The treatment consisted of three daily doses of anti-
malarial to be administered on Days 1, 2, and 3 pi (Figure 23). 
In parallel, the AS-15MF population passaged along the course of selection in the absence of drug 
treatment (referred to as AS-15MF36P herein) was also tested. For that purpose, CD1 mice were divided 
into two groups of nineteen animals. One group received 10
7
 pRBC of the population AS-15MF36P and 
the other group was inoculated with 10
7
pRBC of the original AS-15MF clone. In a similar fashion as 
described above, each of these groups were subdivided into three groups of five animals that were 
treated with ATN, MF or ATN in combination with MF. The remaining four animals received the 
DMSO vehicle (Figure 23). 
Similarly, the level of resistance acquired by the AS-ATNMF-1 clone was also assessed. For that 
purpose, CD1 mice were divided in five groups of seventeen animals and were inoculated with 10
7 
pRBC of the following parasites: i) AS-ATNMF-1 selected here, ii) its parental, the ATN-resistant AS-
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ATN clone, iii) the AS-ATN parasite population left untreated and passaged in parallel with the treated 
group during the selection course, referred herein as AS-ATN27P, iv) the MF-resistant AS-15MF clone, 
and v) the CQ-resistant, ATN and MF-sensitive AS-3CQ clone. Each group of mice was further divided 
into four groups of animals. Three of which were treated with 3 daily doses (Days 1, 2, and 3 pi) of 
ATN, MF or ATN in combination with MF. The fourth group was left untreated and received only the 
DMSO vehicle (Figure 23).  
In all cases, the parasitaemias were assessed daily from Day 4 onwards and the results are 
expressed as daily average % parasitaemia of all mice in each group.  
In order to prevent suffering, the animals were sacrificed through cervical dislocation whenever 
reaching parasitaemias above 40% and displaying symptoms of disease.  
              
       
Figure 23 – Schematic representation of drug sensitivity test carried out to assess the level of resistance exhibited 
by AS-MFATN-5 selected from the AS-15MF clone after several rounds of treatment with stepwise increasing 
doses of ATN. A similar protocol was used for determining the level of resistance of AS-ATNMF-1, selected by 
exposing AS-ATN clone to several rounds of treatment with increasing doses of the combination ATN + MF. The 
parental clones as well as AS-3CQ were used as controls. In case of the AS-ATNMF-1 clone, the parasite 
population passaged in absence of drug response to each drug was also assessed. For determining the response of 
AS-15MF36P parasite population to different drug treatments, only the original clone AS-15MF was used as 
control. 
 
 
 
2.4. SELECTION OF RESISTANT PARASITES THROUGH GENETIC CROSSING 
2.4.1. PARASITE CROSSING 
In order to generate artesunate + mefloquine (ATN + MF)-resistant parasites through genetic 
recombination between artesunate (ATN)- and mefloquine (MF)-resistant parasites, a genetic cross 
between AS-ATN and AS-15MF was performed. Thus, one aliquot of blood of each clone was thawed 
and inoculated into two donor CD1 mice per clone. In addition, one aliquot of blood containing AJ was 
also used as control, due to its ability to be easily transmitted (Figure 24A). Parasites were then allowed 
MF ATN ATN + MF 
 
INOCULUM  10EXP 7 pRBC 
Non-treated  
control 
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to grow in these mice for at least five days after which animals were all bled out. Collected blood was 
diluted so that 0.1 ml would contain 10
5
 pRBCs. Concurrently, acceptor mice were treated with the 
erythropoiesis-stimulating agent Erythropoietin (EPO) (Sigma) prior to (and after) being injected with 
blood from the donor mice. Thus, eight CD1 mice received a daily intraperitoneal injection of 0.1 µg of 
EPO, during five consecutive days. On the third day of EPO treatment, mice were subdivided into four 
groups, and each group received an intraperitoneal injection containing infected blood extracted from 
the donor mice as mentioned above. Thus, the first group was inoculated with 10
5
 pRBCs of the AJ 
clone, the second group received 10
5
 pRBCs of AS-15MF and the third group received 10
5
 pRBCs of 
AS-ATN. Blood infected with AS-15MF parasites was mixed in equal proportions with blood 
containing AS-ATN parasites, and this mixture was inoculated into the last group of two mice (Figure 
24B).   
Simultaneously, one-day-old female Anopheles stephensi mosquitoes were divided into four cages 
containing about two hundred female-reared mosquitoes. Mosquito drinking water was further 
supplemented with 200 µM Xanthurenic Acid (XA) (Aldrich) diluted freshly from 20 mM stock solution 
(Section 1.1) and was replaced every two days.  
In order to assure that the majority of the mosquitoes would feed on blood, therefore increasing the 
chances of successful transmission, on Day 5 pi, drinking water was removed two hours prior to blood 
meal to promote starvation. Acceptor mice were anaesthetised and used to feed the mosquitoes for 20 
minutes. After removing the mice, drinking water was again supplemented with 200 µM XA and made 
available for 24h (Figure 24C). After that, XA supplement was removed and mosquitoes remained with 
standard 10% Glucose, 0.05% p-Aminobenzoic Acid supplemented water from now on. 
On the fourth day after the blood meal, the drinking water was once more removed and after two 
hours, eight uninfected mice were anaesthetised and two animals per cage were used to boost-feed the 
mosquitoes for 20 minutes. Similarly to the procedure described above, the drinking water was restored 
after the end of the blood meal. 
On the tenth day after the first blood meal – using the infected acceptor mice – ten mosquitoes 
were taken from each cage. Their midguts were dissected and observed at light microscopy for the 
presence of oocysts.  
On the fourteenth day after the first blood meal in order to transmit the infection drinking water 
was removed two hours prior to the blood meal and eight uninfected CD1 mice were anaesthetized. Two 
animals were placed on each mosquito cage and the mosquitoes were allowed to feed for 20 minutes 
(Figure 24D). After recovering from the anaesthesia the mice were kept under standard conditions. A 
schematic representation of the genetic cross procedure is presented in Figure 24. 
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Figure 24 – Schematic representation of the genetic cross performed using AS-ATN and AS-15MF clones as 
parentals. The AJ clone was used as a control, due to its ability to be easily transmitted. (A) CD1 mice were 
inoculated with each clone and served as donors. (B) EPO treated acceptor mice were injected with 10
5
 pRBC of 
each parasite or a mixture in equal proportions of AS-ATN and AS-15MF (AS-ATN + AS-15MF). (C) These 
animals were used to feed XA treated Anopheles stephensi mosquitoes. Mosquitoes’ midguts were inspected for 
the presence of oocysts and were allowed to feed on uninfected mice in order to transmit the infections. (D) Mice 
parasitaemias were followed. The parasites cross-progeny (AS-ATN x AS-15MF) was further analysed. 
 
 
 
In order to verify the effectiveness of the transmission procedure, the animals’ parasitaemias were 
followed for the following ten days. The animals showing detectable parasitaemias on Day 9 were 
exsanguinated. The progeny resulting from the genetic cross between AS-ATN and AS-15MF (AS-ATN 
x AS-15MF) was further analysed. Thus, the animals carrying these parasites were exsanguinated and a 
drop of blood was collected into Whatman Nº4 filter paper for DNA extraction (as will be described in 
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detail in Section 3.1) and will be referred to as Sample 1. The remaining blood was used for inoculating 
eight uninfected CD1 mice with 10 exp6 pRBC (Figure 25).  
The next step was to select the parasite progeny with different drugs in order to eliminate the 
sensitive parasites from the population. To this extent, the animals were divided into three groups treated 
as follows: i) DMSO vehicle; ii) 20 mg/kg/day of ATN; iii) 2 mg/kg/day of MEF; and iv) 1 mg/kg/day 
of MF in combination with 7.5 mg/kg/day of ATN (Figure 25). The parasitaemias of the eight animals 
were followed and on Day 7 pi the animals were exsanguinated. The blood of the two animals in each 
group was pooled together and a drop was dried into Whatman Nº4 filter paper for DNA extraction (as 
described below in Section 3.1) and will be refered to as Samples 2 – to – 5, as shown in Figure 25. The 
remaining blood was processed (Section 1.4) and stored into liquid nitrogen. 
 
 
 
 
 
Figure 25 – Parasite progeny resulting from the genetic cross was selected with different drug treatments.  Mice 
carrying the cross-progeny AS-ATN x AS-15MF had their blood preserved in filter paper for DNA extraction 
(Sample 1). Then, the mice were exsanguinated and their blood was inoculated into eight mice divided in four 
groups. Each group was treated as follows: DMSO vehicle (non-treated control), 20 mg/kg/day of ATN, 2 
mg/kg/day of MF or 1 mg/kg/day of MF in combination with 7,5 mg/kg/day of ATN. Parasitaemias were followed. 
Mice were exsanguinated and blood preserved for DNA extraction (Samples 2 to 5, respectively).  
 
 
2.4.2. ANALYSIS OF PARASITE CROSS 
In order to attest that the parasite progeny obtained as described above was a product of the genetic 
cross between AS-ATN and AS-15MF clones, the genetic traits belonging to both parents was 
investigated. 
AS-ATN x AS-15MF 
2 mg/kg/day MF 20 mg/kg/day ATN Non-treated control 1 mg/kg/day MF +  
7,5 mg/kg/day ATN 
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For that purpose, each of the five DNA samples obtained above were analysed by PCR for two 
genetic markers. One of them is the pcubp1 (PCHAS_020720) where the V2467F mutation is exclusive 
of the AS-ATN parental clone, and results from a G to T substitution in position 8089 of the coding 
sequence of this gene (according to the lattest Sanger annotation) (Hunt et al, 2005). AS-15MF does not 
carry the wild type allele of this gene. Instead it carries a SNP placed downstream to the one present in 
AS-ATN, a G8182T. This mutation codes for another V to F substitution, this time in aminoacid 2728. 
The presence of either of the two mutations seems to be in linkage with ATN or ART resistance, 
respectively (Hunt et al, 2005). 
The second marker analysed was the PCHAS_100330 gene, which codes for a lysine 
decarboxylase (P.falciparum PFD0285c), where the SNP A2467C causes de non-synonimous mutation 
T823P (Borges, 2009). This mutation is exclusive of the AS-15MF parental clone, while AS-ATN 
carries the wild type allele. The presence of this mutation seems to be in linkage with resistance to MF, 
but its presence is not mandatory for the expression of the resistat phenotype. 
PCR conditions, oligonucleotide primers and further analysis will be described in detail in Section 
3.2. 
 
 
3. GENOTYPING 
3.1. DNA EXTRACTION  
DNA was extracted from mouse blood by two different methods, according to the size and 
preservation of the blood sample. The methods are described in detail bellow.  
DNA form dried blood spots preserved in Whatman nº4 filter paper was extracted using the 
Chelex-100 method. Briefly, 1 cm
2
 of filter paper was incubated overnight in 1 ml PBS (Sigma) + 0.5% 
saponin (Sigma) at 4ºC. The solution was removed and the filter paper was incubated with 1 ml PBS at 
4ºC for 30 minutes. After the removal of the PBS, the filter paper was incubated at 100ºC with pre-
heated 200 µl PBS + 5% Chelex-100 (Bio-Rad) for 10 minutes and vortexed vigorously every 5 
minutes. The tubes were centrifuged at 14000 rpm for 2 minutes and the supernatant was placed into a 
fresh tube. The supernatant (containing the DNA) was centrifuged again in order to insure the complete 
removal of the Chelex-100 matrix and stored at -20ºC. 
For large amounts of blood obtained from of one mouse or many mice, DNA was extracted by 
Phenol:chlorophorm. Concisely, mice were exsanguinated by puncture in the brachial artery and blood 
was mixed with ice cold Citrate Saline Solution. The mixture was passed twice through cellulose (CF11, 
Sigma) 5 ml column and in addition, it was also filtrated using two Plasmodipur™ filters (Euro-
Diagnostica), to ensure the complete removal of the leucocytes. The filtrates were centrifuged at 3000 
rpm for 5 minutes at room temperature and the supernatant was discarded. The volume of the 
erythrocyte pellet was estimated and resupended into twice the volume of PBS + 0.15% saponin, in 
order to disrupt the erythrocytes’ membranes, releasing the parasites. The mixture was mixed gently 
until its colour turned from red to burgundy. The lysis was stopped by the addition of an excess of PBS, 
followed by centrifugation at 4000 rpm for 5 minutes.  The supernatant was discarded and parasite pellet 
obtained was resuspended into PBS and centrifugation and wash repeated. The supernatant was 
discarded and the parasite pellet was kept in -70ºC for further use. 
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Upon thawing on ice, the parasite pellets were resuspended into 5 volumes of pre-warmed Parasite 
Lysis Buffer (Section 1.1) containing 0.125 mg/ml Proteinase K. The mixture was maintained at 37ºC 
overnight. Phenol (Ambion) pH 7.9 (equilibrated with TE Buffer) was added in an equal volume and 
mixed thoroughly for 2 minutes. The mixture was then centrifuged at 5000 rpm for 3 minutes. The 
aqueous phase was transferred to a fresh tube and mixed with an equal volume of phenol:chlorophorm 
(1:1) (Ambion) pH 7.9 and centrifuged as before. The aqueous phase was carefully removed (in order to 
avoid contamination with proteins present in the interface) and transferred to a new tube where it was 
mixed with an equal volume of chlorophorm. After mixing and repeating the centrifugation, the aqueous 
phase was transferred to a fresh tube and 1 µl of RNAse H 1.5 U/µl (Promega) was added per 100 µl of 
aqueous phase. The mixture was incubated at 37ºC for 10 minutes.  
The DNA precipitation was made by the addition of 1/9 volume of 3M sodium acetate (pH 5.2). 
Two volumes of ice-cold absolute ethanol were added to this mixture and it was incubated on ice for 30 
minutes, followed by centrifugation at maximum speed for other 30 minutes. The ethanol was removed 
and the DNA pellet was washed twice in ice cold 70% ethanol. Finally, the mixture was centrifuged at 
12000 rpm for 1 minute and the supernatant was discarded. The pellet was let air dry and re-suspended 
into 50 to 100 µl of TE buffer and incubated at 37ºC for 10 minutes. 
 
 
3.2. PCR 
Along the course of this work, different genes were analysed with different purposes. For instance, 
the two clones selected by drug pressure (Section 1.2) were investigated for the presence of novel 
mutations in specific candidate genes. Thus, an overlapping fragment DNA sequencing strategy was 
applied in order to cover the whole coding sequence of each gene under investigation. The sequences of 
the P.chabaudi orthologs of the P.faciparum pfatp6 (PfA0310c) and pfubp-1 (PfA0220w) genes were 
first retrieved from PlasmoDB. These sequences correspond to P. chabaudi orthologues 
PCHAS_020540 and PCHAS_020720, respectively, and were used as template for designing PCR 
oligonucleotides to amplify and sequence the two genes. However, by the time this analysis was 
performed, the lattest assembly of the P.chabaudi genome was not available yet. An updated version 
was recently released (available the Welcome Trust Sanger Institute website dating of September of 
2009) and the coding sequence of the gene pcubp1 is now annotated as composed by 8766 nucleotides. 
So, only the last 3500bp segment of the currently annotated sequence of this gene was investigated here. 
On the other hand, no differences were found when comparing the coding sequence previously available 
of the pcatpase6 gene and its latest annotated version.  
Oligonucleotide primer sequences as well as the cycling conditions for the pcatpase6 
(PCHAS_020540) gene were described previously by Afonso et al, 2006 whereas the primer sequences 
and cycling conditions for the gene pcubp1 (PCHAS_020720) were described previously by Hunt et al, 
2007. The only exceptions are the primers surrounding the mutation exclusive of AS-ATN (Hunt et al, 
2007), the G8089T substitution (nucleotide position according to the new Sanger annotation). The 
forward sequence used here was 5’-GTTACCAATTGATACGACTG-3’ and the reverse sequence 5-
CAGAATTAGTATGAGGTGGC-3’. The cycling conditions were: denaturation at 94ºC for 3 minutes, 
15 cycles of 94ºC for 15 seconds, 40ºC for 45 seconds and 68ºC for 4 minutes, followed by 30 cycles of 
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94ºC for 1 minute, 45ºC for 45 seconds and 72ºC for 3 minutes. The final elongation was run for 10 
minutes at 72ºC.  
The progeny resulting from the genetic cross between the parasites AS-ATN and AS-15MF was 
also investigated for mutations. In this case, the aim was not the identification of novel mutations 
appearing in the coding sequence of genes of interest. The intent here was to seek for known mutations 
previously described as being present in the parental clones used for the cross, serving as genetic 
markers. For that purpose, two genes were inspected. The gene pcubp1, described previously in this 
Section, was analysed regarding the presence of the G8089T mutation, which is exclusive of AS-ATN 
clone. Thus, the primers and cycling conditions applied were the same as described above. In addition, 
another SNP could be identified in the same segment flanked by the two primers used for the analysis of 
this gene. This is the G8182T substitution, and can be found in AS-15MF. 
Another gene used as marker of the parental clones used for the genetic cross was P.chabaudi’s 
PCHAS_100330 (P.falciparum PFD0285c). This gene codes for a lysine decarboxylase and the 
mutation A2457C is present in AS-15MF clone, as decribed in Chapter II, Section II.1.2.1. The 
sequences of the primers used for amplifying the region around this mutation were forward 5’-
TGGTTTGCTTATGCTTGTTTC-3’ and reverse 5’-CCATTTCTCCTATTTGTATTTC-3’. The cycling 
conditions were 95ºC for 3 minutes, followed by 48ºC for 1 minute, 65ºC for 1 minute, and then by 35 
cycles of 94ºC for 1 minute, 50ºC for 1 minute and 65ºC for 1 minute. The final elongation step was 
made at 65ºC for 10 minutes.  
For all reactions performed here, 1 µl of DNA extracted by Chelex-100 method (Section 3.1) was 
used as template in 50 µl reactions. The other reagents were added to 10x Green GoTaq® Flexi Buffer 
(Promega) to a final concentration of 1,5 mM MgCl2, 0.2 mM deoxynucleoside triphosphate (each), 0.2 
pmol/µl forward and reverse primers, and 1,25 U of Go Taq Flexi DNA Polymerase (Promega). 
The products resulting after PCR were analysed by electrophoresis in TAE Buffer on an ethidium 
bromide stained 1% agarose gel. When a single band was observed, the products were purified using the 
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare). After purification, the products 
were sent for being analysed by di-deoxy sequencing using the commercial services provided by 
STABVIDA laboratories. The sequences obtained here were aligned using Multi-Alin (Corpet, 1988), a 
multiple sequence alignment software available online 
(http://bioinfo.genotoul.fr/multalin/multalin.html). The chromatograms were also investigated in some 
cases, using Chromas 2.33 software (Technelysium) obtained online (http://www.technelysium.com.au). 
 
 
3.3. RNA EXTRACTION 
Total RNA was extracted from blood stage parasites in order serve as template for cDNA 
synthesis.  
For that purpose, CD1 mice were inoculated with infected blood. When reaching peak 
parasitaemia, the animals were bled out and the mixture of blood and Citrate Saline Solution was filtered 
in a cellulose (CF11, Sigma) 5 ml column. Subsequently, it was centrifuged at 3000 rpm for 5 minutes at 
room temperature and the supernatant was discarded. The volume of the erythrocyte pellet was 
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estimated and an equal volume of Citrate Saline Solution was added to it and mixed gently. The mixture 
was divided into vials containing at least 300 µl each. The vials were kept at -70ºC prior to use. 
For RNA extraction, the blood on the vials was defrost on ice, and the Aquapure RNA Blood Kit 
100 (BioRad) was used. The protocol was followed as the manufacture’s instructions, except for minor 
changes described bellow. Briefly, 300 µl of blood was mixed by inversion with 900 µl of RBC Lysis 
Solution, provided with the kit. The mixture was incubated at room temperature for 10 minutes and then 
centrifuged at 14000 rpm for 10 minutes at 4ºC. The supernatant was discarded leaving approximately 
20 µl of residual liquid that was thoroughly mixed with the pellet. Subsequently, 300 µlof the kit’s RNA 
Lysis Solution was added and mixed by pipetting repeatedly. 100 µlof the Protein-DNA Precipitation 
Solution was added and the mixture was incubated on ice for 10 minutes. The samples were centrifuged 
at 14000 rpm for 5 minutes at 4ºC and the pellet was discarded. 300 µl of 100% Isopropanol was added 
to the supernatant and centrifuged at 14000 rpm for 5 minutes at 4ºC. The supernatant was poured out 
and the tube was briefly dried using an absorbent paper. The pellet was washed in 70% Ethanol. After 
being centrifuged again at the same conditions as before, the supernatant was rejected and the tube was 
allowed to air dry for 15 minutes. 50 µl of RNA Hydration Solution was added to the dry pellet and the 
tube was kept on ice for 30 minutes.  
The RNA sample obtained as described above was either used immediately for cDNA synthesis or 
kept at -70ºC. 
 
 
3.4. cDNA SYNTHESIS 
cDNA synthesis was carried out using the RNA samples extracted from mouse blood infected with 
different clones, as described in the previous section (Section 3.3). 
Before starting the cDNA synthesis, the samples were treated with DNAse to ensure the removal 
of any contaminant DNA. Thus, 4 µl of the RNA sample was mixed with 1,0 µl of 10x DNAse Buffer 
(FERMENTAS
TM
), 1,0 µl of 1U/µl DNAse (FERMENTAS) and 5,0 µl of DEPC treated water and 
incubated for 15 minutes at room temperature. 1 µl of 25mM EDTA was added to the reaction mixture 
and incubated at 65ºC for 5 minutes. 
The reverse transcription of the DNAse treated RNA began by the addition of 2 µl of 10x 
concentrated Hexanucleotide Mix (Roche). The tube was placed in a dry bath at 70ºC for 5 minutes and 
later cooled down on ice. After that, a mixture consisting of 4 µl of 10x M.Mulv Buffer 
(FERMENTAS), 2 µl of deoxynucleoside triphosphate mix (10 mM each), 3 µl of 100mM DTT, 0.5 µl 
of 400U/µl RNA inhibitor Ribolock™ (FERMENTAS), and 7,5 µl of DEPC treated water was prepared. 
17 µl was added to the mixture of DNAse treated RNA and Hexanucleotides and it was incubated at 
25ºC for 5 minutes. 1 µl of 200 U/µl M-MuLV Reverse Transcriptase (FERMENTAS) was added and 
the reverse transcription was performed by one cycle of 25ºC for 10 minutes, 42ºC for 1 hour, and 70ºC 
for 10 minutes. The samples were allowed to cool down in ice and kept at -20ºC prior to use. 
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3.5. REAL-TIME PCR ANALYSIS 
Real-Time PCR TaqMan assays were performed in order to assess the copy number and RNA 
expression profile of mdr1 gene in the clones selected in this work. The values were obtained by the 2
-
∆∆ct
 method (Livak and Schmittgen, 2001), using the pcα-tubulin ii as housekeeping gene.  
For that purpose, the sequences of the P.chabaudi homologous of the P.falciparum pfmdr1 gene 
(PFE1150W) and alpha-tubulin ii gene (PFD1050w) were obtained from Plasmo DB. These genes are 
annotated as PCHAS_123820 and PCHAS_052240, respectively.  Their sequences were used as 
template for the design of oligonucleotide primers and probes. 
Both assays were devised to be performed simultaneously (in the same plate and under the same 
conditions) using the commercial services provided by TIB MOLBIOL. The sequences of the primers 
and probes are depicted on Table 9. Probes were labelled with 6-FAM (6-carboxyfluorescein, 
succinimidyl ester) at the 5’ end, and the dye’s fluorescence was quenched by the presence of Black 
Berry™ Quencher 650 on the 3’ end of the probe. 
 
                                 PRIMER SEQUENCE 
  
mdr1 foward 
  
            5'-CAC ACA ATT TGA AAG ACG TTG ACT-3' 
  
mdr1 reverse 
  
            5'-ATT TAA TGA AGA ATC GCT ACT TCC G-3' 
  
α-tubulin ii foward 
  
            5'-TGC TCC AAT TAT TAG TGC TGA AAA AG-3' 
  
α-tubulin ii reverse 
  
            5'-ACA GCA AGC CAT ATA TTT TCC ATG TC-3' 
  
  
  
                               PROBE SEQUENCE 
mdr1 
  
5'-6FAM-TCA TGG TGA ATC CAT TTT CCA TTG CTT CT--BBQ-3' 
  
α-tubulin ii 
  
5'-6FAM-CCT GCA TCT ATG ATG GCA AAA TGT GAT CCT--BBQ-3' 
  
 
Table 9 – Primers and probe sequences for mdr1 (PCHAS_123820) and α-tubulin ii (PCHAS_052240) genes used 
for quantification of copy number (genomic DNA) and RNA expression (cDNA) of the mdr1 gene by Real-Time 
PCR. 
 
 
The reaction mix was prepared by adding primers and probes to Faststart Universal Probe Master 
Mix with ROX (Roche), to a final concentration of 900 µM and 250 µM respectively.  
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In order to assess the number of copies of mdr1 gene shown by the clones selected here, 2 µl of 
DNA extracted from dried blood spots as described in Section 3.1 was added to the reaction mix, in 
triplicates, to a final volume of 20 ul. AS-SENS, AS-ATN and AS-15MF clones were used as controls, 
since the latter harbours a duplication of the mdr1 gene (Cravo et al, 2003) whereas the former two carry 
a single copy. 
For the RNA expression analysis, 2 µl of cDNA synthesised from RNA extracted as described in 
the previous sections was added to the reaction mix, also in triplicates, to a final volume of 20 µl. AS-
3CQ clone, which has a single copy of this gene, was used as control instead of AS-SENS. Similarly to 
the copy number determination, AS-ATN and AS-15MF clones were also used as controls. 
The cycling conditions for copy number analysis were 95ºC for 10 minutes followed by 50 cycles 
of denaturation at 95ºC for 15 seconds and annealing/extension at 57ºC for 1 minute, carried out in a 
Gene Amp 5700 Light Cycler (Applied Biosystems). 
The cycling conditions for the RNA expression analysis were the same used for the copy number 
assays. However the experiments were carried out using the 7500 Fast Real-Time PCR System (Applied 
Biosystems). 
The assays were repeated at least 5 times, and the mean values and standard errors calculated. A 
Student’s T-Test was used to verify statistic significance of the results found here. 
 
 
3.6. WESTERN BLOT ANALYSIS 
In order to determine expression of gene mdr1’s product P-gh1 in the ATN + MF resistant 
parasites AS-ATNMF-1, protein extracts were prepared from erythrocyte stage parasites. Thus, mice 
were injected with infected blood and upon reaching peak parasitaemia were exsanguinated. The blood 
was diluted in Citrate Saline Solution and then filtrated once using a cellulose (CF11, Sigma) 5 ml 
column and centrifuged at 3000 rpm for 5 minutes. The pellet was washed twice in ice-cold PBS and re-
suspended into two volumes of PBS. The mixture was divided into 500 µl aliquots. RBC lysis was 
performed by adding 1 ml of Hypotonic Ammonium Chloride Solution and incubating at 4ºC for 3 
minutes. The samples were centrifuged at 10000 rpm for 7 minutes at 4 ºC and supernatant was 
discarded. The pellet was washed twice in PBS and finally centrifuged at 10000 rpm at 4ºC for 7 
minutes. The volume of the pellet was estimated and re-suspended into twice the volume of Loading 
Buffer. Samples were kept at -20ºC and sent to analysis by Western Blot performed by Cecilia Sanchez 
as part of a collaboration maintained with Heidelberg University.  
Thus, upon arrival, samples were prepared as follows: protein amounts were determined by 
Bradford assay (BioRad, Germany). Samples were then run on NuPAGE Novex Tris-Acetate gels 
(Invitrogen, Germany) and transferred onto a 0.2 µm PDVF membrane (BioRad, Germany). Membranes 
were blocked overnight at 4°C using 5% milk in PBS. Primary antibodies (α-Pgh-1 and α-tubulin, 
diluted 1:1,000 and 1:2,000, respectively) were incubated for 1 h at room temperature in 1% BSA + 
PBS. Membranes were washed three times using PBS + 0.1% Tween for 10 min at room temperature 
and then blocked again in 5% milk in PBS for 1 h. Secondary antibodies (Alexa Fluor 680 goat anti-
rabbit IgG, or Alexa Fluor goat anti-mouse IgG, both diluted 1:10,000) were added to 1% BSA + PBS 
for 30 min at room temperature. After washing four times in PBS + 0.1% Tween for 5 min, signals were 
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read using an Odyssey-Li-cor infrared imaging system (Li-cor Biosciences). Fluorescence intensities for 
Pgh-1 were normalized using fluorescence intensities measured for tubulin. The resulting values were 
then expressed as relative to AS-3CQ and AS-ATN. 
The results were then expressed as means of five experiments and a Student’s T Test was used to 
determine statistical significance of results obtained. 
 
 
3.7. GENOME-WIDE IDENTIFICATION OF MUTATIONS 
3.7.1. SOLEXA GENOME RESEQUENCING 
In order to perform a complete analysis covering all the genome of AS-ATNMF-1 clone, DNA 
obtained as described in Section 3.7 was processed using standard methods according to the 
manufacturer’s recommendation (http://www.illumina.com/technology/sequencing_technology.ilmn). 
Samples were run at the Genepool facilities at the University of Edinburgh, UK, using the Illumina 
Solexa high-throughput sequencing technology. Sequencing was performed with 50 bp reads, using a 
paired-end read approach. Two software packages were used to align sequences against a reference 
genome (the isogenic AS-WTSI genome, curated by the Wellcome Trust Sanger Institute) and identify 
genome wide mutations, namely MAQ (Mapping and Assembly with Quality) (Li et al, 2008) and 
SSAHA2 (Sequence Search and Alignment by Hashing Algorithm) (Ning et al, 2001). The SSAHA2 
analysis was done in collaboration with Thomas Otto at the Wellcome Trust Sanger Centre in 
Cambridge, while MAQ analysis was done in collaboration with Urmi Trivedi at the Genepool in 
Edinburgh. 
SNP detection was performed by both MAQ and SSAHA2 softwares, using in-built algorithms, 
with a read depth of 3 set as the minimum threshold for SNP detection and no upper threshold selected. 
In order to filter out SNPs arising in the sensitive progenitor AS-SENS, the lists of SNPs obtained for 
AS-ATNMF1 was compared against a list previously obtained for AS-SENS (Hunt et al, 2010). The two 
filtered lists (for MAQ and SSAHA2) were then combined.  
Small indels (< 3bp) were detected using SSAHA2's internal algorithm only. The list of small 
indels was filtered against a similarly obtained list for AS-SENS (Hunt et al, 2010). Larger indels (≥ 
3bp) and copy number variation (CNV) detection was performed using SSAHA2 as previously 
described (Hunt et al, 2010). Briefly, the approach is based upon comparing coverage between the 
mutant clone and the sensitive progenitor in order to detect differences that indicate potential mutations.  
Coverage was normalised for each clone to take into account differences in average coverage (e.g. 
because some clones were sequenced with a greater number of Solexa lanes, thus yielding greater read 
depth). So, the coverage in each position was divided by the mean coverage of the whole genome in 
order to obtain a so-called “relative coverage” for each clone. Then, the “relative coverage” for each 
nucleotide in the resistant clone was compared to the relative coverage of the sensitive clone, obtaining 
the “comparative coverage”. The comparative coverage along a given chromosome can be visualised by 
using Artemis Software (Rutherford et al, 2000).  
Two simple algorithms were used to indicate areas of significantly decreased or increased coverage 
(Hunt et al, 2010).  Since AS-ATNMF-1 was sequenced using paired-end reads but AS-SENS was 
originally sequenced using single end reads, this approach could not be adopted using this clone, due to 
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the excessive variation introduced by the different re-sequencing strategies adopted. Instead, a clone 
selected for sulphadoxine resistance (AS-50SP) and re-sequenced using paired-end reads (Martinelli 
unpublished results) was selected to act as a “filter”, with the caveat that false positives and negatives 
are likely to appear. Due to a complete sequencing and analysis of other clones in the lineage (Hunt et 
al, 2010), we felt confident that this limitation could be overcome by resorting to the data previously 
obtained to resolve any uncertainties and discover false negatives. 
The positions of all the mutations described here are in accordance with the latest version of the 
P.chabaudi genome available on Welcome Trust Sanger Institute website 
(ftp://ftp.sanger.ac.uk/pub/pathogens/P_chabaudi/). 
 
 
3.7.2. VALIDATION OF MUTATIONS BY DI-DEOXY SEQUENCING 
Some SNPs and indels identified as described in the previous section were chosen for confirmation 
through traditional di-deoxy sequencing. For that purpose, a region of about a 1000 bp around each 
mutation was used for designing oligonucleotide primers and the fragments were amplified by PCR. 
DNA samples were obtained from dried blood spots for all clones in AS lineage, as described in Section 
3.1. DNA and PCR reagents were added as described in Section 3.2.  There was no variation in cycling 
conditions used for all reactions, except for annealing temperatures, which varied according to the 
primers. Cycling conditions were 93ºC for 3 minute, followed by 35 repeats of denaturation at 93ºC for 
30 seconds, annealing for 45 seconds, and elongation at 72ºC for 1 minute. A final elongation step was 
performed at 72ºC for 10 minutes, and samples were kept at 4ºC until processing. The sequences of 
oligonucleotide primers and their respective annealing temperatures are listed in Table 10. 
The products thus obtained were resolved into an agarose 1% gel, as previously described in 
Section 3.2, and when showing a single band, were purified and sequenced using the commercial 
services of STABVIDA Laboratories. The chromatograms were inspected using the Chromas 2.33 
software (Technelysium). 
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GENE SEQUENCE ANNEALING TEMPERATURE
(position)
PCAS_020900 sense GGT ATG ATC CAT TAT CTT GTT CG 51 ºC
anti-sense TGT ATC AGG ATC TAG TAG TTC G
PCAS_031370 sense GCT TGC TTA TGC ATA CTT CG 53 ºC
anti-sense TCG CGA AAT CGA ACT TAA AAT AC
PCAS_031520 sense GAG GGT TTA TAG TGT TTG TAT C 54 ºC
pos. 523111 to 523127 anti-sense CAT TCA AAC TCA TCA GCC TTA G
PCAS_031520 sense GAA CAG ACA TTT CTT GAT TTT GC 54 ºC
pos. 524946 to 524964 anti-sense CTA TTC AGG CAA TGG TAA CC
 3'-PCAS_061710 sense CAT TCA GCT TGT AAC TTG GG 56 ºC
anti-sense GAG AAG GTA TTA TGG TTC CTG
PCAS_070250 sense CCC GCC CCA GCA AAA TAA AC 54ºC
anti-sense GCT GAA AAG AAA GCG GAA GAG
PCAS_072830 sense TAA ATC TTC ATT GAT ATC TGG 51ºC
anti-sense CAT TCC CAA GTC CCT TAA AA
PCAS_072420-3' sense CGT ATA AAG GCT GTG ACA AC 52 ºC
34 bp deletion chr 7 anti-sense CAG GTT CGT TTT GTA CAT ACC
5'-PCAS_083770 sense GAA AGT GAA GCA CCA TTC GG 56 ºC
anti-sense CAC TGT GTC ATA TTC AAG ATT TG
5'-PCAS_092710 sense GCA TGC ATG TAG ATC ATA ACA C 54 ºC
anti-sense GTT TAC ATT CTT CGC TGC TAT C
PCAS_121630 sense CCC TTT ATC ACC CGA ATA TTT C 55 ºC
anti-sense CAT ATT TTT TAA GGG GTA AGT GC
PCAS_130140 sense CTC TGG GTC CGA AAT CAA TG 51 ºC
anti-sense GTC ACC ATT AGG CCC ATA AG 
PCAS_133430 sense GGT TGT TGT TTA GGA TTA GGT C 49 ºC
anti-sense CAT ACC ACC ATA TCT GAT TAT TG
PCAS_132020 sense CCA GAT ATT AAG CAA TAC AGC AC 56 ºC
anti-sense CGG CCA CAC ATA TAT TAA GGA
PCAS_143160 sense GAG GAC GCG AAA AGG AAA G 53 ºC
 
 
 
 
Table 10 – List of primers and their respective annealing temperatures. Results obtained by Solexa were analysed 
by di-deoxy sequencing using the primers listed above. 
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3.7.3. BIOINFORMATICSANALYSIS OF MUTATIONS 
The role of any mutation located within the coding sequence of a predicted protein was further 
analysed through the use of widely available bioinformatics tools. The wild type sequence was retrieved 
from the PlasmoDB database (www.plasmodb.org). The predicted sequence of the mutated protein was 
obtained by the translation of the manually mutated nucleotide sequence by the Sequence Manipulation 
Suite Software available online (Stothard, 2000). Subsequently, mutated and wild-type nucleotide and 
amino-acid sequences were aligned against each other using the alignment software Multi-align (Corpet, 
1988).  
Any potential role of the predicted protein was retrieved from the PlasmoDB database. 
Additionally, the predicted protein sequence was used for performing a BLAST search (non-redundant 
protein sequences (nr) database using Blastp (protein-protein BLAST) algorythm) (Altschul et al, 1997; 
Altschul et al, 2005) in order to identify the presence of regions showing similarities to known 
conserved domains in other proteins and organisms. Protein sequences were also inspected for 
conserved domains and functional sites using PROSITE (Hulo et al, 2007) and Pfam (Welcome Trust 
Sanger Institute). Although this information can sometimes be found using BLAST, localisation of 
predicted transmembrane domains in the protein sequences was also made by the use of HMMTOP 
(Tusnady and Simon, 1998). 
 
 
3.8. LINKAGE GROUP SELECTION 
3.8.1. GENETIC CROSS AND DRUG TREATMENT 
In order to perform a genetic cross between the ATN + MF- resistant AS-ATNMF-1 selected as 
described previously (Section 2.1) and the drug-sensitive genetically unrelated AJ, the protocol was very 
similar to the one used in Section 2.2. However, it contains a few modifications. Briefly, four CBA 
donor mice were divided into two groups. The first inoculated with the AS-ATNMF-1 clone and the 
other one inoculated with AJ. After reaching parasitaemias above 10%, blood was extracted by the tail 
vein and used to prepare the mixed infections. Seven C57BL/6 acceptor mice (here the acceptor mice 
were not treated with EPO) were divided into three groups: i) one mouse was inoculated with 10
5
 pRBC 
of AS-ATNMF-1; ii) one mouse received 10
5
 pRBC of AJ; iii) five animals received a mixture of equal 
proportions of the two clones, containing 10
5
 pRBC. On Day 8 pi, when reaching parasitaemias above 
5%, the seven mice were anaesthetised and used for feeding around two hundred Anopheles stephensi 
mosquitoes (both male and female) for 30 minutes. The mosquitoes here were not previously treated 
with XA. The mosquitoes’ drinking water (10% Glucose + 0.05% PABA solution) had been removed 12 
hours prior to feeding, and was replaced immediately after the end of the blood meal.  
Similarly to Section 2.2, four days after the blood meal, uninfected mice were used to boost-feed 
the mosquitoes, and on the tenth day ten mosquitoes per cage had their midguts dissected and inspected 
for the presence of oocysts. The oocysts were preserved in PBS and DNA was extracted using the High 
Pure PCR Template Preparation Kit (Roche), following the manufacturer’s instructions. Later, nested 
PCR products were obtained for the pcubp1 gene (PCHAS_020720) using the primers shown in Table 
11. DNA and PCR reagents were added as described in Section 3.2. Cycling conditions were: 95ºC for 1 
minute, followed by 30 cycles of 95ºC for 1 minute, 52ºC for 1 minute and 65ºC for 1 minute. Final 
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extension was made at 65ºC for 10 minutes. Samples were then resolved in 1% agarose gels, and further 
processed as described in detail in Section 3.2.  
 
  
PRIMER SEQUENCE  
Outer Forward   5'-ATG CAA ACT TAC TTT CAA AAC G-3' 
      
Outer Reverse   5'-TTG TTG CAT TTC GAG CAT TTG-3' 
      
Inner Forward   5´-CAA ATA AAA AAT ATG TTT CAC CAG-3' 
      
Inner Reverse   5'-CGA GCA TTT GTA TTT ATT GTT TCC-3' 
      
 
Table 11 – Primer sequences used for nested PCR amplification of pcubp1 gene using DNA extracted from 
oocysts dissected from mosquitoes’ midguts.  
 
The amplified fragment contains four polymorphisms when comparing the sequences obtained for 
AS and AJ parentals. It is then possible to determine the proportions of the alleles from each parental, by 
observing the electropherogram peak heights at each polymorphic position. This method is known as 
Proportional Sequencing (Hunt et al, 2005) and will be described in detail below (Section 4). 
On the fourteenth day, mosquitoes were allowed to feed on two CBA uninfected mice per cage in 
order to transmit the infection. For that purpose, mosquitoes’ drinking water was removed at least 12 
hours prior to the blood meal and anaesthetised uninfected mice were made available to mosquitoes for 
30 minutes. After recovering from anaesthesia, the mice were kept on standard conditions and 
parasitaemias followed for 10 days. 
On Day 10 after the transmission, all the mice carrying the uncloned progeny resulting from AS-
ATNMF-1 x AJ cross were exsanguinated and their blood was mixed. The parasites were propagated 
into new mice in a two-step process: i) 10
6
 pRBC from the mixed blood was inoculated into five CBA 
female mice. On Day 7 the mice were exsanguinated and their blood pooled together. ii) 10
7
 parasites 
from this second pool were inculated into new five CBA female mice. On Day 7, when reaching 
parasitaemias above 20%, blood was extracted from the five mice and mixed.  
After propagation, the selection of the uncloned progeny was made as follows: thirty CBA female 
mice were divided into six groups of five mice, and each one received a 10
7
 pRBC inoculum. The mice 
were then treated with three daily doses of different anti-malarial drugs on Days 1, 2 and 3 pi as follows: 
i) 25 mg/kg/day of ATN; ii) 40 mg/kg/day of ATN; iii) 2 mg/kg/day of MF; iv) 2 mg/kg/day of MF in 
combination with 20 mg/kg/day of ATN; v) 100 mg/kg/day of ART; and vi) DMSO vehicle. The 
parasitaemias were assessed daily from Day 6 onwards. 
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3.8.2. SAMPLE PREPARATION 
Upon reaching peak parasitaemia the mice carrying the drug treated uncloned parasite progeny 
resulting from AS-ATNMF-1 x AJ cross were exsanguinated and the blood used for DNA extraction by 
phenol-chloroform, as described at Section 3.1. 
The DNA concentration in each sample was determined using a QUIBIT™ fluorometer using 
Quant-iT™ dsDNA assay kit (Invitrogen). Dilutions were prepared so each reaction would contain 
between 1 pg/ml and 300 pg/ml.  
DNA samples were analysed by quantitative Pyrosequencing™ (Cheesman et al, 2007) using a 
genome-wide library of approximately 150 Pyrosequencing™ SNP assays, produced by the 
Pyrosequencing™ Assay Design Software version 1.0.6 (Biotage AB) to distinguish between AS/AJ 
alleles. These assays consist in two oligonucleotide primers (one of which is biotinylated) and a 
sequencing primer that anneals to the sequence close to the SNP. Primer sequences are listed in 
Appendix VI. 
The DNA samples were amplified by PCR using each pair of oligonucleotide primers, under the 
same conditions described in Section 3.2. The cycling conditions used in this case were: 96ºC for 1 
minute, followed by 30 cycles of 94ºC for 1 minute, 51ºC for 1 minute and 72ºC for 2 minutes. The final 
elongation step was run at 65ºC for 10 minutes. The samples were analysed in 1% agarose gel, stained 
with Safe View Nucleic Acid Stain. 
 
 
3.8.3. PYROSEQUENCING 
The Pyrosequencing™ analysis of the samples was carried out by adding 10 µl of PCR product 
obtained as described in the previous section to 38 µl Binding Buffer (Biotage), 30 µl of high purity 
Milli-Q water (Millipore) and 2 µl of Streptavidin Sepharose™ High Performance beads (GE 
Healthcare), on a 96-well PCR plate. The plate was placed on a shaker until further processing.  
The content of the wells was then removed by suction and the biotinylated PCR product attached 
to the beads was trapped to the probes of a Pyrosequencing™ Vacuum Prep Tool (Biotage). The probes 
were washed in a 70% ethanol solution for 5 seconds, following a wash in denaturation solution 
containing 0.2 M Sodium Hydroxide for 5 seconds, and a third wash, in Wash Buffer (Biotage) for 5 
seconds. The probes were allowed to vacuum dry the products for other 5 seconds. 
A second plate was prepared by adding 0.5 of sequencing primer to 11.5 µl of Annealing Buffer 
(Biotage) in a Pyrosequencing instrument-specific 96-well plate (Biotage). This plate was placed under 
the Pyrosequencing™ Vacuum Prep Tool and the vaccum released, allowing the beads to be mixed with 
the wells’ content. The plate was heated at 80ºC for 2 minutes and let cool down to room temperature. 
The plate was subsequently analysed on the PSQ™ HS-96A instrument using the Pyro Gold reagents 
(Biotage).  
The Comparative Index (CI) was calculated as the proportion of the sensitive allele (AJ) in the 
treated population relative to the untreated populations (Culleton et al, 2005).  
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4. FITNESS COST ANALYSIS 
In order to assess the biological cost the parasites might incur as consequence of the acquisition of 
resistance to ATN + MF, the fitness of AS-ATNMF-1 clone was estimated in comparison with its 
progenitor, AS-ATN.  
In addition, it is also known that consecutive passaging through mice might lead to an increase in 
parasite fitness (Mackinnon and Read, 1999; Walliker et al, 2005). To attest that, AS-ATNMF-1 growth 
was compared with the parasite population passaged in absence of drug treatment, AS-ATN27P. 
For that purpose, two clones were mixed in different proportions and grown together in the same 
host. Changes in proportions of parasites were followed along time using a method known as 
Proportional Sequencing (Hunt et al, 2005). By this method, the proportion of different alleles present in 
a mixture is estimated by measuring the peak heights shown by the DNA sequence gel electropherogram 
in a polymorphic position. As exemplified in Figure 26, the proportion of the allele A is determined by 
the height of peak A as a percentage of the sum of the two peaks (A and B) in that position, so:  
 
%Aallele = Aheight x 100 / (Aheight + Bheight) 
 
 
 
 
 
 
Figure 26 – Example of an electropherogram visualised using Chromas 2.33. A G to T polymorphism can be 
observed (black arrows). The heights of peaks A and B are measured and percentage of the each allele was 
calculated as the percentage of the sum of the two peaks. 
 
 
4.1. VALIDATION  
Although this method provides the determination of proportions of different alleles with high 
accuracy, limitations intrinsic of DNA amplification and sequencing make necessary validation with a 
calibration curve.  
To that extent, four mice were divided into two groups. Mice bearing the AS-ATNMF-1 clone or 
the parasites passaged in absence of drug, AS-ATN27P (Section 2.1), were exsanguinated upon reaching 
peak parasitaemia. Their blood was diluted into Citrate Saline Solution so that 0.1 ml had the equivalent 
A 
B 
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of 10
6
 pRBC. The blood was subsequently mixed in the following proportions (AS-ATNMF-1:AS-
ATN27P): 100:0, 90:10, 75:25, 50:50, 25:75, 10:90, and 0:100.  
A drop of blood from each mixture was dried in Whatman Nº4 filter paper and DNA was extracted 
by Chelex-100 method (Section 3.1). 
DNA samples were subsequently amplified by PCR, using oligonucleotide primers specific for the 
region flaking a G to T substitution in position 1155448 on Chr 14 found by Solexa, and confirmed to be 
exclusive of the artesunate + mefloquine-resistant clone, AS-ATNMF-1 (Chapter II, Section II.2.2.3). 
The amplified fragments were sequenced by di-deoxy sequencing using the commercial services of 
STABVIDA laboratories. The chromatograms were visualised using Chromas 2.33 software and the 
heights of the overlapping peaks corresponding to the mutation were measured.  
The percentages were calculated for both forward and reverse sequences and the proportions were 
plotted on a graph against the expected values. 
 
 
4.2. COMPETITION ASSAYS 
In order to estimate AS-ATNMF-1 parasites’ fitness, CD1 mice were divided into two groups, 
inoculated with AS-ATNMF-1 or AS-ATN27P. Upon reaching peak parasitaemias, the animals were 
exsanguinated and their blood was diluted so 0.1 ml contained the equivalent of 10
6
 pRBC. The blood 
carrying each parasite was mixtured in the following proportions: 100:0, 90:10, 50:50, 10:90, 0:100.  
A group of fifteen CD1 mice were divided into five groups of three animals inoculated 
intraperitoneally with 0.1 ml of one of the mixtures of parasites. Mice’s parasitaemias were assessed 
every two days, from Day 4 pi onwards.  
A drop of blood was collected from the tail of each mouse and dried in filter paper at the same 
days the parasitaemias were checked. DNA was extracted (Section 3.1), fragment surrounding position 
1155448 on Chr 14 was amplified by PCR, and sequenced. The proportions of AS-ATN27P 
(1155448G) and AS-ATNMF-1 (1155448T) alleles in each sample were determined by proportional 
sequencing analysis using the reverse sequence only. The results are expressed as mean percentage of 
two mice for both alleles, at each time point. 
Additionally, the assay was repeated using the original parental AS-ATN in mixtures with AS-
ATNMF-1 derived from it, and the proportions were assessed along time. 
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